Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
REPORTING ADVERSE DRUG REACTIONS ASSOCIATED WITH
HERBAL PRODUCTS:
CONSUMER, HEALTH FOOD STORE PERSONNEL AND PHARMACIST
PERSPECTIVES
by
Rishma Walji, BSc, ND
A thesis submitted in conformity with the requirements
for the degree of Doctor of Philosophy
Graduate Department of Pharmaceutical Sciences
University of Toronto
© Copyright by Rishma Walji 2008
ii
ABSTRACT
Reporting adverse drug reactions associated with herbal products: consumer, health food store
personnel and pharmacist perspectives.
Rishma Walji, PhD thesis 2008, Department of Pharmaceutical Sciences, University of Toronto
Background: Natural health products (NHPs) are sold over-the-counter and are often perceived
to be safe, despite potential risks. The current Canadian reporting system collects information on
suspected adverse drug reactions (ADRs) and suffers from severe under-reporting. As retailers,
pharmacists and health food store personnel may be in a position to facilitate collection of herbal
ADR reports because of their accessibility to consumers.
Objective: To investigate retailer and consumer responses to herbal ADRs.
Methods: In-depth interviews were conducted with retailers and consumers across Toronto until
theoretical saturation was achieved (n=36). Participants were purposefully selected to ensure
diverse backgrounds and experiences. Interviews were transcribed and coded for key emerging
themes.
Results: Consumers tended to self-prescribe NHPs and were only likely to discuss their NHP use
with people they trusted – usually health food store personnel, family and friends. Many
consumers did not have good relationships with their conventional health providers,
which inhibited discussions about NHP-related ADRs. When consumers did disclose suspected
ADRs to retailers, the retailers generally did not report these NHP-related ADRs to Health
Canada. Most pharmacists found workplace challenges insurmountable, although pharmacist
approaches to herbal ADRs tended to vary depending on their professional disposition.
Pharmacists who saw themselves as knowledge generators were more likely to report. Health
food store personnel offered generous product return policies and actively returned NHPs
iii
suspected of causing an ADR to the manufacturer. However, they had no knowledge of the
Canadian ADR reporting system and thus did not submit any reports.
Conclusion: Consumers tended to disclose suspected NHP-related ADRs only rarely and to
retailers with whom they had developed previous good relationships. This highlights the
importance of improving patient-practitioner (or retailer) communication. Pharmacists generally
did not report ADRs due to workplace challenges, unless they had a very strong professional
disposition. These results have important implications with respect to pharmacy education.
Health food store return policies resulted in suspected ADR reports to the manufacturers.
Manufacturers are mandated to report ADRs to Health Canada, so this finding may have
important implications within industry for the future of ADR reporting systems involving
herbal products and public health.
iv
ACKNOWLEDGMENTS
There are a number of people without whom this thesis might not have been written, all
of whom I would like to sincerely thank. Financial support for this doctoral research was
provided by two Ontario Graduate Scholarship Awards, two studentship grants from the
Interdisciplinary Network for Complementary and Alternative Medicine (IN-CAM), a doctoral
fellowship award from the Comparative Program on Health and Society and a proposal writing
grant from the Natural Health Products Directorate.
My gratitude goes to the individuals who participated in this research, thank you for your
time and cooperation. Without you this study would not have been possible.
I am extremely grateful to my supervisor Dr. Heather Boon. Your advice, expertise,
enthusiasm, timely comments and encouragement provided an ideal learning environment.
Thank you also to my committee members (Dr. Joanne Barnes, Dr. Zubin Austin, Dr. Sandy
Welsh, Dr. G. Ross Baker), your collective expertise and input provided a wealth of depth to my
research and helped me to enhance my own skills.
To all of my professors, especially Dr. J. Eakin, Dr. D. Gastaldo, Dr. P. McDonnough,
Dr. J. Cohen-Kohler, Dr. J. Barnsley – your classes provided me with challenges and insights
that helped me grow as a researcher.
To my friends and colleagues, especially Natasha Kachan, Raza Mirza, Laura Esmail, M.
Bianca Seaton and Donald Wong for enduring with me the trials and tribulations of student life,
and for providing support in their individual areas of expertise.
Finally, I thank my family who were by my side through every step of this degree. To
Alok: thank you for your unwavering support, patience, advice, encouragement, love, and
especially for believing in me. This accomplishment is as much yours as it is mine. To my
parents Shiraz and Shahida Walji: thank you for your guidance and your consistent support.
From you, I’ve learned that with vision, perseverance, and faith – anything is possible.
v
TABLE OF CONTENTS
ABSTRACT.................................................................................................................................. II
ACKNOWLEDGMENTS ..........................................................................................................IV
LIST OF TABLES ...................................................................................................................VIII
APPENDIX K: ETHICS APPROVAL …………………………………………………….….
143.................................................................................................................................................IX
LIST OF PUBLICATIONS......................................................................................................... X
LIST OF ABBREVIATIONS.....................................................................................................XI
CHAPTER 1. INTRODUCTION ............................................................................................... 1
1.1 STATEMENT OF THE PROBLEM ................................................................................................ 3
1.2 PURPOSE OF THE RESEARCH ................................................................................................... 3
1.3 OBJECTIVES............................................................................................................................ 4
1.4 STRUCTURE OF THESIS............................................................................................................ 4
1.5 REFERENCES .......................................................................................................................... 6
2.1 ADVERSE DRUG REACTIONS .................................................................................................. 7
2.2 UNIQUE FIELD OF NHPS ....................................................................................................... 10
2.3 SAFETY OF NHPS ................................................................................................................. 11
2.4 CONSUMER REPORTING ........................................................................................................ 12
2.5 RETAILERS AND NHPS ......................................................................................................... 13
2.5.1 Health food store personnel................................................................................................... 13
2.5.2 Pharmacists ...................................................................................................................... 14
2.6 OVERALL THEORETICAL FRAMEWORK ................................................................................ 16
2.6.1 Critical Realism................................................................................................................. 16
2.6.2 Theoretical Traditions ......................................................................................................... 18
2.6.2.1 Consumerism......................................................................................................... 18
2.6.2.2 Market forces......................................................................................................... 19
2.6.2.3 Professions theory ................................................................................................. 20
2.6.2.4 Bourdieu’s Theory of Practice .............................................................................. 21
2.7 CONCLUSIONS ...................................................................................................................... 22
2.8 REFERENCES ........................................................................................................................ 24
CHAPTER 3. METHODS AND METHODOLOGY............................................................ 29
3.1 QUALITATIVE METHODOLOGY ............................................................................................. 29
3.2 METHODS ............................................................................................................................. 29
3.3 DATA COLLECTION .............................................................................................................. 32
3.4 ANALYSIS............................................................................................................................. 33
3.5 PRIVACY .............................................................................................................................. 34
3.6 METHODOLOGICAL ISSUES.................................................................................................. 35
3.6.1 Positionality ................................................................................................................. 35
3.6.2 Reflexivity ..................................................................................................................... 37
3.6.3 Rigour........................................................................................................................... 40
3.7 ETHICS ................................................................................................................................. 41
vi
3.8 PRESENTATION OF RESULTS ................................................................................................. 42
3.9 REFERENCES ........................................................................................................................ 43
CHAPTER 4. RESULTS – CONSUMER INTERVIEWS..................................................... 50
CONSUMERS AND HERBAL-RELATED ADVERSE REACTIONS ........................................................ 50
4.1 ABSTRACT............................................................................................................................ 50
4.2 INTRODUCTION..................................................................................................................... 52
4.3 METHODS ............................................................................................................................. 53
4.4 RESULTS............................................................................................................................... 54
4.4.1 Identifying the ADR...................................................................................................... 54
4.4.2 Likelihood of reporting ................................................................................................ 55
4.4.3 Responsibility for self-prescribing ............................................................................... 56
4.4.4 Trust ............................................................................................................................. 56
4.4.5 Access ........................................................................................................................... 58
4.5 DISCUSSION.......................................................................................................................... 59
4.6 CONCLUSION ........................................................................................................................ 62
4.7 IMPLICATIONS ...................................................................................................................... 62
4.8 REFERENCES ........................................................................................................................ 64
CHAPTER 5. RESULTS – HEALTH FOOD STORE INTERVIEWS................................ 67
ADVERSE EVENT REPORTING FOR HERBAL MEDICINES: A RESULT OF MARKET FORCES.............. 67
5.1 ABSTRACT............................................................................................................................ 67
5.2 BACKGROUND ...................................................................................................................... 69
5.3 METHODS ............................................................................................................................. 72
5.4 RESULTS............................................................................................................................... 72
5.5 DISCUSSION.......................................................................................................................... 76
5.6 CONCLUSIONS AND POLICY IMPLICATIONS .......................................................................... 80
5.7 REFERENCES ........................................................................................................................ 82
CHAPTER 6. RESULTS – PHARMACIST INTERVIEWS................................................. 85
PHARMACISTS AND REPORTING OF HERBAL PRODUCT ADVERSE DRUG REACTIONS: WHOSE
RESPONSIBILITY IS IT? ................................................................................................................ 85
6.1 ABSTRACT............................................................................................................................ 85
6.2 INTRODUCTION..................................................................................................................... 86
6.2.1 Herbal product regulations.......................................................................................... 88
6.2.2 NHPs, ADR reporting, NHPs and Pharmacists........................................................... 89
6.3 METHODS ............................................................................................................................. 91
6.4 ANALYSIS............................................................................................................................. 92
6.5 RESULTS............................................................................................................................... 92
6.5.1 Self perception of competency...................................................................................... 92
6.5.2 Responsibility ............................................................................................................... 95
6.5.3 Workplace challenges .................................................................................................. 98
6.5.4 Professional disposition ............................................................................................. 101
6.6 DISCUSSION........................................................................................................................ 103
6.7 IMPLICATIONS .................................................................................................................... 105
6.8 CONCLUSIONS .................................................................................................................... 106
6.9 REFERENCES ...................................................................................................................... 107
vii
CHAPTER 7. SUMMARY AND IMPLICATIONS............................................................. 111
7.1 CONSUMER INTERVIEWS .................................................................................................... 111
7.2 HEALTH FOOD STORE INTERVIEWS ..................................................................................... 112
7.3 PHARMACIST INTERVIEWS.................................................................................................. 112
7.4 IMPLICATIONS FOR CLINICAL CARE ................................................................................... 113
7.5 POLICY IMPLICATIONS........................................................................................................ 114
7.6 THEORETICAL CONTRIBUTIONS.......................................................................................... 115
7.7 METHODOLOGICAL INSIGHTS ............................................................................................. 117
7.8 LIMITATIONS ...................................................................................................................... 120
7.9 NEXT STEPS ....................................................................................................................... 121
7.10 CONCLUSIONS .................................................................................................................. 123
7.11 REFERENCES .................................................................................................................... 125
viii
LIST OF TABLES
TABLE 1: Consumer demographic information ……………………………………………. 60
TABLE 2: Health food store personnel demographic information …………………………. 78
TABLE 3: Pharmacist demographic information …………………………………………… 103
TABLE 4: Core questions from semi-structured interviews that pertain to risk and safety … 103
ix
LIST OF APPENDICES
APPENDIX A: STUDY INFORMATION SHEET - CONSUMERS ....................................... 127
APPENDIX B: STUDY INFORMATION LETTER – RETAILERS ....................................... 129
APPENDIX C: PARTICIPANT CONSENT FORM - CONSUMERS...................................... 131
APPENDIX D: PARTICIPANT CONSENT FORM - RETAILERS ........................................ 132
APPENDIX E: INTERVIEW GUIDE – CONSUMERS ........................................................... 133
APPENDIX F: INTERVIEW GUIDE – RETAILERS .............................................................. 135
APPENDIX G: CODING TREE – CONSUMERS .................................................................... 137
APPENDIX H: CONCEPTUAL MAP – CONSUMERS .......................................................... 138
APPENDIX I: CODING TREE - RETAILERS ......................................................................... 139
APPENDIX J: CONCEPTUAL MAP – RETAILERS............................................................... 142
APPENDIX K: ETHICS APPROVAL …………………………………………………….…. 143
APPENDIX L: ADVERSE DRUG REACTION REPORTING FORM …………………….. 145
x
LIST OF PUBLICATIONS
A. THESIS PUBLICATIONS
1. Walji, R: Boon, H; Barnes, J; Austin, Z; Welsh, S; Baker, G.R. Consumers and Herbal
Product Related Adverse Drug Reactions. Patient Education and Counseling. (Submitted
June 27 2008)
2. Walji, R: Boon, H; Welsh, S; Austin, Z; Barnes, J; Baker, G.R. Pharmacists and reporting of
herbal product adverse effects: Whose responsibility is it? Social Science and Medicine. (In
preparation, to be submitted in Sept 2008).
3. Walji, R: Boon, H; Barnes, J; Austin, Z; Welsh, S; Baker, G.R. Adverse effect reporting for
herbal medicines: A result of market forces. Healthcare Policy. (In press).
B. OTHER PUBLICATIONS
4. Walji, R; Boon, H. (2008) Natural Health Product Regulations. Trends in Food Science and
Technology. 19: 494-497.
5. Walji, R; Kwan, D; Boon, H. Supplementation in Diabetes: OTC Medications –National
Continuing Education Program. Pharmacy Practice. October 2007.
6. Walji, R; Boon, H; Guns, E; Oneschuk, D; Younus, J. (2007) Black cohosh (Cimicifuga
racemosa [L.] Nutt.): Safety and Efficacy for Cancer Patients. Supportive Care in Cancer.
15 (8): 913-921
7. Walji, R; Boon, H. (2006) Redefining the Randomized Controlled Trial in the context of
Acupuncture Research. Complementary Therapies in Clinical Practice. 12 (2): 91-96.
8. Cheung, AM; Walji, R (2002) Most herbal remedies have no benefit for menopausal
symptoms. Annals of Internal Medicine. 137 (10): 805-13
xi
LIST OF ABBREVIATIONS
ADR Adverse drug reaction
CAM Complementary and alternative medicine
d/c Discontinue
F/f Friends and family
HFS Health food store
MD Medical doctor
NHP Natural health product
PHM Pharmacist
1
CHAPTER 1. INTRODUCTION
Despite the popular belief that herbs and other natural health products (NHPs) are safe, these
products are pharmacologically active and therefore have inherent risk. The topic of adverse
drug reactions (ADRs) associated with herbs is increasing in importance now that almost seven
in ten Canadians have used an NHP at some time in their lives. Seventy-seven percent agree that
NHPs can be used to maintain or promote health, while sixty-eight percent consent that NHPs
can be used to treat illness. (NHPD, 2005b) Adverse drug reactions (ADRs) are defined as
unintended consequences suspected to be related to the use of medicinal products, including
herbal medicines. (World Health Organization, 1995) Herbal supplements are complex products
where synergistic pharmacokinetic and/or pharmacodynamic interactions are of relevance.
(Spinella, 2002; Williamson, 2001) The lack of systematically collected safety information
about herbal medicines results in deficiencies in our understanding of the potential risks of herbs
and herb-drug interactions.
Due to some concerns about herbal product quality Health Canada increased quality
assurance in 2004 by regulating the manufacturing processes of NHPs. (NHPD, 2003) Although
the NHP Regulations may increase the quality of herbal products themselves, ADRs can still
occur as a result of the products’ pharmacological properties, drug-herb interactions, allergy or
inappropriate dosage. ADRs are only identified when reported to appropriate channels such as
the Canadian Vigilance Program (CVP) (formerly the Canadian Adverse Drug Reaction
Monitoring Program – CADRMP). In Canada, the CVP is a spontaneous voluntary adverse drug
reactions reporting program. Under-reporting is the major limitation associated with such
spontaneous reporting systems. (Alvarez-Requejo, Carvajal, Begaud, Moride, Vega, & Arias,
1998; Fletcher, 1991a) Several reasons for under-reporting of ADRs associated with herbal
2
products have been postulated. It is likely that practitioners may not be aware of the reporting
system procedures for herbal products or they may have difficulty in obtaining information about
ADRs filed by other practitioners. It is also possible that health care providers do not have the
time or resources to dedicate to a voluntary task in the face of their other duties. (Green,
Mottram, Rowe, & Pirmohamed, 2001; Herdiero, Polonia, Gestal-Otero, & Figueiras, 2004)
One key issue with respect to herbal product ADR reporting appears to be the widespread
perception among the public that NHPs are completely safe and thus have no inherent adverse
effects. (Boon, Brown, Gavin, Kennard, & Stewart, 1999; Drew & Myers, 1997a; McNeill,
1999; Montbriand, 1993) This is complicated by the fact that many patients who use herbal
products do not disclose this use to conventional health care providers. (Boon, Stewart, Kennard,
Gray, Sawka, & Brown, 2000; Eisenberg, Davis, & Ettner, 1998; Frank, Godwin, Verma, Kelly,
Birenbaum, & Seguin, 2001; Verhoef, Sutherland, & Brkich, 1990) When patients experience
symptoms that may be the result of herbal product use or herb-drug or herb-herb interaction,
these may never be investigated if the patient does not identify these are ADRs associated with
the herbal product or if health care providers are not aware of the NHPs the patient is taking.
Patients have been shown to be less likely to report ADRs with NHPs to health care providers
than they are to report similar events associated with drugs. (Barnes, Mills, Abbot, Willoughby,
& Ernst, 1998) The incidence of herbal ADRs is difficult to determine because they are available
over-the-counter (OTC) and are thus often used without direction from a health care practitioner.
When a consumer experiences an ADR, they make judgments about whether they think it is
related to the herbal product that they have taken. They then decide whether they want to report
that event. It is therefore important to examine how consumers identify their adverse drug
reactions and how they respond to this situation.
3
This thesis focuses on real life experiences of consumers who believe they have
experienced an ADR to a herbal product and some of the people with whom consumers share
their ADR experiences. It will explore in-depth, consumers’ perceptions and experiences as well
as investigate pharmacist and health food store personnel responses to consumers who have had
ADRs.
1.1 Statement of the problem
It is difficult to estimate the incidence of ADRs associated with herbal products because
of under-reporting by health care providers and the fact that consumers’ use of herbal products is
often not monitored by a health care provider. In order to understand the risks of herbal
products and possible interactions, it is necessary to improve current reporting systems.
Literature on ADR reporting primarily focuses on reasons for health provider under-reporting
related to pharmaceutical medications, with very little information on NHP ADR reporting.
There is also a lack of information that explores consumers’ role in identifying and reporting
ADRs. Understanding how consumers and retailers experience and respond to ADRs, and how
they make decisions regarding reporting their experiences may aid in the understanding of
everyday herbal product use and risk as well as contribute to improvements in current data
collection methods.
1.2 Purpose of the research
The purpose of this research was to contribute to an evolving understanding of safety
issues associated with herbal products, and more specifically how they are addressed by retailers
and consumers. These groups were chosen because NHPs are often self-prescribed so consumer
perspectives and reactions to ADRs are considered key to understanding communication about
these safety issues. In addition, retailers such as pharmacists and health food store personnel
4
have access to consumers at the point of sale and therefore are well placed to have exposure to
ADR information. To address that purpose and gain an in-depth understanding, qualitative
methods of inquiry were employed.
1.3 Objectives
The specific objectives of this study were to:
1. Explore and describe the perceptions about safety issues and reporting of
ADRs of pharmacists and health food store personnel at the point-of-sale;
and
2. Explore and describe the behaviours and beliefs of consumers with respect
to herbal product related ADRs.
Following from the purpose of the research, underlying generative mechanisms that will be
explored include: How do patients/consumers respond to an ADR? What makes them decide
how to handle the situation and who to talk to? What are the barriers and facilitators to
communicating about their ADR? How do pharmacists respond to ADRs? What triggers them to
report? What barriers exist to reporting? How do health food store personnel respond to ADRs?
What motivates them to respond?
1.4 Structure of thesis
The individual phases of this work, that is, the qualitative components examining
consumer and retailer experiences and perspectives, addressed different, but related, aspects of
the overall research purpose. When combined, those components form an integrated whole,
resulting in an overall thesis that consists of seven chapters. The structure of this thesis is paper-
based, which means that papers from each of the three populations studied have been drafted for
publication in scientific journals. They will be added to the thesis as submitted and therefore
5
will repeat methods and some background details. This repetition is a function of the particular
type of thesis structure. Details of each chapter are discussed below.
Chapter 1 presents an overall introduction to the research topic. It justifies the need for
the research and the approach taken to achieve the stated objectives. Chapter 2 presents a review
of the relevant literature, introduces the theoretical perspectives and provides details and
justification of the methods used to address the objectives of the research. Chapter 3 presents a
comprehensive discussion of the qualitative methodology used for analysis, including a
description of the theoretical paradigm and selected key methodological challenges.
Chapters 4, 5, and 6 present the results of the research. Each chapter is written as a
complete paper and includes an abstract, research questions, background/introduction specific to
the chapter, methods, results, discussion, and/or conclusion. Chapter 4 provides the results of the
phase of research conducted with consumers. Chapter 5 presents the phase of research
conducted with health food store personnel. Chapter 6 documents the results of research
conducted with pharmacists.
By integrating the findings of each of the individual papers, Chapter 7 provides a
discussion that addresses and answers the goals of the research. This chapter also makes
recommendations for further research as they apply to the findings and discusses limitations of
the research. Lastly, it presents the conclusions of the thesis.
6
1.5 References
Alvarez-Requejo, A., Carvajal, A., Begaud, B., Moride, Y., Vega, T., & Arias, L. (1998). Under-
reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme
and sentinel system. European Journal of Clinical Pharmacology, 54(6), 483-488.
Barnes, J., Mills, S.Y., Abbot, N.C., Willoughby, M., & Ernst, E. (1998). Different standards for
reporting ADRs to herbal remedies and OTC medicines: face-to-face interviews with 515
users of herbal remedies. British Journal of Clinical Pharmacology, 45, 496-500.
Boon, H., Brown, J., Gavin, A., Kennard, M., & Stewart, M. (1999). Breast cancer survivors'
perceptions of complementary/alternative medicine (CAM): making the decision to use
or not to use. Qualitative Health Care, 9(5), 639-653.
Boon, H., Stewart, M., Kennard, M., Gray, R., Sawka, C., & Brown, J. (2000). The use of
complementary/alternative medicine by breast cancer survivors in Ontario: prevalence
and perceptions. Journal of Clinical Oncology, 18(13), 2515-2521.
Drew, A., & Myers, S. (1997). Safety issues in herbal medicine: implications for health
professions. Medical Journal of Australia, 166, 538-541.
Eisenberg, D., Davis, R., & Ettner, S. (1998). Trends in alternative medicine use in the United
States, 1990-1997: results of a follow-up national survey. Journal of the American
Medical Association, 280(18), 1569-1575.
Fletcher, A. (1991). Spontaneous adverse drug reaction reporting vs. event monitoring: a
comparison. J R Soc Med, 84(6), 341-344.
Frank, C., Godwin, M., Verma, S., Kelly, A., Birenbaum, A., & Seguin, R. (2001). Natural
health product use in a day hospital population Geriatrics Today: Journal of the
Canadian Geriatric Society, May, 64-67.
Green, C.F., Mottram, D.R., Rowe, P.H., & Pirmohamed, M. (2001). Attitudes and knowledge of
hospital pharmacists to adverse drug reaction reporting. British Journal of Clinical
Pharmacology, 51, 81-86.
Herdiero, M.T., Polonia, J., Gestal-Otero, J.J., & Figueiras, A. (2004). Factors that influence
spontaneous reporting of adverse drug reactions: A model centralized in the medical
professional. Journal of Evaluation in Clinical Practice, 10(4), 483-489.
McNeill, J. (1999). Interactions between herbal and conventional medicines. The Canadian
Journal of CME, December, 97-113.
Montbriand, M. (1993). Freedom of choice: an issue concerning alternative therapies chosen by
patients with cancer. Oncology Nursing Forum, 20, 1195-2101.
NHPD (2003). Natural health products regulations. In N.H.P. Directorate (Ed.): Health Canada.
NHPD (2005). Baseline natural health products survey among consumers: Health Canada.
Spinella, M. (2002). The importance of pharmacological synergy in psychoactive herbal
medicines. Alternative Medicine Review, 7, 130-137.
Verhoef, M., Sutherland, R., & Brkich, L. (1990). Use of alternative medicine by patients
attending a gastroenterology clinic. Canadian Medical Association Journal, 142(2), 121-
125.
Williamson, E. (2001). Synergy and other interactions in phytomedicines. Phytomedicine, 8,
401-409.
World Health Organization (1995). Note for guidance on clinical safety data management:
definitions and standards for expedited reporting, CPMP/ICH.377/95.
7
CHAPTER 2. LITERATURE REVIEW
The purpose of this chapter is to critically review the published literature on herbal
adverse drug reactions (ADRs) and provide context for the study. Current understandings of
adverse drug reactions have been derived from research on pharmaceutical products, both
prescription and over-the-counter. Thus, the literature was reviewed with the purpose of
providing a framework through which to understand the occurrence of adverse drug reactions,
how they are managed by patients and practitioners, and the unique environment around herbal
and other natural health products. There is also a discussion of the theoretical framework used
for this study.
2.1 Adverse Drug Reactions
ADRs are defined as unintended consequences suspected to be related to the use of medicinal
products, including herbal medicines. (World Health Organization, 1995) Spontaneous reporting
systems, such as the Canada Vigilance Program (previously named the Canadian ADR
Monitoring Program), are used by many countries as a way of collecting information about
suspected ADRs. Voluntary reports of suspected serious or unexpected ADRs, and those
associated with recently marketed products are particularly encouraged. (Fletcher, 1991b) The
reports typically contain information about the symptoms associated with the reaction, the dose
of the drug or product used, any concomitant medications and other relevant information related
to the reaction. For a copy of the ADR reporting form, refer to Appendix L. Health Canada
accepts all reports of suspected ADRs, with an emphasized priority on serious and
undocumented reactions.
Reporting of ADRs to spontaneous reporting systems is estimated at under 10% of ADRs
that occur. (Hazell, 2006) In contrast to Canada’s voluntary system, compulsory ADR reporting
8
exists in countries such as France and Sweden, However, it is not clear how this requirement is
enforced (Wilholm, 2002) and these systems also suffer from severe under-reporting. (Hazell,
2006; Backstrom, 2004)
In Canada, physicians, pharmacists, other healthcare providers and consumers are
encouraged to submit reports which are assessed by Health Canada to identify product safety
concerns that require action. The goal of the preliminary evaluation is to assess the likelihood of
an association between the reaction and the health product. Typical information which must be
taken into account includes the frequency, severity, plausibility, quality of the information
contained in the ADR reports, amount of product used, time needed for appearance of the
reaction, underlying diseases, simultaneous use of other medications, and evidence of
disappearance or reappearance of the reaction once the product was discontinued or
reintroduced. Additional investigative studies and consultations with other regulatory agencies
are often necessary to confirm the health product-ADR relationship. If action is needed, Health
Canada may require changes/additions to product labelling, dosing, or removal of products from
the market.
Although NHPs are widely used, few ADRs are reported to pharmacovigilance systems.
(Barnes, 2003; Green, Mottram, Rowe et al., 2001; Health Canada, 2007) What is not clear is
whether the small number of reports received by Health Canada indicates that NHPs are so safe
there is very little to report or simply reflects that fact the NHP-related ADRs are under-reported.
It is well established that under-reporting of suspected ADRs is an important limitation of
spontaneous reporting systems. (Fletcher, 1991b; Mann & Andrews, 2002; Rogers, Israel, Smith,
Levine, McBean, Valente et al., 1988)
9
Previous research indicates that health care providers tend not to report ADRs associated
with conventional drugs. (Charrois, Hill, Vu, Foster, Boon, Cramer et al., 2005; Inman, 1985)
Health professionals appear to be more likely to report ADRs if they: a) see the reaction as
serious; are confident that the product caused the reaction; b) are not busy; c) received
continuing education about ADR reporting; and d) have been motivated to report ADRs in the
past and if there is a specialist in ADR reporting on staff. (Green, Mottram, Rowe et al., 2001;
Lee, Chan, Raymond, & Critchley, 1994; Sweis & Wong, 2000) Workplace challenges, such as
lack of time, are cited as major obstacles for ADR reporting. (Granas, Buajordet, Stenberg-
Nilsen, Harg, & Horn, 2007; Inman, 1996; Irujo, Beitia, Bes-Rastrollo, Figueiras, Hernandez-
Diaz, & Lasheras, 2007)
Under-reporting is likely to be greater for herbal medicines and other NHPs than for
pharmaceutical drugs. Safety monitoring is more difficult for herbal products than for
conventional medications for many reasons. (Barnes, 2003) In particular, NHPs are often
perceived as completely safe, and self-prescribed without advice of a qualified practitioner. It
appears that patients are less likely to report ADRs due to herbal products than similar events due
to pharmaceuticals, possibly because they consider ADRs associated with herbal medicines to be
less worrying or because they do not think that herbal ADRs should be reported to conventional
healthcare professionals. (Barnes, Mills, Abbot et al., 1998) Healthcare professionals are
therefore often unaware of patients’ NHP use (Barnes, 2003; Barnes, Mills, Abbot et al., 1998;
NHPD, 2005b; Wheaton, Blanck, Gizlice, & Reyes, 2005; Winslow & Shapiro, 2002), how to
identify ADRs associated with NHPs and what to report (Charrois, Hill, Vu, Foster, Boon,
Cramer et al., 2007; Herdiero, Polonia, Gestal-Otero et al., 2004). In Canada, NHPs have only
been categorized as medicinal products and regulated by Health Canada since January 2004.
10
(NHPD, 2003) It is unclear whether the lack of NHP ADR reports suggests that they are truly
rare, or reflects a history of inadequate effort (in Canada and internationally) to encourage,
collect and assess reports of NHP ADRs.
2.2 Unique field of NHPs
NHPs make up a distinct class of products that are extremely diverse in composition and
are available over-the-counter (OTC), without a prescription. This means that they, like other
OTC products, are widely available and can be used at the consumer’s discretion. Several
aspects unique to natural health products are not adequately addressed in literature on
pharmaceutical medications. Most models of safety monitoring depend on physician contact and
follow-up with patients. They also depend on pharmacist records of dispensing those
medications. NHPs on the other hand, are similar to OTC products in that they are available
without physician and/or pharmacist interaction. In light of this fact, studies evaluating NHP
adverse events need to be modified to account for differences in exposure information collection,
direct advertising to consumers, event incidence recording methods, risk factor identification and
definitions of adverse events for NHPs specifically. For instance, when a consumer purchases
the NHP, there need not be input from health care providers because the NHP is available over-
the-counter – the patient is free to self-prescribe. This means that there is a lack of recorded
exposure and event incidence information in the health care community. It also means that
patients may be taking products while unaware of potential risks or contraindications. The
availability of NHPs without a prescription also means that manufacturing companies are free to
market their products directly to the consumer. Research that specifically evaluates the use of
OTC medications relies on sales information for the product to provide baseline exposure
information. These models identify the store location, which product was sold, the number of
11
units sold and the date. While these OTC monitoring models are able to identify demand and
annual cyclical trends, there is no mechanism to identify patient characteristics and thus they
cannot identify adverse events associated with those products.
Herbal NHPs are unique in that they may have natural variation based on environmental
conditions during growth, harvest and storage, which can affect the concentration of active
constituents and the profile of constituents present. (Barnes, 2003) These variations create
differences in the products used and may impact the incidence of adverse events. In some cases
adverse events have been associated with NHPs contaminated with pesticides, heavy metals,
toxins. (Chan, 2003; Ionnides, 2002) Health Canada implemented regulations to increase quality
assurance on the manufacturing processes of NHPs. (Fitzpatrick, 2004; NHPD, 2003) These
regulations will help to ensure the quality of NHPs themselves, but they will not be completely
implemented for several years. Even when quality can be assured, NHPs are often manufactured
as standardized extracts or concentrated forms of particular herbal constituents. The chemical
composition of these products, their biochemical properties as well as their potential for
interaction with other NHPs and drugs may impact adverse event incidence. Furthermore,
regulatory differences and patient perceptions of the overall safety of NHPs differentiate them
from other OTC drugs. Current research therefore, on OTC drugs and pharmaceutical
medications is not necessarily applicable to NHPs.
2.3 Safety of NHPs
NHPs are complex products that have important pharmacological properties. (Spinella,
2002; Williamson, 2001) ADRs may occur when the product is used alone, or when used in
combination with other products or drugs. The incidence of adverse events due to NHPs and
NHP-drug interactions is difficult to determine because they are available over-the-counter and
12
are thus often used without direction from a health care practitioner. Risk associated with the
use of NHPs generally increases in patients who have confounding health, genetic and
environmental factors, including those engaging in polypharmacy. (Foster, Arnason, & Briggs,
2005) A toxicological study conducted at the Guys’ Hospital in London identified 785 possible
or confirmed adverse events (out of 1297 symptomatic inquiries) associated with the use of
traditional and herbal remedies and dietary supplements in a 5-year period (1991-1995) reported
to the National Poisons Information Service (London) (NPIS(L)). (Shaw, Leon, Kolev, &
Murray, 1997)
The need to evaluate NHP safety and efficacy is becoming more urgent especially since
there is an increasing amount of evidence regarding adverse events associated with certain
NHPs. (Williamson, 2001) For example, there have been safety concerns with herbs such as
black cohosh, ephedra and kava. (Dasgupta & Bernard, 2006; Health Canada, 2005; Wooltorton
& Sibbald, 2002) Anecdotal and literature reports of adverse events and clinical studies with
NHPs are increasing; however, they are often conflicting because of confounding factors
influencing the production and use of NHPs. In the past, adverse effects, sometimes life
threatening, have been associated with NHPs contaminated with pesticides, heavy metals, and
toxins. (Chan, 2003; Ionnides, 2002; Koh & Woo, 2000) With improved regulation, it is hoped
that safety concerns due to poor quality products will be less common.
2.4 Consumer reporting
The decision to report an adverse event appears to be based on the user’s perceptions of the
severity of the adverse event as well as having access to resources to help report that event.
Resources are available for the public should they experience an adverse event. Reports can be
filed through a health care practitioner or directly to Health Canada. Knowledge of these
13
existing resources and access to them may influence whether or not an adverse event is reported.
For example, if a consumer consults their health practitioner for advice on the products and
potential interactions or contraindications, it may impact how the product is used, which then
influences the likelihood of experiencing an adverse event.
Patient beliefs about the general safety of NHPs may impact whether or not they report
an adverse event. It has been shown that patients are less likely to report adverse events
associated with NHPs than with conventional OTC medicines. (Barnes, Mills, Abbot et al., 1998)
Furthermore, patients may not discuss NHP use with medical doctors because they expect a
negative response from their doctor. (Hsiao, Hays, Ryan, Coulter, Anderson, Hardy et al., 2005)
If they believe in the general safety of NHPs and do not disclose use to their medical doctors,
this may decrease the likelihood of reporting any adverse events.
2.5 Retailers and NHPs
2.5.1 Health food store personnel
Herbal medicines and other NHPs are available over-the-counter in Canada at community
pharmacies, grocery outlets and health food stores (HFS), as well as from the internet. The
Canadian regulatory status of NHPs (i.e. non-prescription, non-‘pharmacy only’) has provided an
opportunity for HFS to respond to public demand, entering the market with a wide product
selection. There are approximately 2700 HFS (typically, retail outlets where at least 50% of
stock comprises NHPs and/or health foods) across Canada, mostly in the provinces of Ontario,
Quebec and British Columbia. (Canadian Health Food Association, 2005) HFS may be
independently operated or belong to a retail chain with multiple outlets city or nationwide. There
are no legal requirements regarding educational background or training for staff, and each store
has different requirements ranging from online courses or in-store training/mentoring to no
14
training/experience requirements. (Glisson, Rogers, Abourashed, Ogletree, Hufford, & Khan,
2003; Mills, Singh, Kawasaki, Bast, Hart, Majlesi et al., 2003) Research evaluating the quality
of advice given by health food store personnel has illustrated the lack of standardization in
training, which may result in poor quality recommendations, potentially leading to ADRs.
(Brazier & Levine, 2002; Glisson, Rogers, Abourashed et al., 2003; Mills et al 2003; Koren et al
2006)
Although HFS are an important source of NHPs, their staff do not have a defined role in
monitoring the safety of the medicinal products they sell. (Healey, Burgess, Siebers, Beasley,
Weatherall, & Holt, 2002) Rather, their business is providing health-related products, meeting
customer demands, and providing adequate customer service to remain viable in a competitive
marketplace. In contrast, conventional healthcare professionals (e.g., doctors, pharmacists) are
bound by professional and ethical standards to report serious or unexpected instances of
suspected ADRs.
2.5.2 Pharmacists
Pharmacists can also be considered retailers of NHPs which are routinely sold at
community pharmacies. As health care professionals, it can be argued that they should be
responsible for monitoring ADRs that are associated with these products. (Kwan, Boon,
Hirshkorn, Jurgens, Welsh, Cohen et al., 2007) Unique statutes in each province regulate the
practice of Canadian pharmacists. Generally, pharmacists are responsible for attending to
patients’ drug-related needs. Given that herbal products are now regulated as a subcategory of
drugs in Canada, it could be argued that reporting of herbal ADRs falls within the pharmacist’s
professional responsibilities, in the same way that reporting adverse reactions for
pharmaceuticals does. (Farrell, Ries, & Boon, 2008) Presently ADR reporting is considered by
15
pharmacist associations as an ethical and moral duty, but is legally still a voluntary task (as is the
reporting of ADRs suspected with drugs). (Farrell & Staughton, 1996)
Undergraduate curricula pertaining to NHPs vary widely across North America (Chang,
Kennedy, Holdford, & Small, 2000; Johnson, 2007; Mackowiak, 2003; Shields, McQueen, &
Bryant, 2003) and as a result, many pharmacists appear to have little knowledge of NHPs.
(Byrne, 2008; Johnson, 2007) While pharmacists are increasingly being identified as important
sources of information on NHPs (Farrell & Staughton, 1996; Kwan, 2006), this role is not
supported by their actual training in NHPs. (Kwan, 2006)
Research indicates that the majority of consumers and pharmacists agrees that
pharmacists need to be knowledgeable about NHPs. Consumers identify the informative role of
the pharmacists as especially important since NHPs can be pharmacologically active and dosing
instructions, as well as safety information for NHPs, are often confusing or missing from labels.
Trends also indicate that many pharmacists receive questions about NHPs from patients and
other health care providers regarding product differentiation, specific indications, and the safety
of drug interactions or for patients with comorbidities. (Kalaria, 2003)
There is an expectation from regulatory associations for pharmacists to have knowledge
regarding NHPs (Kwan, 2006; Miller, Hume, Harris, Jackson, Kanmaz, Cauffield et al., 2000),
and yet only 12% of Canadian pharmacists said they are very satisfied with the quality of
information available on herbal products. (Kwan, 2006) Overall, trends indicate that
pharmacists’ knowledge about NHPs in general is low. (Kwan, 2006) Pharmacists themselves do
not feel their knowledge of NHPs is adequate to make recommendations regarding use (Kwan,
2006). In addition, the rate of documenting, monitoring and inquiring about patients’ use of
NHPs by pharmacists is low, but pharmacists who received training in alternative medications
16
or worked in in-patient settings were significantly more likely to make such inquiries in one
study (Kwan, 2006).
Pharmacists’ attitudes towards the safety and efficacy of NHPs also vary widely. (Kwan,
2006) Studies have found that approximately half of the pharmacist respondents felt that NHPs
are not safe (Dolder, Lacro, Dolder, & Gregory, 2003; Welna, Hadsall, & Schommer, 2003),
while another study showed that many pharmacists described NHPs as having a high degree of
placebo effect. (Bouldin, Smith, Garner, Szeinbach, Frate, & Croom, 1999) On the other hand,
19-48% of pharmacists reported thinking that NHPs are effective. (Dolder, Lacro, Dolder et al.,
2003; Welna, Hadsall, & Schommer, 2003) These results varied based on the geographical
location where the pharmacist practiced as well as the type of herb discussed. Interestingly,
more than half of US pharmacists agreed that their colleagues did not accept herbal medicines.
These differing attitudes of pharmacists towards NHPs may be important to explore when
attempting to explain practice behaviours related to safety monitoring and ADR reporting.
2.6 Overall Theoretical Framework
2.6.1 Critical Realism
This study examined the topic of herbal product adverse event reporting using critical
realism, situated within the critical social paradigm. Critical realism asserts that there is a reality
independent of our perception of it (Russell, 1945). Reality consists of three levels: empirical,
actual and real. The empirical level constitutes the perceptions, impressions and sensations of an
experience. The actual level is made up of events and the worldly state of affairs. The empirical
and actual are not possible without the real level of underlying structures, mechanisms and
powers. (Bhaskar, 1975) In essence, reality is composed not only of events and our experiences
or impressions of them, but also of structures and mechanisms, powers and tendencies that may
not be directly observable, but nevertheless underlie actual events that we experience. (Lawson,
17
1994) One of the key defining features of critical realism is that epistemological and ontological
matters cannot and should not be collapsed or conflated. (Bhaskar, 1975, 1989; Williams, 2003)
That is, what we know and how we know it (epistemology) should not be confused with what
there is to know (ontology). Critical realism is therefore based on the ontological claim that the
world exists independently of our thoughts or knowledge about it, and hence the meanings we
place upon it. (Schmidt, 2001; Williams, 2003; Wilson & McCormack, 2006) In the context of
this study, it follows that the concept of adverse events is more than a social construct. Labels
such as “side effects”, “negative reactions” or “healing reactions”, describe how people view the
phenomenon, but they do not themselves constitute the phenomenon. This study therefore
presupposed the existence of adverse events, but attempted to discover how retailers and
consumers understand and respond to this independent event.
In particular through the study, a focus was placed on comprehending generative
mechanisms behind adverse event reporting. Generative mechanisms, in critical realism, refer to
the structures and relations that explain how things work beneath a surface, or observable,
appearance. (Bunge, 1997; Fleetwood, 2001; Harre, 1970; McEvoy & Richards, 2003; Pawson &
Tilley, 1997; Sayer, 2000) However, in the real world it cannot be said that the pharmacist will
always and in every case ‘cause’ a report to be filed – what if the patient does not communicate
his/her symptoms to the pharmacist? What if the pharmacist is too busy to file the report? The
understanding of underlying generative mechanisms, the powers or tendencies of the pharmacist
to file a report, is both complex and deep. The principle research objectives for this study will
thus be focused on attempting to uncover the generative mechanisms underlying consumer and
retailer responses to ADRs.
18
Within this overall theoretical paradigm, this thesis draws on a number of different
theoretical traditions, discussed below.
2.6.2 Theoretical Traditions
2.6.2.1 Consumerism
Decision-making in health care has been classified into three categories: paternalistic,
shared and consumerist. (Murray et al, 2007) In paternalistic models, doctors make health care
decisions based on what they believe to be in the best interests of the patient. In shared models,
the physician and patient deliberate together to determine the best course of action. In the
consumerist model, the patient makes his/her own decisions about health care. Technology and
the trend towards health promotion may have resulted in more individuals preferring the
consumerist model of decision-making. Consumerist theories are based on the principle that
health care can be considered to be a commodity like any other consumer good. Many
individuals are empowered to function as consumers when making choices about health
maintenance and disease prevention activities. Since they view health care as a commodity,
where it has been argued that the ‘new consumer’ is less willing to settle for instructions on how
to behave. (Lupton, 1997) Instead the new consumer challenges his/her physician with questions
about how and why s/he is taking a treatment, rejecting traditional expectations that “patients”
will be passive. (Lupton, 1997; McDonald, Mead, Cheraghi-Sohi, Bower, Whalley, & Roland,
2007)
When individuals are behaving as consumers, expert knowledge in areas such as
medicine and science is no longer simply accepted at face value but rather is open to skepticism
and to challenge on the part of lay people due to an increasing public awareness of the
uncertainties in science (Beck, 1994; Lupton, 1997a). In the area of complementary and
alternative medicine, it has been shown that patients are unlikely to discuss their use of herbal
19
products with their doctor (Barnes, Mills, Abbot et al., 1998). This is often because of perceived
negative attitudes of the health care provider or a strained doctor-patient relationship (Barnes,
2002; Winslow & Shapiro, 2002). The ‘new consumer’ is defined as being: information strong,
information seeking, and increasingly demanding (Herzlinger, 1997; Traulsen, 2004). The
public is more literate, better educated, and has access to more information resources than in the
past (Traulsen, 2004). Canadians are also known to spend a lot of time doing research on
medical information via the internet (Zamaria, Caron, & Fletcher, 2005).
Consumerism has been found to represent a significant challenge to medicinal
surveillance. (Hibbert, Bissell, & Ward, 2002) Consumers seek out their own information
regarding NHPs and many turn to “less informed sources” such as family, friends or the internet
for advice, instead of consulting with a health care practitioner (Rowell & Kroll, 1998). It is
argued that consumers turn to informal networks for NHP information largely because they
believe that NHPs are “safe” because they are made from natural ingredients (Bailey, Cohen,
Steblecki, Boon, Kurata, & Jantzi, 2008; Boon, January 16, 2008; Brown, Barner, & Shah, 2005;
Miller, Hume, Harris et al., 2000; NHPD, 2005a), and can be trusted based on historical
acceptance/traditional use (Boon, January 16, 2008; Kondro, 2004; Miller, Hume, Harris et al.,
2000). This trend towards finding informal sources of information rather than discussing choices
with health care providers makes safety monitoring more difficult.
2.6.2.2 Market forces
Marketing theories provide yet another perspective that informs the study described in
this thesis because many NHPs are purchased in health food stores that are primarily guided by
market forces. Market force theories are focused on explaining factors such as market
transparency, warranty and the consumer experience of goods in consumer purchase decisions.
20
For example, marketing studies find that money-back guarantees are valuable to consumers
because they reduce the purchase risk of finding a good product match or a product of good
quality. These guarantees can signal a seller’s confidence in the quality of their products.
(McWilliams & Gerstner, 2006) The economic rationale for return policies is that of warranty.
Return policies insure customers against products that they are uncertain about, making risk-
averse customers willing to pay for the product. (Che, 1996) The “no-questions-asked” full
refund policy is customary with many retailers. In these cases, the rationale has to do with their
“experience good” nature. That is, customers don not fully know their preferences for the
products until after they gain some experience with them. (Che, 1996) Return policies allow
customers to defer their purchasing decisions until after gaining some experience with the
products. A customer who is dissatisfied can nullify his or her purchase decision by returning it.
In the case of herbal medicines, the uncertainty of the product’s benefit and the wide
range of product options may create uncertainty in the buyer’s mind. From a retailer’s
perspective, the strategy of offering a risk-free method to purchase self-prescribed NHPs, is an
important way to maintain a good customer relationship. This customer relationship then
facilitates friendship forming with the retailer, building trust and enabling a free flow of
information. (Price & Arnould, 1999) Relevant to this thesis is the flow of safety information and
the creation of a “safe” environment in which to discuss safety concerns.
2.6.2.3 Professions theory
A third perspective relevant to this thesis is that of professions theory. Pharmacists’
scope of practice (and the place of adverse event reporting therein) can be better understood by
drawing on Abbott’s system of professions theory and conceptualization of jurisdiction.
Jurisdiction refers to the link between a profession and its work. Abbott argues that members of
21
professions define their jurisdiction by claiming exclusive rights over particular tasks. (Abbott,
1988) In the case of ADR reporting, it is a task that was not claimed by pharmacists per se, but
instead was conferred upon them by Health Canada. Pharmacists are not claiming exclusive
rights over this task, it is a shared tenancy between pharmacists, medical doctors and other health
care professionals. It is not an obligatory requirement in Canada (although is in some countries),
but rather a voluntary act to be performed in the interest of advancing product knowledge and
safety of health care overall. Since Abbott describes a system of professions where the
allocation of tasks is negotiated and then exclusively claimed by one, his theory informs the
research, but is not enough to fully contextualize the findings.
Understanding professions theory is important in order to characterize pharmacists’ role
as health care providers in the area of NHP safety monitoring. However, Abbott and other
professions literature theorists explain professional conduct in terms of the entire profession,
perhaps in relation to other professions, as a whole and somewhat consistent unit. In ADR
reporting, it is important to recognize that pharmacists may act differently based on individual
characteristics or perceptions, despite what is expected of them as a pharmacist in that
profession. Thus, it is necessary to review one final theoretical perspective as guidance for this
study.
2.6.2.4 Bourdieu’s Theory of Practice
Although not a theoretical perspective that was originally used to deign the study,
Bourdieu’s theory of practice (Bourdieu, 1977) was identified near the end of data collection and
analysis to be a useful way of helping to understand the pharmacists’ descriptions of their beliefs
and behaviour. Bourdieu’s logic of practice emphasizes the importance of practices within the
social world. According to Bourdieu, people (who are social agents) operate according to an
22
implicit practical logic – a practical sense – and dispositions. That is, they act according to their
“feel for the game”, or their habitus within a particular field. For Bourdieu, the modern social
world is divided into “fields”, social arenas in which people maneuver and struggle in pursuit of
desirable resources, or capital. (Bourdieu, 1986) Habitus can be defined as a system of
dispositions (lasting, acquired schemes of perception, thought and action). Each individual
develops these dispositions in response to objective conditions her or she encounters. Bourdieu
developed a theory of the action, around the concept of habitus, which seeks to show that social
agents develop internal strategies that are adapted to the needs of the social worlds that they
inhabit. After examining the data from the pharmacist group, it was apparent that there seemed
to be a continuum of pharmacist practice behaviours. We had difficulty explaining pharmacists’
positions along this until we began using Bourdieu’s theory of practice. The concepts of habitus
and field helped to situate our findings within this theory and enabled us to explain pharmacist
behaviour in the context of ADR reporting. The usefulness of this theoretical perspective is
further developed in chapter 6.
2.7 Conclusions
Despite the existence of literature discussing ADRs and ADR reporting, with regards to
NHPs, there exists a considerable lack of definitive data on the safety profiles of these products.
Missed information due to lack of data collection ability for OTC products generally and in
particular for NHPs, makes regulation and monitoring extremely difficult. Compounding these
issues is the fact that consumers often believe that NHPs are safe and thus do not discuss them
with health providers prior to use. This results in the possibility of inappropriate dosage
regimens or possible drug interactions, resulting in particular from self-prescribing. This study is
needed to explore ADR reporting from consumer and retailer perspectives to understand key
23
themes and issues surrounding the barriers to improving our ability to collect information about
ADRs associated with herbal products. In-depth information is required, through qualitative
research, to allow a better understanding of the complexities involved in this topic.
24
2.8 Refere[FoP1]nces
Abbott, A. (1988). The System of Professions. An Essay on the Division of Expert Labor
Chicago: University of Chicago Press
Backstrom, M., Mjorndal, T., Dahlqvist, R. Under-reporting of serious adverse drug reactions in
Sweden. Pharmacoepidemiology and Drug Safety, 13(7): 483-487.
Bailey, T.M., Cohen, J.C., Steblecki, J.A., Boon, H.S., Kurata, C.V., & Jantzi, J.A. (2008).
Natural health product regulation in Canada: Recent changes, proposed changes and the
politico-legal dimensions. Pharmaceutical Finance, Economics and Policy, 17(2).
Barnes, J., Mills, S.Y., Abbot, N.C., Willoughby, M., & Ernst, E. (1998). Different standards for
reporting ADRs to herbal remedies and OTC medicines: face-to-face interviews with 515
users of herbal remedies. British Journal of Clinical Pharmacology, 45, 496-500.
Barnes, J. (2002). Pharmacists must not shun complementary health approaches. The
Pharmaceutical Journal, 268, 359.
Barnes, J. (2003). Pharmacovigilance of herbal medicines: a UK perspective. Drug Safety,
26(12), 829-851.
Beck, U. (1994). The reinvention of politics: towards a theory of reflexive modernization. In U.
Beck, Giddens, A., Lash, S. (Ed.), Reflexive Modernization: Politics, Tradition, and
Aesthetics in the Modern Social Order (pp. 1-55). Polity: Cambridge.
Bhaskar, R. (1975). A realist theory of science London: Verso
Bhaskar, R. (1989). The possibility of Naturalism Hemel Hempstead: Harvester Wheatsheaf
Boon, H. (January 16, 2008). Natural Health Product Regulations: Impact on Industry and
Consumers, PHM 1125 Week #2 Lecture. University of Toronto.
Bouldin, A., Smith, M., Garner, D., Szeinbach, S., Frate, D., & Croom, E. (1999). Pharmacy and
herbal medicine in the US. Social Science & Medicine, 49, 279-289.
Bourdieu, P. (1977). Outline of a Theory of Practice Cambridge: Cambridge University Press
Bourdieu, P. (1986). The forms of capital. In J.G. Richardson (Ed.), Handbook of theory and
research for the sociology of education (pp. 241-258). New York: Greenwood Press.
Brazier, N., & Levine, M. (2002). An evaluation of the quality of herbal product information
provided by health food store retailers and pharmacists in a Canadian city. Can J Clin
Pharmacol, 9(2), 108-109.
Brown, C.M., Barner, J.C., & Shah, S. (2005). Community Pharmacists' Actions When Patients
Use Complementary and Alternative Therapies with Medications. Journal of the
American Pharmacists Association, 45(1), 41-47.
Bunge, M. (1997). Mechanism and explanation. Philosophy of the Social Sciences, 47, 410-465.
Byrne, A. (2008). Natural health products (NHPs) and Canadian pharmacy students: core
competencies, Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy. Toronto:
University of Toronto.
Canadian Health Food Association (2005). Natural health products state of the industry report
2005: Backgrounder.
Chan, K. (2003). Some aspects of toxic contaminants in herbal medicines. Chemosphere, 52,
1361-1371.
Chang, Z.G., Kennedy, D.T., Holdford, D.A., & Small, R.E. (2000). Pharmacists' knowledge and
attitudes toward herbal medicine. The Annals of Pharmacotherapy, 34, 710-715.
Charrois, T., Hill, R., Vu, D., Foster, B., Boon, H., Cramer, K., & Vohra, S. (2005). Survey of
community pharmacist reporting of adverse drug reactions associated with natural health
25
products in CAM research in Canada: sharing successes and challenges - Abstracts from
the 2nd annual IN-CAM Symposium, November 12&13. Journal of Complementary and
Integrative Medicine, 2(1), Article 12.
Charrois, T.L., Hill, R.L., Vu, D., Foster, B.C., Boon, H.S., Cramer, K., & Vohra, S. (2007).
Community identification of natural health product-drug interactions. The Annals of
Pharmacotherapy, 41(7), 1124-1129.
Che, Y.-K. (1996). Customer return policies for experience goods. The Journal of Industrial
Economics, 44(March), 17-24.
Dasgupta, A., & Bernard, D.W. (2006). Herbal remedies: effects on clinical laboratory tests.
Arch Pathol Lab Med, 130(4), 521-528.
Dolder, C., Lacro, J., Dolder, N., & Gregory, P. (2003). Pharmacists' use of and attitudes and
beliefs about alternative medications. American Journal of Health-System Pharmacy, 60,
1352-1357.
Farrell, A.M., & Staughton, R.C. (1996). Garlic burns mimicking herpes zoster [letter]. Lancet,
347(9009), 1195.
Farrell, J., Ries, N.M., & Boon, H. (2008). Pharmacists and Natural Health Products: A
systematic analysis of professional responsibilities in Canada. Pharmacy Practice, 6(1),
33-42.
Fitzpatrick, K. (2004). Regulatory issues related to functional foods and natural health products
in Canada: possible implications for manufacturers of conjugated linoleic acid. American
Journal of Clinical Nutrition, 79(6S), 1217-1220.
Fleetwood, S. (2001). Causal laws, functional relations and tendencies. Review of the political
economy, 13(201-220).
Fletcher, A.P. (1991). Spontaneous adverse drug reaction reporting vs event monitoring: a
comparison. J R Soc Med, 84(6), 341-344.
Foster, B.C., Arnason, J.T., & Briggs, C.J. (2005). Natural health products and drug disposition.
Annual Review of Pharmacological Toxicology, 45, 203-226.
Glisson, J.K., Rogers, H.E., Abourashed, E.A., Ogletree, R., Hufford, C.D., & Khan, I. (2003).
Clinic at the health food store? Employee recommendations and product analysis.
Pharmacotherapy, 23(1), 64-72.
Granas, A.G., Buajordet, M., Stenberg-Nilsen, H., Harg, P., & Horn, A.M. (2007). Pharmacists'
attitudes towards the reporting of suspected adverse drug reactions in Norway.
Pharmacoepidemiology and Drug Safety, 16, 429-434.
Green, C.F., Mottram, D.R., Rowe, P.H., & Pirmohamed, M. (2001). Attitudes and knowledge of
hospital pharmacists to adverse drug reaction reporting. British Journal of Clinical
Pharmacology, 51, 81-86.
Harre, R. (1970). The principles of scientific thinking Oxford: Oxford University Press
Healey, B., Burgess, C., Siebers, R., Beasley, R., Weatherall, M., & Holt, S. (2002). Do natural
health food stores require regulation? N Z Med J, 115(1161), U165.
Health Canada, M.-D. (2005). Black cohosh: international reports of liver toxicity, Canadian
Adverse Reaction Newsletter (p. 4).
Health Canada (2007). Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Adverse Reaction Database: Health Canada.
Herdiero, M.T., Polonia, J., Gestal-Otero, J.J., & Figueiras, A. (2004). Factors that influence
spontaneous reporting of adverse drug reactions: A model centralized in the medical
professional. Journal of Evaluation in Clinical Practice, 10(4), 483-489.
26
Herzlinger, R.E. (1997). Market-driven health care: who wins, who loses in the transformation
of America's largest service industry New York: Addison-Wesley Publishing Co Inc.
Hibbert, D., Bissell, P., & Ward, P. (2002). Consumerism and professional work in the
community pharmacy. Sociology of Health & Illness, 24(1), 46-65.
Hsiao, A., Hays, R., Ryan, G., Coulter, I., Anderson, R., Hardy, M., Diehl, D., Hui, K., &
Wenger, N. (2005). A self-report measure of clinician's orientation toward integrative
medicine. Health Services Research, 40, 1553-1569.
Inman, W.H. (1985). Under-reporting of adverse drug reactions. British Medical Journal,
290(6478), 1355.
Inman, W.H. (1996). Attitudes to adverse drug reaction reporting. British Journal of Clinical
Pharmacology, 41, 434-435.
Ionnides, C. (2002). Pharmacokinetic interactions between herbal remedies and medicinal drugs.
Xenobiotica, 32, 451-478.
Irujo, M., Beitia, G., Bes-Rastrollo, M., Figueiras, A., Hernandez-Diaz, S., & Lasheras, B.
(2007). Factors that influence under-reporting of suspected adverse drug reactions among
community pharmacists in a Spanish region. Drug Safety, 30(11), 1073-1082.
Johnson, T. (2007). Canadian Pharmacy Students Knowledge of Herbal Medicine,
Pharmaceutical Sciences. Toronto: University of Toronto.
Kalaria, D. (2003). Complementary and Alternative Medicine: A Pharmacist's Perspective on
Patient Needs. HealthcarePapers, 3(5), 67-70.
Koh, H., & Woo, S. (2000). Chinese proprietary medicine in Singapore: regulatory control of
toxic heavy metals and undeclared drugs. Drug Safety, 23, 351-262.
Kondro, W. (2004). Natural health products: New labels, new credibility? Canadian Medical
Association Journal, 170(6), 941.
Koren, G., Oren, D., Rouleau, M., Carmeli, D., & Matsui, D. (2006) Comparison of verbal
claims for natural health products made by health food stores staff versus pharmacists in
Ontario, Canada. Can J Clin Pharmacol, 13(2): e251-256.
Kwan, D., Boon, H., Hirshkorn, K., Jurgens, T., Welsh, S., Cohen, J., Heschuk, S., & Eccott,
L.M. (2007). The professional responsibilities of pharmacists with respect to natural
health products: Focus group discussions with pharmacists and consumers. Canadian
Pharmacists Journal, 140(6), 377.
Kwan, D., Hirschkorn, K., Boon, H. (2006). U.S. and Canadian pharmacists' attitudes,
knowledge, and professional practice behaviors toward dietary supplements: a systematic
review. BMC Complementary and Alternative Medicine, 6, 31.
Lawson, T. (1994). A Realist Theory for Economics. In R. Backhouse (Ed.), New Directions in
Economic Methodology. New York: Routledge.
Lee, K.K., Chan, T.Y., Raymond, K., & Critchley, J.A. (1994). Pharmacists' attitudes toward
adverse drug reaction reporting in Hong Kong. Ann Pharmacother, 28(12), 1400-1403.
Lupton, D. (1997). Consumerism, reflexivity and the medical encounter. Social Science &
Medicine, 45(3), 373-381.
Lupton, D. (1997a). Consumerism, reflexivity, and the medical encounter. Social Science &
Medicine, 45(3), 373-381.
Mackowiak, E. (2003). Natural product education. American Journal of Pharmaceutical
Education, 67(1), 15-16.
Mann, R., & Andrews, E. (2002). Introduction. In R. Mann, & E. Andrews (Eds.),
Pharmacovigilance (pp. 3-10). Chicester, England: Wiley.
27
McDonald, R., Mead, N., Cheraghi-Sohi, Bower, P., Whalley, D., & Roland, M. (2007).
Governing the ethical consumer: identity, choice and the primary medical encounter.
Sociology of Health & Illness, 29(3), 430-456.
McEvoy, P., & Richards, D. (2003). Critical realism: a way forward for evaluation research in
nursing? Journal of Advanced Nursing, 43(4), 411-420.
McWilliams, B., & Gerstner, E. (2006). Offering lower price guarantees to improve customer
retention. Journal of Retailing, 82(2), 105-113.
Miller, L.G., Hume, A., Harris, I.M., Jackson, E.A., Kanmaz, T.J., Cauffield, J.S., Chin, T.W.E.,
& Knell, M. (2000). ACCP White Paper on Herbal Products. Pharmacotherapy, 20(7),
877-891.
Mills, E., Singh, R., Kawasaki, M., Bast, L., Hart, J., Majlesi, A., Kiani, P., & Wilson, K. (2003).
Emerging issues associated with HIV patients seeking advice from health food stores.
Can J Public Health, 94(5), 363-366.
Murray, E., Pollack, L., White, M., Lo, B. (2007) Clinical decision-making: Patients'
preferences and experiences. Patient Education and Counseling, 65: 189-196.
NHPD (2003). Natural health products regulations. In N.H.P. Directorate (Ed.): Health Canada.
NHPD (2005a). Baseline natural health products survey among consumers: Health Canada.
NHPD (2005b). Baseline Natural Health Products Survey Among Consumers, March 2005:
Ispos-Reid.
Pawson, R., & Tilley, N. (1997). Realistic Evaluation Thousand Oaks: Sage
Price, L.L., & Arnould, E.J. (1999). Commercial friendships: Service provider-client
relationships in context. Journal of Marketing, 63(October), 38-56.
Rogers, A.S., Israel, E., Smith, C.R., Levine, D., McBean, A.M., Valente, C., & Faich, G.
(1988). Physician knowledge, attitudes, and behavior related to reporting adverse drug
events. Arch Intern Med, 148(7), 1596-1600.
Rowell, D.M., & Kroll, D.J. (1998). Complementary and Alternative Medicine Education in
United States Pharmacy Schools. American Journal of Pharmaceutical Education, 62(4),
412-419.
Russell, B. (1945). A History of Western Philosophy And Its Connection with Political and
Social Circumstances from the Earliest Times to the Present Day. New York: Simon and
Schuster.
Sayer, A. (2000). Realism and social science London: Sage.
Schmidt, V.H. (2001). Oversocialized epistemology: a critical appraisal of constructivism.
Sociology, 35, 135-157.
Shaw, D., Leon, C., Kolev, S., & Murray, V. (1997). Traditional remedies and food supplements.
A 5-year toxicological study (1991-1995). Drug Safety, 17(5), 342-356.
Shields, K.M., McQueen, C.E., & Bryant, P.J. (2003). Natural Product Education in Schools of
Pharmacy in the United States. American Journal of Pharmaceutical Education, 67(1),
43-48.
Spinella, M. (2002). The importance of pharmacological synergy in psychoactive herbal
medicines. Alternative Medicine Review, 7, 130-137.
Sweis, D., & Wong, I.C.K. (2000). Adverse drug reaction reporting according to hospital
pharmacists in Great Britain. Drug Safety, 23(2), 165-172.
Traulsen, J.M., Noerreslet, M. (2004). The new consumer of medicine - the pharmacy
technicians' perspective. Pharmacy World & Science, 26, 203-207.
28
Welna, E., Hadsall, R., & Schommer, J. (2003). Pharmacists personal use, professional practice
behaviours, and perceptions regarding herbal and other natural products. Journal of the
American Pharmacists Association, 43(5), 602-610.
Wheaton, A., Blanck, H., Gizlice, Z., & Reyes, M. (2005). Medicinal herb use in a population-
based survey of adults: prevalence and frequency of use, reasons for use, and use among
their children. Annals of Epidemiology, 15, 678-685.
Williams, S.J. (2003). Beyond meaning, discourse and the empirical world: critical realist
reflections on health. Social Theory & Health, 1, 42-71.
Williamson, E. (2001). Synergy and other interactions in phytomedicines. Phytomedicine, 8,
401-409.
Wilson, V., & McCormack, B. (2006). Critical realism as emancipatory action: the case for
realistic evaluation in practice development. Nursing Philosophy, 7(1), 45-57.
Winslow, L., & Shapiro, H. (2002). Physicians want education about complementary and
alternative medicine to enhance communication with their patients. Arch Intern Med,
162, 1176-1181.
Wooltorton, E., & Sibbald, B. (2002). Ephedra/ephedrine: cardiovascular and CNS effects.
Canadian Medical Association Journal, 166(5), 633.
World Health Organization (1995). Note for guidance on clinical safety data management:
definitions and standards for expedited reporting, CPMP/ICH.377/95.
Zamaria, C., Caron, A.H., & Fletcher, F. (2005). Canada Online! A comparative analysis of
Internet users and non-users in Canada and the world: Behaviour, attitudes and trends
2004, World Internet Project: UCLA Center for Communication Policy.
29
CHAPTER 3. METHODS AND METHODOLOGY
3.1 Qualitative Methodology
Qualitative methods were best suited for this study because it was necessary to explore
retailer and consumer perspectives in sufficient depth to allow an understanding of the issues at
hand. Retailers and consumers had valuable experiences and exposure that shed light on this
complex issue, in particular because the population of herbal product users is so diverse (Park,
2005) and difficult to study. Additionally, herbal products themselves constitute a highly
contextualized category of medicines, in that they have their own unique classification and
perceptions associated with them. Consumers, health professionals and retailers alike have
different perspectives about natural products than they do about drugs. (Barnes, Mills, Abbot et
al., 1998; Health Canada, 2005; Hsiao, Hays, Ryan et al., 2005) Other pharmaceutical research is
therefore not directly applicable to the herbal medicine context. What is known from previous
literature is that people use herbal medicines, and that they experience adverse events. (Drew &
Myers, 1997b; Eisenberg, Davis, & Ettner, 1998; Health Canada, 2005) The gap in literature
consists of how those adverse events are experienced empirically and how they affect reporting
behaviour. (Bond & Hannaford, 2003; Ernst & Barnes, 1998) This study focused on retailer and
consumer insights as well as their reporting behaviours after exposure to an adverse event.
Qualitative methods are thus best suited for these unexplored, complex and contextualized
generative mechanisms.
3.2 Methods
This study employed semi-structured interviews (Creswell, 1998a), which were
conducted with retailers: pharmacists and health food store personnel; as well as consumers, in
order to discover how they understand the topic of adverse events and reporting systems. As per
30
our methodological paradigm, critical realism, the study was not designed as an investigation of
“what adverse events really are”, but instead focused on what retailers and consumers “claim to
know” about adverse events and their processes, as well as both groups respond to them. This
differentiation is essential to critical realism whereby there is a distinction made between what
reality is and how reality is interpreted.
3.2.1 Sample
The sample was purposefully selected in order to obtain a diverse range of opinions.
(Creswell, 1998a) Whilst seeking truth, critical realism recognizes that different representations
of truth can exist through different perspectives. (Dzurec & Abraham, 1993) Thus each
perspective, although potentially different, was seen as a valid account of the phenomena.
(Proctor, 1998) Interviews were conducted with pharmacists (n=12), health food store personnel
(n=12) and consumers (n=12). To be included in this study, participants had to satisfy the
following criteria:
Pharmacists
• Practicing in a community pharmacy that sells herbal products, within the Greater
Toronto Area.
• Able to conduct an interview in English.
Participants were selected to obtain a sample that included participants with a range of
number of years in practice, number of hours working per week, gender, training and
geographical location of work. Interviews took place between June 2006 and May 2007. Of the
pharmacists recruited: 9 of 12 were female, 8 had been in practice for over 5 years; 9 were
working full time; and 9 worked in a chain pharmacy.
Health food store personnel
31
• Working in a community health food store1 that sells herbal products, within the
Greater Toronto Area.
• Able to participate in an interview conducted in English.
Participants were selected to obtain a sample that included participants with a range of
number of years in the field, number of hours working per week, gender, position in the store
(managers, owners, sales clerks), and training and geographical location of work. Interviews
took place between July 2006 and June 2007.
Of the 12 health food store personnel recruited: 8 were female; 4 were owners or managers
while the rest were sales staff; 4 had worked for over 5 years in the business; 3 had formal
training in complementary and alternative medicine; 3 worked in a large chain, 4 worked in a
small chain and 5 worked in an independent health food store.
Consumers
• Have self-identified as having had an adverse event to a natural health product2
• Able to participate in an interview conducted in English.
We originally tried posters, listservs and other methods to obtain a sample of consumers that
had experienced a suspected adverse event and varied with respect to sociodemographic
characteristics. However, due to the difficulty in finding anyone who had experienced a
suspected adverse event that was willing to be interviewed, a purposive sample could not be
recruited. Instead, the project began with a convenience sample of contacts from friends and
colleagues, which was then expanded using the snowball technique to recruit enough participants
to reach theoretical saturation in the key emerging themes. The convenience sample of
1 Health food store was defined as any store that sold at least 50% natural health products, with or without foods,
including chain stores and independent stores, not including pharmacies, specialty stores (such as those that sold
only traditional Chinese medicines). 2 The definition of natural health product was taken to include anything that the patient identified as a natural health
product, not necessarily coinciding with Health Canada’s official definitions
32
participants from the university and the researchers’ social contacts were not key informants per
se, as they were not individuals who could provide unique insight into the experience of an
suspected NHP-related adverse event. However, the contacts were able to discuss the project
with family and friends, which led to recruiting of their contacts. The snowball technique is a
sampling strategy that consists of seeking referrals from participants, where one participant gives
the researcher the name of more possible participants. (Creswell, 1998a) This technique is used
in populations where it is difficult to identify potential participants. Interviews were conducted
in person where possible and over the phone for long-distance participants. Interviews took
place between September 2007 and December 2007.
Of the 12 consumers recruited: 11 were female; 4 described their reaction as mild while 5
described it as moderate and 3 described it as severe. Their ages ranged from 22-43 years.
3.3 Data Collection
A letter introducing the study was given to all participants (see Appendix A and B). After
several failed attempts at sending the letter by mail and by fax, potential participants were
approached in person at the respective retail outlets to deliver the letter. Consumers were
contacted by phone, email and in-person after a referral during the snowball technique. After
answering questions about the study, written informed consent (see C and D) was received by
each participant in-person, by mail or by fax and a mutually agreeable time was arranged to
conduct the interview. Telephone interviews were only conducted with the few consumers who
resided outside of the Greater Toronto Area. Otherwise, all other consumer interviews and all
retailer interviews were conducted in person.
Before the interview, the researcher: explained the purpose of the study; described the
amount of time it would take to complete the interview; informed the participant that they could
33
withdraw from the interview at any time or refuse to answer any questions; discussed how the
data would be used; explained that the interview would be transcribed; and addressed any
questions the participant may have had.
All interviews for this study ranged from 30 minutes to 90 minutes and data collection
continued until saturation was reached in key emerging themes. Saturation is the point at which
no new themes emerge from the data. (Guest, Bunce, & Johnson, 2006; Patton, 1990) Interviews
were audio-taped and transcribed verbatim.
Interview questions were developed based on key sensitizing concepts from the literature
on NHPs and ADR reporting. (See Appendix E and F) In addition, input from professionals in
the field (the thesis committee) was included and the semi-structured interview guide was
enhanced. After the first few interviews, interview questions were adjusted to include key
emerging topics for subsequent interviews based on the experiences from previous interviews.
While the questions covered the core areas of our interests, respondents were encouraged to add
their own comments and opinions. On completion of the interview, respondents were asked if
there was anything that they wanted to add or was there anything that was not discussed about
which they would like to comment.
3.4 Analysis
Interview transcripts were transcribed verbatim into written text and entered into a
qualitative computer software program NVivo 7 (Richards & Richards, 2002a) for analysis.
Participant responses to the semi-structured interview questions were analyzed using interpretive
content analysis (Huberman & Miles, 1994). Interpretive content analysis is an iterative process
that facilitates analysis of text describing processes, activities, perceptions and beliefs. It is these
processes, activities or beliefs that represent a collection of symbols expressing layers of
34
meaning. The analysis involved uncovering those layers of meaning and relationships among
phenomenon described by participants in order to understand the generative mechanisms behind
their actions.
The interview transcripts were analyzed for repetitive themes and relationships among these
themes. While the interview guide determined the general content of the interviews, the broad
range of themes and relationships among them could not be identified ahead of time but emerged
from the data analysis. Each transcript was coded independently by a minimum of two
investigators using content analysis (Huberman & Miles, 1994). The thesis committee also
reviewed the themes that emerged from interviews and provided input on the coding tree. (See
Appendix G, H, I and J) Data analysis was performed throughout the data collection period in
order to enable adjustments of the interview questions to address new issues or topics that
emerged from earlier interviews (Creswell, 1998b).
3.5 Privacy
All of the information collected for this study was kept strictly confidential. The
participants’ names were not used during the research process. A professional transcriber was
hired to transcribe interviews. The participants were identified by a unique study identifier code
to ensure privacy, and the names of persons and organizations identified in the interviews were
removed from the transcriptions. All of the data are kept on a password-protected computer
known only to the researchers. No information was released or printed that would disclose any
personal identity. Tape recordings and transcriptions will be kept in a secure locked cabinet for
eight years at the University of Toronto and will then be destroyed. To ensure confidentiality, no
names or identifying information will be presented with the quotations in any reports of study
results.
35
3.6 Methodological Issues
3.6.1 Positionality
A key facet of qualitative methodologies has been the importance of recognizing the role
that positionality plays in research. (Maton, 2003; Skelton, 2001) Positionality refers to those
aspects of identity, for example race and gender, which indicate the frames of reference from
which researchers collect, organize, disseminate and preserve information. (Waxman, 1993) As
the main instrument of the study, my position as the researcher has implications for how I might
regard and represent the world. This is so because my adopted position based on my position in
the field affects every phase of the research process, from the way I originally construct the
research question, design and conduct the study, to the ways in which reports and publications
arising from the study are presented. (Borbasi, Jackson, & Wilkes, 2005) I also have a
commitment to a particular social agenda, in this study, policy improvement. As the researcher,
my views and experiences will weigh heavily on my approach to interviewing, analysis and
interpretation. It is therefore necessary for me as a researcher to reflect upon my own identity
and positionality.
I am a female researcher, with South Asian heritage. I have graduate level education and
have been trained as a Naturopathic practitioner. My background, my training as a health care
professional and my specialty in complementary and alternative medicine will play a role both in
the data collection process as well as in my analysis. In the informed consent forms, my
designation as a Naturopathic Doctor and a PhD student were clear. When introducing myself to
participants, it was more productive with respect to recruitment to highlight my status as an ND
to health food store personnel and as a pharmacy graduate student to pharmacists. With respect
to consumers, I explained my position as a researcher. With regards to data collection, my
36
positionality may have consequences for the kind of knowledge that I may obtain, for instance in
relation to the underlying structures at work within my area of research.
For example, from the perspective of natural medicine, while I could be considered an
“insider” to health food store personnel for example, I might be considered an “outsider” to
pharmacists. This has implications for my recruitment process as well as the opinions that my
participants are willing to share. One pharmacist for example, agreed to participate without
knowing all the details of my background – he knew only of my position as a PhD student.
During the interview, he expressed a strong negative stance against herbal medicines. It is
possible that this perspective might not have been articulated if he had known more about my
position as a Naturopathic Doctor. In another instance, I contacted a health food store manager
to request an interview. During our conversation, I explained that I was a student in
Pharmaceutical Sciences and he seemed apprehensive about the interview. As we discussed the
research project, I mentioned my interest in herbs and my position as a Naturopath. He
immediately changed his tone and agreed to participate.
The above examples demonstrate how my position influenced the research process by
impacting generative mechanisms, which may be revealed or hidden during interactions with my
participants. These underlying structures or powers are not directly observable, but they
influence the actual and empirical levels of reality.
There has been some literature published on the topic of how position influences data
collection. Interviewees have been observed to respond differently to interviewers according to
their gender, age and social class. (Silverman, 1993; Warren, 1988) It is also important to note
that information given to the researcher might be different if the researcher is a health
professional. (Barnes, Mills, Abbot et al., 1998; Murphy, Dingwall, Greatbatch, Parker, &
37
Watson, 1998) These issues have already potentially impacted my study and as a result, I will
need to handle these positionality influences reflexively (discussed in the next section).
Another consideration is my viewpoint when evaluating the data. The characteristics of my
identity described above contribute to my specific and situated viewpoint. I have only a partial
view of the situation based on my position, and I act accordingly. Positionality can thus also be
viewed in terms of ‘spatial’ position. In critical realism, the more perspectives from which
something can be viewed, the better. This is because it would help to get a broader, more
complete picture of the situation by including different representations of reality. In the analysis
process, critical realism demands that I attempt to identify and characterize the actual and real
levels of reality by analyzing the empirical level. These experiences and perceptions of the
empirical level are relayed via semi-structured interviews from the participants. They constitute
both what the participants claim to know as well as my interpretation of their knowledge claims.
By using several data sources (from different populations), I enable a different ‘spatial’ position
whereby I can evaluate the social context of their interview responses. This gives me a different
perspective through which I can consider the data, thus enabling a more comprehensive analysis.
The different sources of data collection are thus used not for validation of the findings but
instead as different insights into reality. These sources of data will assist in identifying social
conflict, and other structural determinants of behaviour. In addition, the fact that more than one
person independently coded the data also validated the results.
3.6.2 Reflexivity
Reflexive research is characterized by ongoing self-critique and awareness that the research
product can be shaped by the politics of location and positioning. (Chatterjee, Noldner, Koch, &
Erdelmeier, 1998) It is a strategy to conceptualize whom the researcher is, what is going on
38
within her, and how a sense of self-consciousness can be put to analytical use. (Aamodt, 1991)
Hertz describes reflexivity as scrutiny of a researcher’s interpretations and how those
interpretations came about. (Hertz, 1997) The purpose of reflexivity is thus to enhance the
credibility of the findings by accounting for research values, beliefs, knowledge and biases. In
this study reflexivity will be used as a strategy for maintaining rigor and highlighting my
positionality. (Cutliffe, 2003; Hanly & Fitzpatrick-Hanly, 2001; Koch, 1994; Maggs-Rapport,
2001)
Critical realists believe that true scientific objectivity is unattainable. As society is
produced by social behaviour, they acknowledge that this behaviour is open to a number of
influences. (Proctor, 1998) Critical realists argue for more awareness of these influences rather
than for artificially controlling them. Awareness enables the researcher to reflect consciously on
his or her role and impact on the research environment and respondents, to develop greater
insight, and a greater ability to understand the phenomena. (Strauss & Corbin, 1990) According
to Hammersley, an account is valid if it represents accurately those features of the phenomena
that it is intended to describe, explain or theorize. (Hammersley, 1992) Given that from a critical
realist perspective we have no independent, immediate and utterly reliable access to reality, we
must judge the validity of claims on the basis of the adequacy of the evidence offered in support
of them. All judgments about the truth of knowledge claims rest on assumptions, many of which
we are not consciously aware of, and most of which have not been subjected to rigorous testing.
(Hammersley, 1991) This includes the knowledge claims that I, as a researcher, might make
about my study.
Rather than treating research findings as reproducing reality, we must recognize that they are
a representation of reality. (Hammersley, 1990) My representation will inevitably reflect the
39
assumptions that I bring to my analysis. As a result, I must make explicit the personal and
theoretical assumptions underpinning my work. (Murphy, Dingwall, Greatbatch et al., 1998) In
a critical realist study the goal is not to commit the “epistemic fallacy”; that is, not to confuse the
knowledge of what exists and that which does exist. Epistemic fallacy allows for the fallibility
of knowledge claims and opens knowledge claims to criticism, testing and the need for further
improvement. (Carolan, 2005) In order to minimize this fallibility of knowledge claims in my
study, reflexivity will be used as a strategy for maintaining rigor. From this perspective, I am
particularly concerned that I draw a distinction between my sense of reality and actual reality.
My perspective emerges from my interaction with the external world, and thus there is a clear
importance of an ‘internal conversation’ about myself, society and the relationship between us.
(Rosenthal, Hall, DiMatteo, Rogers, & Archer, 1979) I have realized that my assumptions are
not fixed. Over time they have changed with my progress in this project. It was important for
me to make my perspectives and assumptions explicit during data analysis in order to assess my
findings in light of these views.
In the present study, the focus is on generative mechanisms behind retailer and consumer
behaviours in response to adverse events. The retailer perceptions are a key part of the analysis
where I, as the researcher, examine not only the episode of interaction, but also the antecedent
conditions. (Rosenthal, Hall, DiMatteo et al., 1979) Retailers and consumers respond to certain
existing circumstances that have an objective existence, regardless of their perceptions. With
this in mind, my analysis was therefore discriminating to the nature of those participating in all
aspects of the social interaction. As the researcher, the main instrument of the study, my
participation in the social interaction was a key part of the context within which I sought to
collect information. Given my broad knowledge about natural medicine, as well as my health
40
care background, I had a responsibility to assess critically not only the participants’ perceptions,
but also my own. I have my own preconceived notions about the generative mechanisms behind
retailer behaviours and thus, it was necessary to evaluate my role and my beliefs analytically. I
have reservations for example, about the quality of education that health food store personnel
have in this field. One of my assumptions was that health food store personnel at the retail level
are not trained well enough to recommend herbal products. One of my interviews however, was
with a woman who opened a health food store after becoming certified as an herbalist and a
nutritionist. Unless I recognized and challenged my own ‘taken-for-granted’ assumptions, there
was a danger that I would fail to recognize that my participants might be drawing on a different,
but equally logical set of assumptions. (Murphy, Dingwall, Greatbatch et al., 1998) Without a
reflexive account I might have been blinded to important data.
Sayer argues that when a critical realist tries to elicit someone’s subjective beliefs about a
topic, she could say she is trying to objectively (truthfully) represent his or her opinion. (Sayer,
2000) Sayer also uses subjectivity to refer to the subjective quality of all knowledge. In other
words, what the researcher believes to be an objective account of the participant’s opinion is in
fact the researcher’s interpretation of the information received. Reflexivity therefore, is a
necessary process through which a researcher comes to understand how structural forces shape
us as individuals and as members of larger society. (Habermas, 1987)
3.6.3 Rigour
There are several ways to ensure rigour in qualitative research. First, the research
questions and methods used should match. (Eakin, 2003) In this study, interviews were deemed
most appropriate to explore participant responses to ADRs because interviews allow an open
dialogue between participant and researcher without ‘group effects’ such as those found in focus
41
group studies. Due to the sensitive nature of safety in a retail setting, ADR reporting, and
practice behaviours, it seemed more appropriate to have one-on-one conversations with retailers,
and pharmacists in particular, than group based discussions. Second, the sampling strategy has
been described fully in order to assure the reader that it matches the purpose of the research and
to allow others to assess whether the findings may be applicable to their settings. (Giacomini,
2000) In this study, a maximum variation sample was sought, in order to adequately capture all
possible perspectives. Third, the role of the researcher needs to be transparent. (Greenhalgh,
1997) In this study, time has been taken to examine the role of the researcher and explicitly
reflect on the position of the researcher and her role in the research process as well as the results.
This reflection allows for the researcher to be objective about her biases and interpret the data
more reliably when looking at it with her own opinions clarified. Fourth, during data analysis
two independent researchers coded each transcript and the entire research committee reviewed
the themes that emerged before the analysis or conclusions were drawn. (Giacomini, 2000) This
strategy of inter-rater evaluation is used in qualitative methods not only as a verification tool but
as a way to increase certainty in the emergent themes. Fifth, an audit trail was kept. (Koch,
1994) Records of any changes in the interview guide or coding tree as well as researcher
comments during and after the interviews were all noted and those notes maintained. This
strategy establishes trustworthiness in the data and the analysis.
3.7 Ethics
In applying for ethics approval, we considered four major ethical concerns: risk, benefit,
consent and confidentiality. The study did not involve direct risk to participants since no active
intervention was used. Participants were aware that participation was voluntary and that they
42
could withdraw from the study at any time. Participants were also free to skip any questions
with which they felt uncomfortable.
Benefit was explained as an opportunity to inform literature and policy on current ADR
issues and concerns. In addition, after participation, interviewees were given the opportunity to
ask about current reporting procedures and in order to gain knowledge on the subject. There was
no financial benefit to participants in the study.
Each participant gave written, informed consent to participate in the study (See Appendices
C and D). The consent form was explained prior to beginning the study and questions were
answered. Participants were informed that steps to ensure confidentiality would be taken.
Participants were identified in any written reports by numbers only, not by names. Any
identifying information was removed from the transcripts and all electronic files were kept
password protected, while hardcopy files were kept in a locked cabinet. Each participant was
aware that complete confidentiality could not be ensured if the interview took place in a public
environment, such as their office at work, where their co-workers might be aware of their
participation. However, each interview was conducted in a one-on-one manner in an attempt to
ensure that their answers were kept confidential.
This protocol received ethics approval from the Ethics Review Office at the University of
Toronto (See Appendix K).
3.8 Presentation of Results
Since this is a paper-based thesis, the results are presented as three distinct papers. Paper
1 (Chapter 4) focuses on the consumer data, paper 2 (Chapter 5) focuses on the health food store
personnel data and paper 3 (Chapter 6) focuses on the pharmacist data. The findings from the
three groups are compared and contrasted in the discussion (Chapter 7).
43
3.9 References
Aamodt, A.M. (1991). Ethnography and epistemology: Generating nursing knowledge. In J.M.
Morse (Ed.), Qualitative Nursing Research: A contemporary dialogue. Newbury Park ,
CA: Sage.
Abbott, A. (1988). The System of Professions. An Essay on the Division of Expert Labor
Chicago: University of Chicago Press
Bailey, T.M., Cohen, J.C., Steblecki, J.A., Boon, H.S., Kurata, C.V., & Jantzi, J.A. (2008).
Natural health product regulation in Canada: Recent changes, proposed changes and the
politico-legal dimensions. Pharmaceutical Finance, Economics and Policy, 17(2).
Barnes, J., Mills, S.Y., Abbot, N.C., Willoughby, M., & Ernst, E. (1998). Different standards for
reporting ADRs to herbal remedies and OTC medicines: face-to-face interviews with 515
users of herbal remedies. British Journal of Clinical Pharmacology, 45, 496-500.
Barnes, J. (2002). Pharmacists must not shun complementary health approaches. The
Pharmaceutical Journal, 268, 359.
Barnes, J. (2003). Pharmacovigilance of herbal medicines: a UK perspective. Drug Safety,
26(12), 829-851.
Beck, U. (1994). The reinvention of politics: towards a theory of reflexive modernization. In U.
Beck, Giddens, A., Lash, S. (Ed.), Reflexive Modernization: Politics, Tradition, and
Aesthetics in the Modern Social Order (pp. 1-55). Polity: Cambridge.
Bhaskar, R. (1975). A realist theory of science London: Verso
Bhaskar, R. (1989). The possibility of Naturalism Hemel Hempstead: Harvester Wheatsheaf
Bond, C., & Hannaford, P. (2003). Issues related to monitoring the safety of over-the-counter
(OTC) medicines. Drug Safety, 26(15), 1065-1074.
Boon, H. (January 16, 2008). Natural Health Product Regulations: Impact on Industry and
Consumers, PHM 1125 Week #2 Lecture. University of Toronto.
Borbasi, S., Jackson, D., & Wilkes, L. (2005). Fieldwork in nursing research: positionality,
practicalities and predicaments. Journal of Advanced Nursing, 51(5), 493-501.
Bouldin, A., Smith, M., Garner, D., Szeinbach, S., Frate, D., & Croom, E. (1999). Pharmacy and
herbal medicine in the US. Social Science & Medicine, 49, 279-289.
Bourdieu, P. (1977). Outline of a Theory of Practice Cambridge: Cambridge University Press
Bourdieu, P. (1986). The forms of capital. In J.G. Richardson (Ed.), Handbook of theory and
research for the sociology of education (pp. 241-258). New York: Greenwood Press.
Brazier, N., & Levine, M. (2002). An evaluation of the quality of herbal product information
provided by health food store retailers and pharmacists in a Canadian city. Can J Clin
Pharmacol, 9(2), 108-109.
Brown, C.M., Barner, J.C., & Shah, S. (2005). Community Pharmacists' Actions When Patients
Use Complementary and Alternative Therapies with Medications. Journal of the
American Pharmacists Association, 45(1), 41-47.
Bunge, M. (1997). Mechanism and explanation. Philosophy of the Social Sciences, 47, 410-465.
Byrne, A. (2008). Natural health products (NHPs) and Canadian pharmacy students: core
competencies, Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy. Toronto:
University of Toronto.
Canadian Health Food Association (2005). Natural health products state of the industry report
2005: Backgrounder.
44
Carolan, M.S. (2005). Society, Biology, and Ecology: Bringing nature back into Sociology's
disciplinary narrative through critical realism. Organization & Environment, 28(4), 393-
421.
Chan, K. (2003). Some aspects of toxic contaminants in herbal medicines. Chemosphere, 52,
1361-1371.
Chang, Z.G., Kennedy, D.T., Holdford, D.A., & Small, R.E. (2000). Pharmacists' knowledge and
attitudes toward herbal medicine. The Annals of Pharmacotherapy, 34, 710-715.
Charrois, T., Hill, R., Vu, D., Foster, B., Boon, H., Cramer, K., & Vohra, S. (2005). Survey of
community pharmacist reporting of adverse drug reactions associated with natural health
products in CAM research in Canada: sharing successes and challenges - Abstracts from
the 2nd annual IN-CAM Symposium, November 12&13. Journal of Complementary and
Integrative Medicine, 2(1), Article 12.
Charrois, T.L., Hill, R.L., Vu, D., Foster, B.C., Boon, H.S., Cramer, K., & Vohra, S. (2007).
Community identification of natural health product-drug interactions. The Annals of
Pharmacotherapy, 41(7), 1124-1129.
Chatterjee, S.S., Noldner, M., Koch, E., & Erdelmeier, C. (1998). Antidepressant activity of
hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry,
31(Supplement), 7-15.
Che, Y.-K. (1996). Customer return policies for experience goods. The Journal of Industrial
Economics, 44(March), 17-24.
Creswell, J. (1998a). Qualitative Inquiry and Research Design: Chosing Among Five Traditions
London: Sage
Creswell, J.W. (1998b). Qualitative Inquiry and Research Design. Choosing Among Five
Traditions Thousand Oaks, CA: Sage Publications, inc.
Cutliffe, J.R. (2003). Reconsidering reflexivity: introducing the case for intellectual
entrepreneurship. Qualitative Health Research, 13(1), 136-148.
Dasgupta, A., & Bernard, D.W. (2006). Herbal remedies: effects on clinical laboratory tests.
Arch Pathol Lab Med, 130(4), 521-528.
Dolder, C., Lacro, J., Dolder, N., & Gregory, P. (2003). Pharmacists' use of and attitudes and
beliefs about alternative medications. American Journal of Health-System Pharmacy, 60,
1352-1357.
Drew, A.K., & Myers, S.P. (1997). Safety issues in herbal medicine: implications for health
professions. Medical Journal of Australia (MJA), 166, 538-541.
Dzurec, L.C., & Abraham, I.L. (1993). The nature of inquiry: linking quantitative and qualitative
research. Advances in Nursing Science, 16, 73-79.
Eakin, J.M., & Mykhalovskiy, E. (2003). Reframing the evaluation of qualitative health research:
reflections on a review of appraisal guidelines in the health sciences. Journal of
Evaluation in Clinical Practice, 9(2), 187-194.
Eisenberg, D., Davis, R., & Ettner, S. (1998). Trends in alternative medicine use in the United
States, 1990-1997: results of a follow-up national survey. Journal of the American
Medical Association, 280(18), 1569-1575.
Ernst, E., & Barnes, J. (1998). Methodological approaches to investigating the safety of
complementary medicine. Complementary Therapies in Medicine, 6, 115-121.
Farrell, A.M., & Staughton, R.C. (1996). Garlic burns mimicking herpes zoster [letter]. Lancet,
347(9009), 1195.
45
Farrell, J., Ries, N.M., & Boon, H. (2008). Pharmacists and Natural Health Products: A
systematic analysis of professional responsibilities in Canada. Pharmacy Practice, 6(1),
33-42.
Fitzpatrick, K. (2004). Regulatory issues related to functional foods and natural health products
in Canada: possible implications for manufacturers of conjugated linoleic acid. American
Journal of Clinical Nutrition, 79(6S), 1217-1220.
Fleetwood, S. (2001). Causal laws, functional relations and tendencies. Review of the political
economy, 13(201-220).
Fletcher, A.P. (1991). Spontaneous adverse drug reaction reporting vs event monitoring: a
comparison. J R Soc Med, 84(6), 341-344.
Foster, B.C., Arnason, J.T., & Briggs, C.J. (2005). Natural health products and drug disposition.
Annual Review of Pharmacological Toxicology, 45, 203-226.
Giacomini, M.K., & Cook, D.J. (2000). Users' guides to the medical literature XXIII: Qualitative
research in health care. A. Are the results of the study valid? Journal of the American
Medical Association, 284, 357-362.
Glisson, J.K., Rogers, H.E., Abourashed, E.A., Ogletree, R., Hufford, C.D., & Khan, I. (2003).
Clinic at the health food store? Employee recommendations and product analysis.
Pharmacotherapy, 23(1), 64-72.
Granas, A.G., Buajordet, M., Stenberg-Nilsen, H., Harg, P., & Horn, A.M. (2007). Pharmacists'
attitudes towards the reporting of suspected adverse drug reactions in Norway.
Pharmacoepidemiology and Drug Safety, 16, 429-434.
Green, C.F., Mottram, D.R., Rowe, P.H., & Pirmohamed, M. (2001). Attitudes and knowledge of
hospital pharmacists to adverse drug reaction reporting. British Journal of Clinical
Pharmacology, 51, 81-86.
Greenhalgh, R., & Taylor, R. (1997). Ppaers that go beyond numbers (qualitative research).
British Medical Journal, 315, 740-743.
Guest, G., Bunce, A., & Johnson, L. (2006). How many interviews are enough?: An experiment
with data saturation and variability. Field Methods, 18, 59-82.
Habermas, J. (1987). Knowledge and Human Interests Cambridge: Polity Press
Hammersley, M. (1990). Reading ethnographic research New York: Longman
Hammersley, M. (1991). Reading Ethnographic Research London: Longman
Hammersley, M. (1992). What's wrong with ethnography? London: Routledge
Hanly, C., & Fitzpatrick-Hanly, M.A. (2001). Critical realism: distinguishing the psychological
subjectivity of the analyst from epistemological subjectivism. Journal of the American
Psychoanalytic Association, 49(2), 515-533.
Harre, R. (1970). The principles of scientific thinking Oxford: Oxford University Press
Healey, B., Burgess, C., Siebers, R., Beasley, R., Weatherall, M., & Holt, S. (2002). Do natural
health food stores require regulation? N Z Med J, 115(1161), U165.
Health Canada, M.-D. (2005). Black cohosh: international reports of liver toxicity, Canadian
Adverse Reaction Newsletter (p. 4).
Health Canada (2005). Baseline Natural Health Products Survey Among Consumers, March
2005: Natural Health Products Directorate.
Health Canada (2007). Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Adverse Reaction Database: Health Canada.
46
Herdiero, M.T., Polonia, J., Gestal-Otero, J.J., & Figueiras, A. (2004). Factors that influence
spontaneous reporting of adverse drug reactions: A model centralized in the medical
professional. Journal of Evaluation in Clinical Practice, 10(4), 483-489.
Hertz, R. (1997). Reflexivity and voice Thousand Oaks, CA: Sage
Herzlinger, R.E. (1997). Market-driven health care: who wins, who loses in the transformation
of America's largest service industry New York: Addison-Wesley Publishing Co Inc.
Hibbert, D., Bissell, P., & Ward, P. (2002). Consumerism and professional work in the
community pharmacy. Sociology of Health & Illness, 24(1), 46-65.
Hsiao, A., Hays, R., Ryan, G., Coulter, I., Anderson, R., Hardy, M., Diehl, D., Hui, K., &
Wenger, N. (2005). A self-report measure of clinician's orientation toward integrative
medicine. Health Services Research, 40, 1553-1569.
Huberman, A.M., & Miles, M.B. (1994). Data management and analysis methods. In N.K.
Denzin, & Y.S. Lincoln (Eds.), Handbook of Qualitative Research (pp. 428-444).
Thousand Oaks: Sage Publications.
Inman, W.H. (1985). Under-reporting of adverse drug reactions. British Medical Journal,
290(6478), 1355.
Inman, W.H. (1996). Attitudes to adverse drug reaction reporting. British Journal of Clinical
Pharmacology, 41, 434-435.
Ionnides, C. (2002). Pharmacokinetic interactions between herbal remedies and medicinal drugs.
Xenobiotica, 32, 451-478.
Irujo, M., Beitia, G., Bes-Rastrollo, M., Figueiras, A., Hernandez-Diaz, S., & Lasheras, B.
(2007). Factors that influence under-reporting of suspected adverse drug reactions among
community pharmacists in a Spanish region. Drug Safety, 30(11), 1073-1082.
Johnson, T. (2007). Canadian Pharmacy Students Knowledge of Herbal Medicine,
Pharmaceutical Sciences. Toronto: University of Toronto.
Kalaria, D. (2003). Complementary and Alternative Medicine: A Pharmacist's Perspective on
Patient Needs. HealthcarePapers, 3(5), 67-70.
Koch, T. (1994). Establishing rigour in qualitative research: the decision trail. Journal of
Advanced Nursing, 19, 976-986.
Koh, H., & Woo, S. (2000). Chinese proprietary medicine in Singapore: regulatory control of
toxic heavy metals and undeclared drugs. Drug Safety, 23, 351-262.
Kondro, W. (2004). Natural health products: New labels, new credibility? Canadian Medical
Association Journal, 170(6), 941.
Kwan, D., Boon, H., Hirshkorn, K., Jurgens, T., Welsh, S., Cohen, J., Heschuk, S., & Eccott,
L.M. (2007). The professional responsibilities of pharmacists with respect to natural
health products: Focus group discussions with pharmacists and consumers. Canadian
Pharmacists Journal, 140(6), 377.
Kwan, D., Hirschkorn, K., Boon, H. (2006). U.S. and Canadian pharmacists' attitudes,
knowledge, and professional practice behaviors toward dietary supplements: a systematic
review. BMC Complementary and Alternative Medicine, 6, 31.
Lawson, T. (1994). A Realist Theory for Economics. In R. Backhouse (Ed.), New Directions in
Economic Methodology. New York: Routledge.
Lee, K.K., Chan, T.Y., Raymond, K., & Critchley, J.A. (1994). Pharmacists' attitudes toward
adverse drug reaction reporting in Hong Kong. Ann Pharmacother, 28(12), 1400-1403.
Lupton, D. (1997). Consumerism, reflexivity and the medical encounter. Social Science &
Medicine, 45(3), 373-381.
47
Lupton, D. (1997a). Consumerism, reflexivity, and the medical encounter. Social Science &
Medicine, 45(3), 373-381.
Mackowiak, E. (2003). Natural product education. American Journal of Pharmaceutical
Education, 67(1), 15-16.
Maggs-Rapport, F. (2001). 'Best research practice': in pursuit of methodological rigour. Journal
of Advanced Nursing, 35(3), 373-383.
Mann, R., & Andrews, E. (2002). Introduction. In R. Mann, & E. Andrews (Eds.),
Pharmacovigilance (pp. 3-10). Chicester, England: Wiley.
Maton, K. (2003). Reflexivity, relationism & research: Pierre Bourdieu and the epistemic
conditions of social scientific knowledge. Space & Culture, 6(1), 52-65.
McDonald, R., Mead, N., Cheraghi-Sohi, Bower, P., Whalley, D., & Roland, M. (2007).
Governing the ethical consumer: identity, choice and the primary medical encounter.
Sociology of Health & Illness, 29(3), 430-456.
McEvoy, P., & Richards, D. (2003). Critical realism: a way forward for evaluation research in
nursing? Journal of Advanced Nursing, 43(4), 411-420.
McWilliams, B., & Gerstner, E. (2006). Offering lower price guarantees to improve customer
retention. Journal of Retailing, 82(2), 105-113.
Miller, L.G., Hume, A., Harris, I.M., Jackson, E.A., Kanmaz, T.J., Cauffield, J.S., Chin, T.W.E.,
& Knell, M. (2000). ACCP White Paper on Herbal Products. Pharmacotherapy, 20(7),
877-891.
Mills, E., Singh, R., Kawasaki, M., Bast, L., Hart, J., Majlesi, A., Kiani, P., & Wilson, K. (2003).
Emerging issues associated with HIV patients seeking advice from health food stores.
Can J Public Health, 94(5), 363-366.
Murphy, E., Dingwall, R., Greatbatch, D., Parker, S., & Watson, P. (1998). Qualitative research
methods in health technology assessment: a review of the literature. Health Technology
Assessment, 2(16), 167-198.
NHPD (2003). Natural health products regulations. In N.H.P. Directorate (Ed.): Health Canada.
NHPD (2005a). Baseline Natural Health Products Survey Among Consumers, March 2005:
Ispos-Reid.
NHPD (2005b). Baseline natural health products survey among consumers: Health Canada.
Park, J. (2005). Use of alternative health care. Health Reports, 16(2), 39.
Patton, M.Q. (1990). Qualitative Evaluation and Research Methods Newbury Park: SAGE
Publications, Inc.
Pawson, R., & Tilley, N. (1997). Realistic Evaluation Thousand Oaks: Sage
Price, L.L., & Arnould, E.J. (1999). Commercial friendships: Service provider-client
relationships in context. Journal of Marketing, 63(October), 38-56.
Proctor, S. (1998). Linking philosophy and method in the research process: the case for realism.
Nurse Researcher, 5, 73-89.
Richards, L., & Richards, T. (2002). NVivo 2.0 [Software for qualitative research]. Melbourne:
QSR Solutions.
Rogers, A.S., Israel, E., Smith, C.R., Levine, D., McBean, A.M., Valente, C., & Faich, G.
(1988). Physician knowledge, attitudes, and behavior related to reporting adverse drug
events. Arch Intern Med, 148(7), 1596-1600.
Rosenthal, R., Hall, J.A., DiMatteo, M.R., Rogers, P.L., & Archer, D. (1979). Sensitivity to
Nonverbal Communication: The Pons Test Baltimore: The Johns Hopkins
University Press
48
Rowell, D.M., & Kroll, D.J. (1998). Complementary and Alternative Medicine Education in
United States Pharmacy Schools. American Journal of Pharmaceutical Education, 62(4),
412-419.
Sayer, A. (2000). Realism and social science London: Sage
Schmidt, V.H. (2001). Oversocialized epistemology: a critical appraisal of constructivism.
Sociology, 35, 135-157.
Shaw, D., Leon, C., Kolev, S., & Murray, V. (1997). Traditional remedies and food supplements.
A 5-year toxicological study (1991-1995). Drug Safety, 17(5), 342-356.
Shields, K.M., McQueen, C.E., & Bryant, P.J. (2003). Natural Product Education in Schools of
Pharmacy in the United States. American Journal of Pharmaceutical Education, 67(1),
43-48.
Silverman, D. (1993). Interpreting qualitative data: methods for analysing talk, text and
interaction London: Sage
Skelton, T. (2001). Cross-cultural research: issues of power, positionality and "race". In M.
Limb, & C. Dwyer (Eds.), Qualitative methodologies for geographers. Issues and
debates. London: Arnold.
Spinella, M. (2002). The importance of pharmacological synergy in psychoactive herbal
medicines. Alternative Medicine Review, 7, 130-137.
Strauss, A., & Corbin, J. (1990). Basics of qualitative research: Grounded theory procedures
and techniques Newbury Park: SAGE Publications, Inc.
Sweis, D., & Wong, I.C.K. (2000). Adverse drug reaction reporting according to hospital
pharmacists in Great Britain. Drug Safety, 23(2), 165-172.
Traulsen, J.M., Noerreslet, M. (2004). The new consumer of medicine - the pharmacy
technicians' perspective. Pharmacy World & Science, 26, 203-207.
Warren, C. (1988). Gender issues in field research Newbury Park, CA: Sage
Waxman, B.F. (1993). Multicultural literatures through feminist/poststructuralist lenses
Knoxville: University of Tennessee
Welna, E., Hadsall, R., & Schommer, J. (2003). Pharmacists personal use, professional practice
behaviours, and perceptions regarding herbal and other natural products. Journal of the
American Pharmacists Association, 43(5), 602-610.
Wheaton, A., Blanck, H., Gizlice, Z., & Reyes, M. (2005). Medicinal herb use in a population-
based survey of adults: prevalence and frequency of use, reasons for use, and use among
their children. Annals of Epidemiology, 15, 678-685.
Williams, S.J. (2003). Beyond meaning, discourse and the empirical world: critical realist
reflections on health. Social Theory & Health, 1, 42-71.
Williamson, E. (2001). Synergy and other interactions in phytomedicines. Phytomedicine, 8,
401-409.
Wilson, V., & McCormack, B. (2006). Critical realism as emancipatory action: the case for
realistic evaluation in practice development. Nursing Philosophy, 7(1), 45-57.
Winslow, L., & Shapiro, H. (2002). Physicians want education about complementary and
alternative medicine to enhance communication with their patients. Arch Intern Med,
162, 1176-1181.
Wooltorton, E., & Sibbald, B. (2002). Ephedra/ephedrine: cardiovascular and CNS effects.
Canadian Medical Association Journal, 166(5), 633.
World Health Organization (1995). Note for guidance on clinical safety data management:
definitions and standards for expidited reporting, CPMP/ICH.377/95.
49
Zamaria, C., Caron, A.H., & Fletcher, F. (2005). Canada Online! A comparative analysis of
Internet users and non-users in Canada and the world: Behaviour, attitudes and trends
2004, World Internet Project: UCLA Center for Communication Policy.
50
CHAPTER 4. RESULTS – CONSUMER INTERVIEWS
Preamble
This chapter was submitted for publication to Patient Education and Counseling on June 27,
2008; it is currently undergoing peer-review.
I, Rishma Walji, performed the entire work as published, under the guidance of Dr.
Heather Boon, Dr. Joanne Barnes, Dr. Zubin Austin, Dr. Sandy Welsh and Dr. G. Ross Baker.
Consumers and herbal-related adverse reactions
4.1 Abstract
Objective: Natural health products (NHPs), such as herbal medicines and vitamins, are widely
available over-the-counter and are often purchased by consumers without medical advice. This
study examined how consumers respond when they experience NHP-related adverse drug
reactions (ADRs).
Methods: Qualitative semi-structured interviews were conducted with 12 consumers who had
experienced a self-identified NHP ADR. Key emergent themes were identified and coded using
content analysis techniques.
Results: Consumers were generally reluctant to discuss their NHP-related ADRs with healthcare
providers. When consumers did discuss them, or seek advice, they generally did not turn to
healthcare providers but rather personnel from health food stores, friends or family with whom
they had developed trusted relationships.
Conclusion: Consumers generally did not report their ADR information to healthcare providers.
Passive reporting systems for collecting information on NHP ADRs cannot be effective if
consumers who experience NHP ADRs do not report their experiences.
51
Practice implications: It is important for healthcare providers to develop good communication
practices with their patients regarding their choices to take NHPs. This positive interaction can
facilitate future discussions if ADRs do occur.
52
4.2 Introduction
Despite the popular belief that herbal medicines and other natural health products (NHPs)
are safe, these products are pharmacologically active and therefore have inherent risk. The need
to understand adverse drug reactions (ADRs) associated with NHPs is increasing now that over
60% of all North Americans report using some form of complementary and alternative medicine
(CAM) (including herbal medicines) in the management of their health. (Center for Disease
Control, 2004; NHPD, 2005) In the United Kingdom, CAM use is estimated at approximately
20%, while in Germany, CAM prevalence rates approach 60%. (Ernst, 2000)
An ADR is a noxious and unintended response to a particular medicinal product, meaning
that there is a reasonable possibility that there is a causal relationship between the product and
the reaction. (World Health Organization, 1995) In Canada, Health Canada collects ADR reports
from healthcare professionals (and less often from consumers) about NHPs through the Canada
Vigilance Program. (Health Canada, 2007) Similar systems exist in most other Western
countries; however, experiences of (and the incidence of) herbal medicine-related ADRs are
difficult to determine because under-reporting of suspected ADRs, a known problem with all
passive reporting systems (Waller & Tilson, 2004), may be more substantial for NHPs than for
conventional drugs. (Barnes, 2003)
One of the reasons for under-reporting of NHP-related ADRs may be that many
consumers believe NHPs are safe because they originate from natural ingredients. (NHPD,
2005) Consumers frequently self-prescribe NHPs, without the advice of a qualified health
provider. (Murray, Pollack, White, & Lo, 2007) Increasing consumerism, an environment in
which individuals are taking their health matters into their own hands, partly explains this.
(Alaszewski & Brown, 2007) Instead of passively following the advice of health providers,
53
individuals shop around for opinions and advice and increasingly challenge healthcare
practitioners with questions about treatments. (Lupton, 1997) If consumers do not find the
answers that they want from their health providers, they will turn to other sources of information
that they feel are trustworthy or informative, such as the internet.
Since NHPs are non-prescription medicines, experiences of herbal-related ADRs must be
reported by consumers to healthcare professionals, or directly by consumers to Health Canada, to
be captured by the national reporting system. Since many consumers self-prescribe NHPs, it is
perhaps not surprising that consumers appear less likely to report ADRs associated with herbal
medicines to their healthcare providers than those associated with conventional over-the-counter
drugs. (Barnes, Mills, Abbot, Willoughby, & Ernst, 1998) In this study, experiences of
consumers who have what they believe to be an NHP-related ADR and their reasons for
choosing to report (or not report) their reactions are investigated.
4.3 Methods
Ethics approval was granted by the Research Ethics Board at the University of Toronto.
Twelve in-depth semi-structured interviews were conducted from September 2007 to December
2007 with NHP consumers who had experienced a self-identified ADR associated with an NHP.
The participants were recruited from the Greater Toronto area, Ottawa and Vancouver through
posters and advertisements as well as through a snowball sampling technique (in which
participants were asked to identify other potential participants within their social circles).
(Creswell, 1998) Interviews were recorded and field notes were hand-written during and
immediately following the interviews. Interviews were transcribed so that the transcriptions and
field notes could be coded by two independent coders using content analysis techniques;
disagreement was resolved through in-depth discussion. A software program, NVIVO 7, was
54
used to organize the data. (Richards & Richards, 2002) Data analysis and coding took place
throughout the process of data collection. The interview guide was updated and modified after
the coding sessions to allow for increasingly detailed data collection in key emerging themes.
Theoretical saturation of the key themes was achieved after 12 interviews. (Creswell, 1998)
4.4 Results
Participants varied in age and demographic background and had experienced a range of
different suspected NHP-related ADRs (see Table 1). The final sample was predominantly
female, and highly educated.
Participants described their ADRs by degree of severity – mild, moderate or severe. In
medical terminology, ADRs are classified by degree of severity and also as serious or non-
serious. Serious reactions are those that are fatal, life threatening (such as liver failure, abnormal
heart rhythms, certain types of allergic reactions), result in persistent or significant disability or
incapacity, require or prolong hospitalization, are congenital anomalies or birth defects, or are
otherwise medically important. (World Health Organization, 1995) All the ADRs experienced
by the participants in this study were non-serious, but differed in degree of severity. For details,
see Table 1.
The main categories used to classify the themes from this research were: 1) how
participants first identified their ADRs and associated them with their NHP treatments; 2) what
influenced their likelihood of reporting the suspected ADR to someone; 3) with whom they
discussed the suspected ADR. The last two themes were further sub-divided into: taking
responsibility for self-prescribing, trust, and access.
4.4.1 Identifying the ADR
Most participants chose the NHPs that they associated with ADRs without advice or
monitoring from a healthcare provider. Thus, when they experienced the ADR, they took it upon
55
themselves to interpret the reaction and then to decide how they would act. The main themes in
this section related to participants methodically evaluating their reactions in order to determine
the cause. They identified that the symptoms they were experiencing were likely related to the
NHP after considering the possibility of alternative explanations for the symptoms, for example,
changes in lifestyle or behaviour. They also proactively explored causality, for example, by
trying a different product and, in some cases, stopping (de-challenge) and then re-starting (re-
challenge) the product:
Question: How did you decide that it was the product that caused these things?
Answer: I guess because I’d never taken it before. In terms of actually, like, change in
my routine as what I was eating or whatever, that was the only thing I could attribute it
to. (Consumer #12)
From using one brand and then switching to another, the fact that they were different
brands but they were the same ingredients I was using. They contained the same things.
I was just trying another brand and I was still getting the same symptoms and then I also
linked it because just at this time when I was taking it, I wasn’t taking any other products
at that time. (Consumer #4)
4.4.2 Likelihood of reporting
Participants’ perceived severity of their ADR influenced the likelihood that they would
seek help or support. If they perceived the reaction to be mild, they would generally attempt to
mitigate the symptoms independently. If the reactions were perceived as being severe, they were
more likely to seek information about what action to take from a third party:
Question: What would make you more likely to talk to someone about your reaction?
Answer: I suppose a cardiac event, like, for sure you would want to tell somebody about
that. I think that would be significant. If you broke out into a rash, you should probably
tell somebody about that. If a product, you know, made you nauseous or dizzy or
something like that, you might want to mention that to somebody as well. (Consumer #7)
If the adverse event is mild then it just won’t come up, but if it is severe [meaning
serious] and it’s an emergency situation or if it has ongoing repercussions in health then
it’s vital that they be disclosed. (Consumer #5)
56
Interestingly, some participants who experienced what they defined as serious ADRs still did
not report the reaction to anyone or seek advice about what to do. Reasons for this are explored
below.
4.4.3 Responsibility for self-prescribing
Most participants reported self-prescribing NHPs. Consumers’ decisions regarding how to
respond to NHP-related ADRs depended largely on whether or not the participants believed
themselves to be responsible for the decision to initiate treatment with the NHP without medical
advice. Many felt that since they had independently made the decision to take NHPs, they also
had a responsibility to “deal with” the negative consequences of that decision on their own:
We often combine products in a way that it can be detrimental to our health and I believe
that this adverse reaction had to do with that more than the product itself… so that just
has to do with irresponsible consumption... So yeah, the adverse reaction is my problem.
(Consumer #5)
I mean I told my doctor about the [pharmaceutical medication] because he was the person
who prescribed it to me. I didn’t tell anybody about the [NHP] because nobody
prescribed it to me so I thought, well, I guess I didn’t think that I should tell anyone. I
think I just didn’t think I should tell anybody! (Consumer #7)
4.4.4 Trust
Two sub-themes under the category of trust were that consumers experiencing NHP-
related ADRs did not report because they did not know who to talk to and/or have anyone they
felt they could trust. The decision not to discuss their NHP-related ADR experiences with others
was typically related to an effort to hide their actions from people (often physicians) who they
perceived would disapprove of their use of NHPs:
I didn’t tell anyone because there wasn’t anyone really to tell about it because I was more
sort of trying things on my own. After I figured out what was going on I knew it was me
doing it to me, by choosing to take it, I knew that that I was the cause of it but my doctor
wouldn’t do anything about it and she would just kind of blow it off so, there would be
no point in taking it to her because I just didn’t have a therapeutic relationship with her.
(Consumer #10)
57
Well our family doctor is, sort of, you know, she likes to take things lightly, so in a sense
sometimes I feel like I shouldn’t even go so I should wait things out before I talk to her
about them because I feel like she’s just going to say the same thing to me, like, oh well,
whatever, just go home and have some rest and it will be okay. It’s a matter of, there
hasn’t been the time, the time has not been permitted to go into much detail about it.
(Consumer #7)
These quotes illustrate the poor relationships many participants had with their
conventional medical practitioners, especially when discussing issues associated with NHPs.
Most were of the opinion that their healthcare providers (most often physicians and pharmacists)
would not support their decisions to try NHPs and this resulted in a lack of communication about
suspected NHP-related ADRs:
It lasted all day and you know, I had to give my job interview and stuff so I just was in
complete discomfort all day. So I tried to go to the pharmacy and get something… it was
a natural product so I knew that it was, like, kind of sketchy already in [the pharmacists’]
opinion and so, then her initial reaction when I said [what had happened], I was like,
there’s no need for me to discuss this any further. (Consumer #1)
If participants thought their friends and family would understand their decision to use
NHPs, they might share their NHP-related ADR experiences with people in their social network.
Other participants, who wanted reassurance or guidance about their experiences, would find
other advisors whom they felt that they could trust.
I’ve had a doctor tell me that I [the doctor] don’t really believe in all that [NHP] stuff. So
I personally wouldn’t bother telling them about my adverse effects. I’d probably just tell
the naturopath, or the health food store. (Consumer #4)
Consumers discussed the possibility of approaching other resources such as retailers at
the location where they purchase NHPs, usually pharmacists and health food store personnel.
Overall, they seemed not to have strong relationships with their pharmacists, which negatively
affected their likelihood of reporting ADRs to pharmacists.
Let’s say that I buy something from [drug store name], if I’m not happy with it generally
if I can’t return it, or if I’ve used it, I probably wouldn’t take it back or take any type of
concern to that particular store because I feel like the people that work there would not
58
necessarily not care but that they just don’t want to deal with that kind of thing. They
have so many other things that they’re selling in that store. It’s just not, it’s not an open
and friendly environment to bring stuff to. With regards to smaller stores, smaller health
food stores, it’s an environment where the owner always tries to have a good customer
relationship. (Consumer #10)
Participants tended to trust their health food store personnel and often had developed
good relationships with the staff working in these retail settings. Consumers reported reliance on
the health food store staff for information and feeling comfortable talking to them about side
effects or problems with their products.
I would trust [staff] more from a health food store because they do - usually the owners
of the store have good information and have some knowledge whereby the pharmacies
would have nothing, and a pharmacist would probably bash it down anyway! (Consumer
#3)
4.4.5 Access
The final theme related to reporting NHP-related ADRs identified by participants was a
concern about access. Several participants were concerned about reporting NHP-related ADRs
due to fear that the products would be removed from the market if there were reports that they
caused negative effects.
It is the only product that I’ve found effective for my health condition. It is something
that I feel when used responsibly it doesn’t cause an adverse reaction. There’s a synthetic
version of it that has really caused a lot of the hype, and there have been some publicized
adverse events related to the herb that do have to do with a combination of things. You
know that it shouldn’t be mixed with certain other things. Some adverse reactions have
to do with that more than the product itself. And due to this, I think that it jeopardizes the
status of products that may be required for certain health conditions and so that just has to
do with irresponsible consumption, or production depending on who’s at fault for that.
(Consumer #7)
Although Health Canada does accept direct reporting of suspected ADRs by consumers,
the consumers interviewed did not seem to know that was an option. The only ones who were
aware of their ability to independently report their suspected ADRs were told by their health
59
providers, or personally had some kind of health care training and were exposed to the reporting
scheme through their professions.
4.5 Discussion
Participants in this study all experienced what they perceived to be an ADR associated
with an NHP. The products were usually self-prescribed and most participants decided either to
handle the situation on their own or, less commonly, to discuss it with someone whom they
trusted. The trusted person was typically someone working in a health food store rather than a
conventional healthcare provider. Participants’ behavioural responses to experiencing an NHP-
related ADR were based partly on their perceptions of the severity of the reaction, reflecting the
importance of individual perceptions in reporting ADRs.
While the demographic profile of the participants in this study is clearly not
representative of the Canadian population, it resembles the average demographic characteristics
of those who use NHPs. (Park, 2005) The diversity of the products used and types of suspected
ADRs enabled an analysis of a range of experiences and saturation in the key themes.
The results of this study indicate that participants were able to identify suspected ADRs
linked to particular NHPs. In fact, the thought processes they used to identify ADRs was
sophisticated in many cases and mirrors the adjudication process used by
ADR/pharmacovigilance experts to determine the likelihood that symptoms are caused by a
specific product including: reviewing temporality of symptom appearance, the effects of
discontinuing the product (de-challenge), re-challenging with the product, and other changes in
medication regimen. Although consumers perceived the severity of the symptoms based on their
level of distress, and not by seriousness (e.g., the need for hospitalization) as healthcare
60
professionals would, their identification of the ADR itself seemed to be based, at least in part, on
a process of elimination to identify a causal link between the product and the reaction.
Most national ADR reporting schemes do not allow reports direct from consumers
because of concerns about low quality reports (e.g., missing important clinical information) and
about the potential for obscuring important signals due to large numbers of reports. (Hammond,
Rich, & Gibbs, 2007; Woo, 2007) Although Health Canada accepts direct reporting of suspected
ADRs by consumers, this is not widely advertised and consumer reports are adjudicated
separately from reports submitted by healthcare providers. Consumers in this study generally
were not aware that they could report to Health Canada and although most agreed that it was
important to collect such information, they seemed more willing to report to persons whom they
trusted rather than to Health Canada directly. In Canada, consumer reports are usually used to
clarify or provide additional support for suspected reactions (or signals) raised from healthcare
provider reports. Our data suggest that one way to enhance reporting rates may be to facilitate
more consumer reporting. Future research in this area appears warranted.
In many cases, participants didn’t report the ADR because they didn’t know where to
turn. Although NHP users are often highly educated and information seeking consumers, after
experiencing an ADR, some participants sought someone trustworthy to whom they could turn
for help. In this study, the trustworthy person was often not a medical doctor or pharmacist but
instead usually a CAM provider or health food store clerk. Participants turned to health food
store personnel because they were seen as being more knowledgeable about NHPs and because
they were willing to listen to the consumers’ concerns without judgment. Although several
consumers described their ADR as moderate or severe, they still did not report their ADR
because they did not know where to turn. This finding supports other research that patients do
61
not act on a severe reaction, particularly if it is related to an NHP. (Barnes, Mills, Abbot et al.,
1998)
A key finding was that the relationship between consumers and their service providers can
act as a barrier or facilitator to reporting suspected ADRs. Other research suggests that
participants perceive high quality healthcare to include recognition of their status as informed
patients and acknowledgement of their personal worth. (Price & Arnould, 1999; Williams,
Coyle, & Healy, 1998) In the present study, participants felt that their physicians or pharmacists
would ‘blow them off [ignore their concerns]’ or ‘bash down [insult]’ their values and beliefs in
NHPs. This type of response negatively impacts the patients’ abilities to maintain open and
honest relationships with their healthcare providers. Participants who did not trust their
conventional practitioners to respect their NHP-related choices sought out other advisors. In this
study, that often included health food store staff. This can be problematic as Canadian health
food stores are not regulated in any way. Thus, there are no common standards for employee
training and research suggests that health food store staff generally have no knowledge of the
ADR reporting systems (Glisson, Rogers, Abourashed, Ogletree, Hufford, & Khan, 2003;
Healey, Burgess, Siebers, Beasley, Weatherall, & Holt, 2002; Walji, Boon, Barnes, Austin,
Baker, & Welsh, 2008)
Despite the increasing awareness of the importance of patient-centered care, which
includes nurturing mutual trust, both trust by the physician in the inherent truth of the patients’
experience and trust by the patient that the physician will help the patient towards the path to
wellness, (Stewart, Brown, Donner, McWhinney, Oates, Weston et al., 2000) participants did
not report positive experiences with physicians. Patient-centered communication has been found
to improve health status and increase the efficiency of care by reducing diagnostic tests and
62
referrals. (Stewart, 2005) With better communication, it also seems likely that patients would be
more willing to discuss ADRs with their physicians and pharmacists.
4.6 Conclusion
Consumers who have experienced an NHP-related ADR are unlikely to discuss their
experiences after having self-prescribed the product. Perceived severity can be an impetus to ask
for help. When consumers do seek advice about suspected ADRs associated with NHPs, they
are most likely to discuss it with friends, family or health food store personnel. Consumers
generally perceive that conventional healthcare providers will not understand their decisions to
use NHPs and thus fear that they will not be supported to address the suspected NHP-related
ADR. This study highlights the need for health professionals to be open-minded about their
patients’ choices regarding NHPs and the importance of developing good communication around
NHPs so that patients will be comfortable sharing suspected ADR experiences.
4.7 Implications
This study has implications for NHP safety monitoring, mainly with regards to patient-
practitioner communication. Healthcare providers must attempt to develop a rapport with their
patients, recognizing that many (likely at least half) may be using NHPs. Previous research
suggests that initiation of NHP dialogue should occur at the first stages of patient contact,
perhaps during regular medicine history taking. To do this, physicians and pharmacists need
effective communication skills to fulfill a variety of roles including collecting medical histories,
answering patients’ questions about NHPs, developing interpersonal relations and suggesting
treatment. (Tasaki, Maskarinec, Shumay, Tatsumura, & Kakai, 2002) It is also important to
recognize that while disclosure of NHP use is essential, successful communication does not
mean that physicians have to approve of patients’ choices.(Verhoef, Boon, & Page, 2008) In the
63
case of NHP-related ADRs, communication of this type seems essential to enabling a trusting
relationship. Our findings suggest that only when physicians are seen as sources of information
and support will consumers disclose their concerns when experiencing an NHP-related ADR.
This study also found that consumers are generally unaware that they are able to report directly
to Health Canada and therefore, there is a need for initiatives to raise awareness among NHP
users of this avenue for reporting suspected NHP ADRs. Spontaneous reporting systems are at
present the mainstay of detecting signals of safety concerns associated with NHPs. (Barnes,
Mills, Abbot et al., 1998) If suspected ADRs associated with NHPs do not reach the system,
either through direct patient reporting or reported through healthcare professionals, then the
detection of safety concerns may be missed or delayed. This has important implications for
protection of the public health.
64
4.8 References
Alaszewski, A., & Brown, P. (2007). Risk, uncertainty and knowledge. Health, Risk and Society,
9(1), 1-10.
Barnes, J., Mills, S.Y., Abbot, N.C., Willoughby, M., & Ernst, E. (1998). Different standards for
reporting ADRs to herbal remedies and OTC medicines: face-to-face interviews with 515
users of herbal remedies. British Journal of Clinical Pharmacology, 45, 496-500.
Barnes, J. (2003). Pharmacovigilance of herbal medicines: a UK perspective. Drug Safety,
26(12), 829-851.
Center for Disease Control (2004). Complementary and Alternative Medicine Use Among
Adults: United States, 2002. In Advance Data From Vital and Health Statistics (Ed.):
U.S. Department of Health and Human Services.
Creswell, J. (1998). Qualitative Inquiry and Research Design: Choosing Among Five Traditions
London: Sage
Ernst, E. (2000). The role of complementary and alternative medicine. BMJ, 321, 1133-1135.
Glisson, J.K., Rogers, H.E., Abourashed, E.A., Ogletree, R., Hufford, C.D., & Khan, I. (2003).
Clinic at the health food store? Employee recommendations and product analysis.
Pharmacotherapy, 23(1), 64-72.
Hammond, I.W., Rich, D.S., & Gibbs, T.G. (2007). Effect of consumer reporting on signal
detection: using disproportionality analysis. Expert Opin Drug Saf, 6(6), 705-712.
Healey, B., Burgess, C., Siebers, R., Beasley, R., Weatherall, M., & Holt, S. (2002). Do natural
health food stores require regulation? N Z Med J, 115(1161), U165.
Health Canada (2007). Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Adverse Reaction Database: Health Canada.
Lupton, D. (1997). Consumerism, reflexivity and the medical encounter. Social Science &
Medicine, 45(3), 373-381.
Murray, E., Pollack, L., White, M., & Lo, B. (2007). Clinical decision-making: Patients'
preferences and experiences. Patient Education and Counseling, 65, 189-196.
NHPD (2005). Baseline natural health products survey among consumers: Health Canada.
Park, J. (2005). Use of alternative health care. Health Reports, 16(2), 39.
Price, L.L., & Arnould, E.J. (1999). Commercial friendships: Service provider-client
relationships in context. Journal of Marketing, 63(October), 38-56.
Richards, L., & Richards, T. (2002). NVivo 2.0 [Software for Qualitative Research] Melbourne:
QSR Solutions
Stewart, M., Brown, J.B., Donner, A., McWhinney, I.R., Oates, J., Weston, W.W., & Jordan, J.
(2000). The impact of patient-centered care on outcomes. J Fam Pract, 49(9), 796-804.
Stewart, M. (2005). Reflections on the doctor-patient relationship: from evidence and
experience. Br J Gen Pract, 55(519), 793-801.
Tasaki, K., Maskarinec, G., Shumay, D., Tatsumura, Y., & Kakai, H. (2002). Communication
between physicians and cancer patients about complementary and alternative medicine:
exploring patients' perspectives. Psychooncology, 11, 212-220.
Verhoef, M.J., Boon, H.S., & Page, S.A. (2008). Talking to cancer patients about complementary
therapies: Physicians' responsibility? submitted for publication?
Walji, R., Boon, H., Barnes, J., Austin, Z., Baker, G.R., & Welsh, S. (2008). Adverse event
reporting for herbal medicines: A result of market forces. Healthcare Policy Submitted
Feb 28, 2008.
65
Waller, P., & Tilson, H. (2004). Managing drug safety issues with marketed products. In J.
Talbot, & P. Waller (Eds.), Stephens' Detection of New Adverse Drug Reactions (pp. 345-
374). Chicester: Wiley.
Williams, B., Coyle, J., & Healy, D. (1998). The meaning of patient satisfaction with health care:
an exploration of high reported levels. Social Science & Medicine, 47(9), 1351-1360.
Woo, J.J. (2007). Adverse event monitoring and multivitamin-multimineral dietary supplements.
Am J Clin Nutr, 85(1), 323S-324S.
World Health Organization (1995). Note for guidance on clinical safety data management:
definitions and standards for expedited reporting, CPMP/ICH.377/95.
66
Table 1: Consumer Demographic Information
Consumer
#
A
g
e
S
e
x
Product Reason for
taking
NHP
ADR α Severity
β Outcome Reporting
behaviour
1 25 F Mental Calm For alertness/
stress
Rash Moderate Recovered
with OTC
treatment
Reported to
PHM
2 28 F Fish oil For health
maintenance
Rash Mild Recovered
after d/c
Reported to
CAM
3 43 M Weight loss
product
For weight
loss
Stimulation,
irritability,
road rage
Severe Recovered
after d/c
Report to f/f
4 24 F Digestive
enzymes
For digestive
concerns
Stomach pain,
bloating,
heartburn
Moderate Rechallenged,
Recovered
after d/c
Did not report
5 31 F 1. Herbal
cleanse
2. [Wished
not to disclose
product type
or name]
1. Cleansing
product
2. For energy
1. flatulence,
bowel
urgency,
stomach
discomfort
2. anxiety,
depression,
nervousness,
nausea
1. moderate
to severe
2. moderate
to severe
1. recovered
after d/c
2. recovered
after d/c
1.Did not
report
2. Did not
report
6 29 F 1. Ginkgo
biloba
2. weight loss
product
3. St. John’s
wort
1. for memory
2. for weight
loss
3. for mood
1. sweating
2. shaky,
disoriented
3.
photosensitivit
y
1. mild
2. severe
3. mild
1. recovered
after d/c
2. recovered
after d/c
3. recovered
after d/c
1.Did not
report
2. Did not
report
3. Did not
report
7 42 F Valerian For sleep Agitated,
unsettled
Moderate Recovered
after d/c
Did not report
8 36 F Fish oil For health
maintenance
Rash Mild Recovered
after d/c
Report to
CAM, f/f
9 38 F Thyroid
glandular
For weight
loss
Headache,
nausea
Severe Changed dose Report to MD
10 28 F Multi-vitamin For health
maintenance
Nausea,
vomiting
Severe Rechallenged,
recovered
after d/c
Report to f/f
11 22 F Weight loss
product
For weight
loss
Heartburn Mild to
moderate
Rechallenged,
recovered
after d/c
Report to f/f
12 34 F Melatonin For sleep Groggy,
uncoordinated
Mild to
moderate
Recovered
after d/c
Did not report
α some participants experienced reactions to more than one product, they are listed in numbers to organize different
experiences. β severity is classified according to patient definition of severity
d/c = discontinuation
CAM = complementary and alternative medicine practitioner
MD = medical doctor
PHM = pharmacist
F/f = friends and family
67
CHAPTER 5. RESULTS – Health Food Store Interviews
Preamble
This chapter was submitted to Healthcare Policy for consideration for publication on
February 29, 2008. The editors asked for a revised version and the paper was resubmitted on
June 27, 2008.
I, Rishma Walji, performed the entire work, that is, the conceptualisation of the study, the
protocol design, the overall study management, the collection, analysis, and interpretation of the
data, and the writing of the manuscript, under the guidance of Dr. H. Boon, Dr. J. Barnes, Dr. Z.
Austin, Dr. G.R. Baker and Dr. S. Welsh.
Adverse event reporting for herbal medicines: A result of market forces
Keywords: natural health products, dietary supplements, health food stores, safety, adverse
events, adverse drug reaction reporting, herbal medicines
5.1 Abstract
Herbal products are readily available over-the-counter in health food stores and are often
perceived to be without risk. The current Canadian adverse event reporting system suffers from
severe under-reporting, resulting in a scarcity of safety data on herbal products. Twelve health
food store personnel in the Greater Toronto Area were interviewed about their responses to
herbal product related adverse reactions.. They generally fostered customer loyalty by offering
generous return policies, which included collecting contact information to be sent with the
returned product to the manufacturers. Despite a lack of knowledge about the formal reporting
system, adverse reaction information was directed to the manufacturers whenever it resulted in a
product return. The relationship between health food stores, industry and Health Canada,
provides a new opportunity to facilitate adverse event reporting. Additional information could be
68
collected during the return process, and educational initiatives could be implemented to augment
current post-market surveillance procedures for herbal products.
69
5.2 Background
The extensive use of natural health products (NHPs), such as vitamins and herbal
medicines, is partially explained by a widespread belief that such products are “natural” and thus
safe. Increasingly, it has become clear that NHPs, especially herbal medicines, can have adverse
effects, including drug interactions.(McNeill, 1999; Pittler & Ernst, 2003) Relatively little is
known about the adverse effects associated with herbal medicines.
Adverse drug reactions (ADRs) are defined as unintended consequences suspected to be
related to the use of medicinal products, including herbal medicines. (World Health
Organization, 1995) Spontaneous reporting systems, such as the Canada Vigilance Program
(previously named the Canadian ADR Monitoring Program), are used by many countries as a
way of monitoring suspected ADRs. Voluntary reports of suspected ADRs; reports of serious or
unexpected ADRs, and those associated with recently marketed products are particularly
encouraged.(Fletcher, 1991) In Canada, physicians, pharmacists, other healthcare providers and
consumers can submit reports which may be assessed to identify product safety concerns that
require action, such as changes/additions to product labelling, dosing, or removal of products
from the market.
Although NHPs are widely used, few ADRs are reported to pharmacovigilance systems.
(Barnes, 2003; Green, Mottram, Rowe, & Pirmohamed, 2001; Health Canada, 2007) It is well
established that under-reporting of suspected ADRs is an important limitation of spontaneous
reporting systems. (Fletcher, 1991; Mann & Andrews, 2002; Rogers, Israel, Smith, Levine,
McBean, Valente et al., 1988) Low ADR reporting rates associated with prescription medicines
are recognized as an international problem.. It is generally accepted that less than 10% of adverse
drug reactions are reported. (Alvarez-Requejo, Carvajal, Begaud, Moride, Vega, & Arias, 1998;
70
Moride, Haramburu, Requejo, & Begaud, 1997; Rogers, Israel, Smith et al., 1988) Under-
reporting is likely to be greater for herbal medicines and other NHPs than for pharmaceutical
drugs for several reasons. For example, healthcare professionals are often unaware of patients’
NHP use (Barnes, 2003; Barnes, Mills, Abbot, Willoughby, & Ernst, 1998; NHPD, 2005;
Wheaton, Blanck, Gizlice, & Reyes, 2005; Winslow & Shapiro, 2002), how to identify ADRs
associated with NHPs and what to report (Charrois, Hill, Vu, Foster, Boon, Cramer et al., 2007;
Herdiero, Polonia, Gestal-Otero, & Figueiras, 2004). In Canada, NHPs have only been
categorized as medicinal products and regulated by Health Canada since January 2004. (NHPD,
2003) It is unclear whether the lack of NHP ADR reports suggests that they are truly rare, or
reflects a history of inadequate effort (in Canada and internationally) to encourage, collect and
assess reports of NHP ADRs.
Herbal medicines and other NHPs are available over-the-counter in Canada at community
pharmacies, grocery outlets and health food stores (HFS), as well as from the internet. The
Canadian regulatory status of NHPs (i.e. non-prescription, non-‘pharmacy only’) has provided an
opportunity for HFS to respond to public demand, entering the market with a wide product
selection. There are approximately 2700 HFS (typically, retail outlets where at least 50% of
stock comprises NHPs and/or health foods) across Canada, mostly in the provinces of Ontario,
Quebec and British Columbia. (Canadian Health Food Association, 2005) HFS may be
independently operated or belong to a retail chain with multiple outlets city or nationwide. There
are no legal requirements regarding educational background or training for staff, and each store
has different requirements ranging from online courses or in-store training/mentoring to no
training/experience requirements. (Glisson, Rogers, Abourashed, Ogletree, Hufford, & Khan,
2003; Mills, Singh, Kawasaki, Bast, Hart, Majlesi et al., 2003)
71
Although HFS are an important source of NHPs, their staff do not have a defined role in
monitoring the safety of the medicinal products they sell. (Healey, Burgess, Siebers, Beasley,
Weatherall, & Holt, 2002) Rather, their business is providing health-related products, meeting
customer demands, and providing adequate customer service to remain viable in a competitive
marketplace. In contrast, conventional healthcare professionals (e.g., doctors, pharmacists) are
bound by professional and ethical standards to report serious or unexpected instances of
suspected ADRs. In reality however, many health professionals do not report, despite
expectations to do so. (Alvarez-Requejo, Carvajal, Begaud et al., 1998; Hazell & Shakir, 2006;
Inman, 1985)
One way health food stores remain competitive is by offering generous return policies for
dissatisfied consumers to reduce the purchase risk of finding a good product match or a product
of acceptable quality. Money-back guarantees can signal a seller’s confidence in the quality of
their products. (McWilliams & Gerstner, 2006) The economic rationale for return policies is that
of warranty. Return policies insure customers against products about which they are uncertain,
making risk-averse customers willing to pay for the product. (Che, 1996) With NHPs,
uncertainty around product benefits and the wide range of product options may raise doubts for
the consumer. This, along with the strong competition from other stores selling similar goods,
provides a reasonable rationale for these return policies.
Against this background, this study examined HFS staffs’ views on herbal product safety
issues. The work forms part of a larger study also involving pharmacists and consumers who
had experienced NHP ADRs. This paper explores how business incentives influence collection
and reporting of adverse effect information in HFS and how return policies may be related to
HFS personnel’s ability to respond to Health Canada’s attempts to collect ADR information
72
associated with herbal products. Herbal products were specifically selected based on the
increased risks associated with these products, compared with other NHPs.
5.3 Methods
Ethics approval was obtained at the University of Toronto. In-depth semi-structured
interviews were conducted with 12 HFS personnel by a single interviewer with extensive
training in qualitative research methods (RW). A purposive sample was chosen to include
participants from independent and chain HFS, from city and suburban areas as well as from
different age and gender groups and with varying HFS experience. Participants from HFS
located in the Greater Toronto Area, identified from telephone directories, internet listings and
by word-of-mouth, were approached in person. Interviews were conducted until theoretical
saturation of the key emerging themes was obtained. (Creswell, 1998) Interviews were audio-
recorded and field notes were hand-written during and immediately following the interviews.
Interviews and field notes were transcribed and coded using content analysis techniques by two
independent coders; disagreement was resolved through in-depth discussion. NVIVO 7 software
was used to organize the data. (Richards & Richards, 2002) Data analysis and coding took place
throughout data collection. The interview guide was updated and modified after the coding
sessions to ensure more elaborate data collection in key emerging themes.
5.4 Results
The results for this study show that HFS personnel were unaware of the reporting system
for ADRs. They also perceived and identified ADRs differently than the medical community.
When the ADR resulted in consumer dissatisfaction however, the product was returned to the
73
manufacturer, eliciting a ‘report’ of some type. Table 2 summarizes participants’ demographic
characteristics.
Generally, HFS personnel did not know that suspected herbal-related ADRs could be
reported to Health Canada, who to contact to report ADRs, or which types of reactions
should be reported.
Q: Are you familiar with the reporting system in Canada for side effects?
A: No. [interviewer explains] A: I didn't know about it at all. (#10)
Most participants described examples of ‘side effects’ (a ‘lay’ term for ADRs as defined
by Health Canada) associated with NHPs reported by consumers. HFS personnel considered
predictable untoward responses, such as a niacin flush, or diarrhea from a ‘detoxification’
product, as examples of possible ADRs about which they might inform consumers prior to
purchase of the product. They reported that these “true” ADRs were rare. More common was a
situation they described as NHPs that “did not agree” with or “did not suit” specific customers.
This could manifest as a stomach upset or “uneasy feeling” after taking the product. Although
these effects would be classified as ADRs by Health Canada, HFS personnel did not consider
these to be cause for concern about the product per se. Rather, this was conceptualized as a need
to help the consumer find a better product “fit”:
I think I would take it back from them thinking that maybe it really didn’t suit them and
then I will ask them why, what happened to you? Why don’t you feel that it suited you or
maybe I will tell them why not try another one to see if it suits you. In that way I could
guide them. (#8)
HFS personnel described more serious symptoms, such as rashes, as the result of
individual allergies, which they did not classify as ADRs. Often, HFS personnel would attribute
‘side effects’ to inappropriate product use by consumers, rather than ADRs (allergies, and effects
associated with inappropriate use are considered ADRs by Health Canada). HFS personnel
74
therefore perceived and identified ADRs differently than the medical community. Participants
stated that they commonly referred customers to their healthcare providers, or the product
manufacturer, for more information if they suspected a patient had a reaction.
Oh I take it very seriously. I want to make sure that… if it was really serious I would say
go and see your doctor and if it was a side effect and I don’t really know why [it
happened] I would give them the phone number and the website to contact the company
so that they can directly call them and double check with them because they have to
know that as well and if they don’t feel comfortable I will call them myself with them
there. (#10)
This example also relates to another key theme that emerged from the data: HFS personnel’s
strong drive to provide customer service. HFS personnel described the importance of developing
and maintaining relationships with their customers, and this extended to provision of advice and
information about NHPs. HFS personnel appear to encourage consumers to see them as an
information source for NHPs to help maintain customer loyalty.
You know at the store level we have to be prudent to gain enough information about the
dangers and risks of products to be able to guide the consumer and they are after all
looking at us for advice. (#2)
[Customers] want technical information and they are looking to us as if we’re naturopaths
in a health food store, not sales associates in a health food store. (#12)
Another component of providing good customer service was swift response to product
dissatisfaction (possibly resulting from ADRs) by accepting returns. The return procedure
included collection of customer contact information, subsequently submitted to the manufacturer
in conjunction with the “reason” for the return in order to recuperate retailer losses on the
product. HFS personnel had difficulty conceptualizing ADRs, and thus also had difficulty
describing how they might respond if one occurred. They talked about how they would return
products to the manufacturer and refund the cost if the customer was dissatisfied with the
product for any reason:
75
Even if it is not a bad reaction… you believe them and you refund it regardless, but just
by their answers. You have to trust them whether you believe it or not you have to return
the product if they have a reaction and then we just take their information and we contact
the company and sometimes the company calls them back. [It happens about] once a
week. (#9)
Thus, participants essentially reported ADRs to product manufacturers as a consequence
of processing product returns. They described their continuing relationships with the
manufacturers, in particular how helpful manufacturing companies staff were at answering
questions about their products and handling returns.
I know this company, because ...we buy many of the products, … They give us very
good information. Especially if they have enough time with you they don’t hurry you
and they explain things and they also tell you things, you know we are not doctors - they
just advise [us] so they are very good. (#8)
Participants described how the return policy was used as a mechanism to generate
customer loyalty and satisfaction by reducing the customer’s perceived risk. It was also used to
evaluate product quality to help decide whether they should continue to be sold in the store.
We have a very good return policy and we actually encourage people to give us the
feedback: if they’re not satisfied we want to hear about it, because we might not carry the
line in the future if there are problems with it. It helps us and it helps us not to lose the
customer as well, where some people if they bought something they have no recourse to
get any money back or refund, they might just stop shopping at this location, or other
locations for that matter. Whereas if they come back here, well we could encourage them
to exchange the product or try something else that may be more to their liking and that
way we could have a satisfied customer that continues to come back. (#4)
The costs of the returned product can only be recuperated by the store that accepts the
return from the customer if the product is returned to the manufacturer with customer contact
information and a reason for the return:
We write up a credit request from the company and we fax the company the credit
request. We phone them and we e-mail them and we put the paper work together, and
leave the product to be picked up by the company at some point. It is just pretty much a
form that just asks for return address, name, phone number, that sort of thing. (#11)
HFS personnel considered manufacturers responsible for providing good quality products.
76
Sometimes batch numbers are also messed up. We have had [product] recalls before. I
would go with the company first. For sure it would be the company’s responsibility.
(#6)
5.5 Discussion
Although HFS staff are unaware of the Canada Vigilance Program for reporting
suspected ADRs, they learn of consumer experiences of suspected ADRs associated with NHPs,
and return products to product manufacturers in cases where consumers may have experienced
ADRs. The arrangement between HFS and manufacturers regarding product returns raises the
question whether this could be harnessed to improve ADR reporting for NHPs.
Providing financial incentives has been used to encourage health professionals to
complete ADR reports, but it is not clear whether this approach improves the number and quality
of ADR reports. (Inman, 1985) For HFS personnel, providing information to the manufacturer
along with the return is the result of a financial incentive – recuperating losses on returned
products. In order to receive financial remuneration for their product costs, they provide
consumer contact information and reason for the return. It is possible that this information could
be utilized to facilitate submission of more information to the manufacturer by retailers that
could then be used for ADR reporting to Health Canada by the manufacturer. Additional
information (such as other medications/products taken at that time, the length of the exposure to
the product, a description of the reaction) would need to be incorporated into the return reports to
allow them to be used as ADR reports. The manufacturer would then send the information to
Health Canada, as is currently required under the Canadian NHP regulations, as expedited
reports for serious ADRs or included in the annual summary for non-serious ADRs. Given the
close relationships between HFS and industry, reporting of ADR information by HFS staff to
manufacturers would seem relatively straightforward to implement.
77
However, reliance on product manufacturers to submit reports of suspected ADRs to
Health Canada has limitations. A key issue for pharmacovigilance for herbal medicines and other
NHPs concerns the accuracy and comprehensiveness of manufacturers’ ADR reports to Health
Canada as part of their legal obligations. Regulatory changes have been implemented to ensure
quality, safety and efficacy of NHPs. Safety information is particularly important for appropriate
regulation of these products. (Citizen Petition, 2008; Harvey, Korczak, Marron, & Newgreen,
2008; NHPD, 2003) When manufacturers or licensees receive information on serious ADRs
(those that require hospitalization, are life-threatening, or result in significant disability or death),
the NHP regulations (which are still being phased in) require them to provide Health Canada
with case reports within 15 calendar days after becoming aware of the reactions. (NHPD, 2003)
Licensees are also required to prepare an annual summary report containing an analysis of all
ADRs occurring for their products within the previous year. Due to the inherent conflict of
interest, questions remain over whether all relevant reports are included and whether the
information presented complies with Health Canada’s requirements.
Another important limitation to submission of information to manufacturers is
confidentiality. Manufacturers require a customer name and contact information as a measure of
authenticity of the return. Health Canada’s ADR reporting form however requires anonymity to
ensure confidentiality of health information.
If submission of suspected ADR reports by health-food stores to Health Canada via
product manufacturers is not an ideal mechanism, how else could the information obtained by
HFS staff reach the pharmacovigilance system? There are three ways in which HFS staff could
be more actively involved in reporting suspected ADRs associated with NHPs. On learning of
ADRs or ‘problems’ with herbal medicines or other NHPs, health-food store staff could:
78
1. Advise the purchaser to contact their doctor or pharmacist. While this approach would
direct purchasers to conventional healthcare professionals (who are generally trained in
identifying ADRs and have a formal role in reporting them), there are still several barriers to a
report reaching Health Canada. For example, consumers appear to be hesitant to disclose use of
NHPs to physicians and other conventional healthcare providers, particularly if they experience
adverse effects associated with NHPs. In addition, the healthcare provider must recognize the
symptoms as a suspected ADR, as well as follow through to complete an ADR report which is
submitted to the Canada Vigilance Program. However, under-reporting from health care
professionals is a problem due to lack of time, knowledge or uncertainty about ADRs and the
ADR reporting system. (Hazell & Shakir, 2006; Herdiero, Polonia, Gestal-Otero et al., 2004;
Sweis & Wong, 2000)
2. Advise the purchaser to report the event directly to the Canada Vigilance Program,
possibly with the assistance of their conventional healthcare provider or HFS personnel.
3. HFS personnel report the event to Canada Vigilance Program on the purchaser’s behalf.
Options 2 and 3 above however, have their own limitations. Both HFS personnel reports
and direct consumer reports would be categorized as public or ‘lay’ reports by Health Canada.
While these reports may serve to improve signal detection on certain products, they may not
have the detail or quality of information required – such as laboratory test results and accurate
records of concomitant medications (although these details can also be missing from health
professional reports). Health care providers are encouraged to submit all reports of suspected
ADRs – it is not necessary for them to attempt to confirm causality or to undertake intensive
investigations of the events. However, the quality and completeness of ADR reports are
important factors in Health Canada’s ability to undertake causality assessments. Although some
79
argue that patient ADR reports may be less likely to represent true reactions than are physician
reports, large-scale reporting from lay persons (such as HFS personnel) might be valuable for
detection of symptomatic reactions to new drugs. (Mitchell, Henry, Sanson-Fisher, & O'Connell,
1988) For example, signals might be identified earlier when patient reports are included in the
data analysis. (Hammond, Rich, & Gibbs, 2007; Jarernsiripornkul, Krska, Richards, & Capps,
2003) Patient reports may be particularly important when little is known about the product and
its use with other products, as is the case with many NHPs. (Woo, 2007) In fact, some research
shows that consumer reports may be of higher quality than physician reports, with more
complete descriptions of the event. (Medawar & Herxheimer, 2003/2004; Medawar,
Herxheimer, Bell, & Jofre, 2002) Another challenge is that HFS staff would need training in
Health Canada’s ADR reporting procedures. HFS personnel training varies widely and HFS
staff are often untrained in disease recognition or medical terminology, making it difficult to
assess whether or not a given return was associated with an ADR. False positives could be
generated if customers exaggerate symptoms to receive refunds on purchased products.
Additionally, suspected ADRs will only be identified if consumers attempt to return the
products. Even if a system was devised to train HFS personnel on ADR recognition and
completion of ADR reports, there is currently no way to enforce standards in the unregulated
retail industry. Furthermore, there is no incentive for HFS staff to report ADRs directly to
Health Canada, other than contributing to protecting the public health so willingness to
participate may vary.
This study has some limitations. First, it involved only a small number of interviews.
Nevertheless, participants varied in their demographic characteristics, and saturation of key
themes indicates that additional interviews were unlikely to raise completely new views.
80
Participants reported very similar return policies and gave similar answers regarding their
knowledge about the Canada Vigilance Program. The highly focused research questions for the
study (regarding perceptions of herbal ADRs and how they are handled) may also have
contributed to saturation. (Guest, Bunce, & Johnson, 2006)
Although the intent of the research was to ask participants primarily about herbal
medicines, they interpreted the term more broadly and discussed perceptions related to all NHPs,
implying that they would behave similarly regardless of the type of NHP associated with an
ADR.
5.6 Conclusions and Policy Implications
Consumers utilize HFS personnel for information about NHPs and to make complaints
about the products they are using. HFS personnel, through business and economic incentives,
are motivated to process returns for dissatisfied consumers and, in so doing, transmit ADR
information to industry. Through the existing process, with certain caveats, there may be an
opportunity to improve ADR monitoring by enhancing the detail of information collected.
Educating HFS personnel about the ADR reporting system to facilitate their direct reporting to
Health Canada, or at minimum informing customers of the option to report to Health Canada,
should be investigated.
This study has important policy implications for ADR reporting and post-market
surveillance of NHPs. The encouragement of HFS personnel reporting might be an important
step in populating the Canada Vigilance Program database with valuable information. Increasing
awareness of the ADR monitoring system within the NHP sector is an essential part of
improving safety monitoring. Important next steps will be to ensure health care providers and
consumers understand the true degree of risk through improved communication. Additionally, it
81
is important to investigate how the HFS industry reacts to an invitation to actively participate in
NHP pharmacoviglance including the quantity, quality and completeness of submitted ADR
reports. Health Canada will need to assess how best to use this new source of information for
protection of the public health.
82
5.7 References
Alvarez-Requejo, A., Carvajal, A., Begaud, B., Moride, Y., Vega, T., & Arias, L. (1998). Under-
reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme
and sentinel system. European Journal of Clinical Pharmacology, 54(6), 483-488.
Barnes, J., Mills, S.Y., Abbot, N.C., Willoughby, M., & Ernst, E. (1998). Different standards for
reporting ADRs to herbal remedies and OTC medicines: face-to-face interviews with 515
users of herbal remedies. British Journal of Clinical Pharmacology, 45, 496-500.
Barnes, J. (2003). Pharmacovigilance of herbal medicines: a UK perspective. Drug Safety,
26(12), 829-851.
Canadian Health Food Association (2005). Natural health products state of the industry report
2005: Backgrounder.
Charrois, T.L., Hill, R.L., Vu, D., Foster, B.C., Boon, H.S., Cramer, K., & Vohra, S. (2007).
Community identification of natural health product-drug interactions. The Annals of
Pharmacotherapy, 41(7), 1124-1129.
Che, Y.-K. (1996). Customer return policies for experience goods. The Journal of Industrial
Economics, 44(March), 17-24.
Citizen Petition (2008). Consumer Healthcare - Treat Weight Loss Claims for Dietary
Supplements as Disease Claims: American Dietetic Association, The Obesity Society,
Shaping America's Health and GlaxoSmithKline Consumer Healthcare - Citizen Petition
Creswell, J. (1998). Qualitative Inquiry and Research Design: Chosing Among Five Traditions
London: Sage
Fletcher, A.P. (1991). Spontaneous adverse drug reaction reporting vs event monitoring: a
comparison. J R Soc Med, 84(6), 341-344.
Glisson, J.K., Rogers, H.E., Abourashed, E.A., Ogletree, R., Hufford, C.D., & Khan, I. (2003).
Clinic at the health food store? Employee recommendations and product analysis.
Pharmacotherapy, 23(1), 64-72.
Green, C.F., Mottram, D.R., Rowe, P.H., & Pirmohamed, M. (2001). Attitudes and knowledge of
hospital pharmacists to adverse drug reaction reporting. British Journal of Clinical
Pharmacology, 51, 81-86.
Guest, G., Bunce, A., & Johnson, L. (2006). How many interviews are enough?: An experiment
with data saturation and variability. Field Methods, 18, 59-82.
Hammond, I.W., Rich, D.S., & Gibbs, T.G. (2007). Effect of consumer reporting on signal
detection: using disproportionality analysis. Expert Opin Drug Saf, 6(6), 705-712.
Harvey, K., Korczak, V., Marron, L., & Newgreen, D. (2008). Commercialism, choice and
consumer protection: regulation of complementary medicines in Australia. The Medical
Journal of Australia, 188(1), 21-25.
Hazell, L., & Shakir, S.A.W. (2006). Under-reporting of adverse drug reactions: A systematic
review. Drug Safety, 29(5), 385-396.
Healey, B., Burgess, C., Siebers, R., Beasley, R., Weatherall, M., & Holt, S. (2002). Do natural
health food stores require regulation? N Z Med J, 115(1161), U165.
Health Canada (2007). Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Adverse Reaction Database: Health Canada.
Herdiero, M.T., Polonia, J., Gestal-Otero, J.J., & Figueiras, A. (2004). Factors that influence
spontaneous reporting of adverse drug reactions: A model centralized in the medical
professional. Journal of Evaluation in Clinical Practice, 10(4), 483-489.
83
Inman, W.H. (1985). Under-reporting of adverse drug reactions. British Medical Journal,
290(6478), 1355.
Jarernsiripornkul, N., Krska, J., Richards, R.M., & Capps, P.A. (2003). Patient reporting of
adverse drug reactions: useful information for pain management? Eur J Pain, 7(3), 219-
224.
Mann, R., & Andrews, E. (2002). Introduction. In R. Mann, & E. Andrews (Eds.),
Pharmacovigilance (pp. 3-10). Chicester, England: Wiley.
McNeill, J. (1999). Interactions between herbal and conventional medicines. The Canadian
Journal of CME, December, 97-113.
McWilliams, B., & Gerstner, E. (2006). Offering lower price guarantees to improve customer
retention. Journal of Retailing, 82(2), 105-113.
Medawar, C., Herxheimer, A., Bell, A., & Jofre, S. (2002). Paroxetine, panorama and user
reporting of ADRs consumer intelligence matters in clinical practice and post-marketing
drug surveillance. International Journal of Risk and Safety in Medicine, 15, 161-169.
Medawar, C., & Herxheimer, A. (2003/2004). A comparison of adverse drug reaction reports
from professionals and users relating to risk of dependence and suicidal behaviour with
paroxetine. International Journal of Risk and Safety in Medicine, 16, 5-19.
Mills, E., Singh, R., Kawasaki, M., Bast, L., Hart, J., Majlesi, A., Kiani, P., & Wilson, K. (2003).
Emerging issues associated with HIV patients seeking advice from health food stores.
Can J Public Health, 94(5), 363-366.
Mitchell, A.S., Henry, D.A., Sanson-Fisher, I.L., & O'Connell, D.L. (1988). Patients as a direct
source of information on adverse drug reactions. BMJ, 297, 891-893.
Moride, Y., Haramburu, F., Requejo, A.A., & Begaud, B. (1997). Under-reporting of adverse
drug reactions in general practice. Br J Clin Pharmacol, 43(2), 177-181.
NHPD (2003). Natural health products regulations. In N.H.P. Directorate (Ed.): Health Canada.
NHPD (2005). Baseline natural health products survey among consumers: Health Canada.
Pittler, M.H., & Ernst, E. (2003). Systematic review: hepatotoxic events associated with herbal
medicines. Alimentary Pharmacology & Therapeutics, 18(5), 451-471.
Richards, L., & Richards, T. (2002). NVivo 2.0 [Software for Qualitative Research] Melbourne:
QSR Solutions
Rogers, A.S., Israel, E., Smith, C.R., Levine, D., McBean, A.M., Valente, C., & Faich, G.
(1988). Physician knowledge, attitudes, and behaviour related to reporting adverse drug
events. Arch Intern Med, 148(7), 1596-1600.
Sweis, D., & Wong, I.C.K. (2000). Adverse drug reaction reporting according to hospital
pharmacists in Great Britain. Drug Safety, 23(2), 165-172.
Wheaton, A., Blanck, H., Gizlice, Z., & Reyes, M. (2005). Medicinal herb use in a population-
based survey of adults: prevalence and frequency of use, reasons for use, and use among
their children. Annals of Epidemiology, 15, 678-685.
Winslow, L., & Shapiro, H. (2002). Physicians want education about complementary and
alternative medicine to enhance communication with their patients. Arch Intern Med,
162, 1176-1181.
Woo, J.J. (2007). Adverse event monitoring and multivitamin-multimineral dietary supplements.
Am J Clin Nutr, 85(1), 323S-324S.
World Health Organization (1995). Note for guidance on clinical safety data management:
definitions and standards for expedited reporting, CPMP/ICH.377/95.
84
Table 2: Health Food Store Personnel Demographic Information
Interview Gender Position Contact
hours*
Years of
experience
Training in Natural
Health Products
Type of
store
1 F Advisory
staff
Part time 10 years 3 years formal
training
Small chain
2 M Manager Full time 16 years Self-study Independent
3 F Staff Part time 3 years 3 week in-store
training
Chain
4 M Manager Full time 5 years 6 month store training Chain
5 M Sales rep Full time 11 months Graduate student in
health care
Chain
6 M Advisory
staff
Full time 9 years 2 years formal
training
Independent
7 F Owner Full time 8 months Self-study Independent
8 F Sales
staff
Full time 7 months 6 week in-store
training
Small chain
9 F Sales
staff
Part time 1 year 6 months formal
training
Small chain
10 F Owner Full time 1.5 years Self-study Independent
11 F Sales
staff
Part time 3 years Self-study Small chain
12 F Sales
staff
Part time 2 years 3 years formal
training
Independent
* Part time < 24 hours per week; Full time ≥ 25 hours per week
85
CHAPTER 6. RESULTS – Pharmacist Interviews
Preamble
This chapter has been prepared for submission to Social Science and Medicine. It will be
submitted following the dissertation defence to allow an opportunity to incorporate any final
comments from the dissertation examiners.
I, Rishma Walji, performed the entire work, that is, the conceptualisation of the study, the
protocol design, the overall study management, the collection, analysis, and interpretation of the
data, and the writing of the manuscript, under the guidance of Dr. H. Boon, Dr. J. Barnes, Dr. Z.
Austin, Dr. G.R. Baker and Dr. S. Welsh. Helpful comments and thoughtful contributions to the
topics discussed in this paper were provided by Dr. P. McDonnough.
Pharmacists and reporting of herbal product adverse drug reactions: Whose responsibility
is it?
6.1 Abstract
We draw upon Bourdieu’s theoretical insights to investigate pharmacists’ roles in herbal
product adverse reaction reporting. Herbal medicines are sold in pharmacies as over-the-counter
products. The current Canadian adverse event reporting system suffers from severe under-
reporting, resulting in insufficient safety data on herbal products. The objective of this study was
to explore pharmacists’ experiences with, and responses to, suspected adverse reactions
associated with herbal products. In-depth, semi-structured interviews were conducted with 12
community pharmacists in Toronto, Canada. The pharmacists generally did not report adverse
events and cited barriers such as lack of time, complexity of reporting and other workplace
challenges within the field of community pharmacy. Using Bourdieu’s theory of habitus and
disposition to understand pharmacist roles in adverse event reporting, it appears that the few
86
pharmacists that did assume a responsibility for adverse event reporting appeared to have
different perceptions of pharmacists’ place within the field of pharmacy. The pharmacists who
did report saw themselves as ‘knowledge generators’, contributing to overall health care
knowledge. There was found to be a continuum of pharmacists from those who performed only
the basic level of care for their presenting patients, to those who try to contribute to the larger
health care system. Placement on this continuum was dependent on the pharmacists’
professional disposition, which seems to be a result of individual experiences and personal
perspectives. Understanding the reasons for pharmacists’ underreporting of suspected adverse
events is key to improving current herbal medicine safety monitoring methods.
6.2 Introduction
Herbal product safety monitoring is increasing in importance, in part, because of
substantial exposure of North Americans and Europeans to herbal medicines and other natural
health products (NHPs). (NHPD, 2005; Thomas, Nicholl, & Coleman, 2001) There have also
been several high-profile safety concerns associated with herbal medicines in the past. (Chitturi
& Farrell, 2008; Health Canada, 2002) As a result, there is increasing recognition of the potential
for serious adverse drug reactions (ADRs) associated with the use of certain herbal medicines.
Since herbal products are widely available in community pharmacies, it can be argued
pharmacists are well placed to facilitate herbal medicine ADR reporting. However, the current
safety monitoring system in Canada suffers from severe under-reporting from health care
professionals, including pharmacists. (Charrois, Hill, Vu, Foster, Boon, Cramer et al., 2005)
Pharmacists’ knowledge, beliefs, and motivation, as well as logistical barriers such as lack of
time, are thought to be important factors in explaining why they so seldom report ADRs. (Green,
Mottram, Rowe, & Pirmohamed, 2001; Irujo, Beitia, Bes-Rastrollo, Figueiras, Hernandez-Diaz,
87
& Lasheras, 2007) If we can understand why some pharmacists report ADRs despite these
barriers, it may be possible to improve the current reporting system.
In this paper, we draw upon Bourdieu’s theoretical insights to explore the link between
pharmacist attitudes, the structures within the community pharmacies in which they work and
their ADR-related reporting actions. Bourdieu enables this link by focusing our attention on an
individual’s place, or perceived place, in society. (Bourdieu, 1993) This subjective perception
provides a subconscious lens through which he or she interprets the world. (Crossley, 2001)
Bourdieu (1990) argues that it is through this system that people view and understand the social
world, and they then act accordingly. Using this theoretical lens, we focus on how pharmacists’
attitudes and actions may depend on their perceived position in their pharmacy, within the
pharmacy profession and within the healthcare system as a whole. We explored the influence of
the way pharmacists see themselves within the profession or the healthcare system, and how they
comprehend their role(s) in community pharmacy on behaviour patterns when performing tasks
such as ADR reporting.
Action, according to Bourdieu, is carried out within a particular structural context, with
both ‘fields’ and ‘capital’ as part of this context. A pharmacist’s field can be described as the
relationship between pharmacists and patients, or between pharmacists and other health care
providers, or even between pharmacists and other pharmacists. Within any given field, one
engages in struggles ongoing in that field. For example, pharmacists may struggle to be accepted
as trusted health care providers by patients or they may attempt to be seen as legitimate in the
eyes of other practitioners within the healthcare system. Within each struggle, one may use or
accumulate capital (that which provides status including economic, social, symbolic or cultural –
such as knowledge and education) in order to achieve a certain position or particular
88
advantages.(Bourdieu, 1986; Bourdieu & Wacquant, 1992) In the case of pharmacists, their
knowledge about drugs can be classified as cultural capital that enables them to answer patients’
questions about medicines. The way they are viewed by these patients, as legitimate sources of
information, for example, is a type of symbolic capital.
Bourdieu (1993) argues that one’s strategy of action is determined by one’s position
within a field and the overall distribution of capital. He predicts that action and decision-making
strategies will differ based on one’s perceived position. A system of internal dispositions, or
habitus, develops as a result of socialization either in childhood or within a shared socialization
experience, such as within a profession or during professional training. These dispositions
become ingrained modes of perception and action. A pharmacist who sees himself/herself only
as a gatekeeper of medications for example, might perceive his/her place to be lower in the
hierarchy of the healthcare system, deferring to physicians at every opportunity. In contrast, a
pharmacist who believes himself/herself to be an agent for meeting a patient’s drug related
needs, might actively solicit information from the patient and follow-up on health issues, or
actively contribute to knowledge generation in the field of medicines as a whole. Since
pharmacists are at the point of contact at community pharmacies, and herbal products are sold
over-the-counter, pharmacists are in a position to serve as resources for herbal products, similar
to other over-the-counter products. Despite variations in perspectives, herbal products can be
considered within the pharmacists’ scope of practice.
6.2.1 Herbal product regulations
In Canada, herbal products are regulated as natural health products (NHPs) along with
vitamins and minerals, homeopathic medicines, probiotics, amino acids and essential fatty acids.
(NHPD, 2003) The 2004 Canadian regulations outline industry requirements for the
manufacture, packaging, labelling, storage, importation, distribution and sale of NHPs. (NHPD,
89
2003) The regulations are meant to increase quality standards for NHPs, including herbal
products, making them safe for over-the-counter use, similar to over-the-counter pharmaceutical
preparations. They also include requirements for reporting suspected herbal-related ADRs,
defined as noxious and unintended responses to particular medicinal products, meaning that there
is a reasonable possibility that there is a causal relationship between a given product and the
reaction. (World Health Organization, 1995)
Health Canada collects suspected ADR reports associated with use of medicines,
including herbal products, through the Canada Vigilance Program, formerly known as the
Canadian Drug Reaction Monitoring Program. (Health Canada, 2007) In Canada, as in many
other countries, the ADR reporting system is a spontaneous, passive system that encourages
reports on a voluntary basis from doctors, pharmacists and other healthcare professionals and,
more recently, the public. The current reporting system suffers from severe under-reporting,
resulting in a lack of ADR information generally and particularly for herbal medicines. (Alvarez-
Requejo, Carvajal, Begaud, Moride, Vega, & Arias, 1998; Fletcher, 1991)
6.2.2 NHPs, ADR reporting, NHPs and Pharmacists
It can be argued that since pharmacists sell herbal products, they should be responsible
for monitoring ADRs that are associated with these products. (Kwan, Boon, Hirshkorn, Welsh, &
Jurgens, Accepted July 1 2008) Unique statutes in each province regulate the practice of
Canadian pharmacists. Generally, pharmacists are responsible for attending to patients’ drug-
related needs. Given that herbal products are now regulated as a subcategory of drugs in Canada,
it could be argued that reporting of herbal ADRs falls within the pharmacist’s professional
responsibilities, in the same way that reporting adverse reactions for pharmaceuticals does.
(Farrell, Ries, & Boon, 2008) Presently ADR reporting is considered by pharmacist associations
90
as an ethical and moral duty, but is legally still a voluntary task (as is the reporting of ADRs
suspected with drugs). (Farrell & Staughton, 1996)
Previous research indicates that pharmacists, like other health care providers, tend not to
report ADRs associated with conventional drugs. (Charrois, Hill, Vu et al., 2005; Inman, 1985)
Health professionals appear to be more likely to report ADRs if they: see the reaction as serious,
are confident that the product caused the reaction, are not busy, received continuing education
about ADR reporting, have been motivated to report ADRs in the past and if there is a specialist
in ADR reporting on staff. (Green, Mottram, Rowe et al., 2001; Lee, Chan, Raymond, &
Critchley, 1994; Sweis & Wong, 2000) Workplace challenges such as lack of time, are cited as
major obstacles for pharmacists in ADR reporting. (Granas, Buajordet, Stenberg-Nilsen, Harg, &
Horn, 2007; Inman, 1996; Irujo, Beitia, Bes-Rastrollo et al., 2007)
Safety monitoring is more difficult for herbal products than for conventional medications
for many reasons.(Barnes, 2003) In particular, NHPs are often perceived as completely safe, and
self-prescribed without advice of a qualified practitioner. It appears that patients are less likely to
report ADRs due to herbal products than similar events due to pharmaceuticals, possibly because
they consider ADRs associated with herbal medicines to be less worrying or because they do not
think that herbal ADRs should be reported to conventional healthcare professionals. (Barnes,
Mills, Abbot, Willoughby, & Ernst, 1998)
In this study, we use Bourdieu’s concepts of field, disposition and habitus to examine
pharmacist behaviours in response to herbal product related ADRs. We use this theoretical lens
to try to understand reporting behaviours as they relate to herbal medicines and differentiate
whether these are similar or different than those found for conventional medicines. We will
91
conclude by describing how professional disposition appears to be important in overcoming
structural challenges to the reporting process.
6.3 Methods
This study was conducted in the Greater Toronto Area of Ontario (Canada). Ethical
approval for the study was granted by the University of Toronto’s Research Ethics Board.
Participants
The data presented here focus on 12 interviews with pharmacists, as part of a larger study
on retailer and consumer experiences with ADRs (n=36). A purposive sample of pharmacists
practicing in community pharmacies was recruited to maximize variation in experiences and
perceptions. Participants were selected to provide a sample that included individuals with a range
of number of years in practice, number of hours working per week, gender, training and
geographical location of work. Key demographic data are presented in Table 3. Pharmacists
participated in in-person, individual, in-depth, semi-structured audio-recorded interviews
between June 2006 and May 2007. Interviews ranged from 30 to 90 minutes and data collection
continued until saturation was reached in key emerging themes. (Creswell, 1998) Core open-
ended questions asked are summarized in Table 4.
Although the number of participants was small, participants varied widely in their
demographic characteristics. Participants in the study reported very similar perspectives about
the main barriers to reporting and the challenges that they face. This is evidence that data
saturation in key themes was reached and additional interviews would not have provided
additional depth to the topics analyzed. (Creswell, 1998; Guest, Bunce, & Johnson, 2006) Since
the research question for the study (experiences of, and responses to, ADRs) was narrow,
saturation was achieved quickly. (Guest, Bunce, & Johnson, 2006)
92
6.4 Analysis
All interviews were transcribed verbatim and manually coded by two independent coders.
A qualitative software program, NVivo Version 7, was used to organize the data. (Richards &
Richards, 2002) The process of coding involved reviewing all transcripts and identifying key
concepts and themes that emerged from the data. (Boyatzis, 1998) Ongoing meetings with the
coders and all authors were held to explore the coded data and dissent was resolved by
discussion.
6.5 Results
Four consistent key themes related to reporting ADRs for NHPs emerged from the data:
self-perception of competency, responsibility, workplace challenges and professional disposition.
In general, pharmacists tended to lack confidence in their knowledge and training about herbal
products. While pharmacists felt that it was their responsibility to report adverse reactions, tjeu
also felt that it was the responsibility of other health care providers, and they tended to pass this
task to them. Workplace challenges such as time and complexity of the reporting process were
identified as major obstacles to reporting adverse reactions. Finally, each individual pharmacist
had a certain perspective on his or her role within the profession, which impacted whether or not
they reported ADRs, despite the other challenges.
6.5.1 Self perception of competency
Pharmacists were generally concerned with their own knowledge base and competency
with regards to advising patients on herbal products. A lack of knowledge on expected outcomes
or possible side effects made it difficult to assess ADRs related to these products. Pharmacists in
this study emphasized the lack of education received on herbal products in their pharmacy
training, regardless of how long ago they graduated.
93
I can say this is good for this or that but in order for me to make a judgment on this
Echinacea purpurea is for this and this is Echinacea ..whatever the other one is, is better
for something else, I feel confused. I feel like I need more training in herbal products.
(#7)
Like say for example, um, grape seed extract. I really have no knowledge of grape seed
extract. So if it interacts with whatever... I really don’t know. (#1)
Lack of knowledge was identified as a barrier to reporting herbal ADRs that is not found
in the literature about ADR reporting for conventional medications. Confidence in their own
knowledge about herbs and what reactions are expected, was an important factor in both the
pharmacists’ perceived ability to counsel patients on herbal medicines as well as their perceived
ability to recognize and interpret a herbal product related ADR:
In terms of drug interactions, in terms of side effect profiles, and dosing, I mean, I won’t
say I’m 100% comfortable addressing those questions, but at least I know where to go for
information, for further clarification, that sort of thing. (#4)
I would say [my herbal knowledge is] above average I guess because of the material that
is available to us through the resources that we have… I personally would look at it like
it is a common side effect and it is not something unusual and I would not report it. If it
was something more unusual than normal and we have the references to say what to
expect then that might be something that we would investigate further. (#6)
The main concern related to difficulty in making a sound clinical judgment. Pharmacists
asserted that they did not know how to probe about herbal medicine reactions and did not know
what was expected as far as safety and efficacy information was concerned. The discourse on
evidence-based medicine practice within the field of health care required pharmacists to make
clinical judgments based on evidence. The lack of training and poor awareness of herbal
medicine evidence created a perception of uncertainty around herbal medicines and greatly
impacted pharmacists’ ability to make such decisions.
For instance the education I received, it’s all about scientific fact and if you don’t know
you can’t recommend or make any judgment. But the products are out there and we don’t
know as much as we’d like to so you have to make professional judgment … we all get
94
monographs with new drugs, what to tell patients – but you don’t see that about herbal
products, there needs to be more information. (#2)
I just wish I knew what I was dealing with so that I could give more confident advice…
Because from our background, we’re so desperate for fact and evidence. (#1)
There is also an element of how the pharmacist is perceived in the patient’s eyes. The
symbolic capital of legitimating their own knowledge is important when discussing herbs with
patients.
I think there’s a lot of things like saw palmetto -- a lot of people think it’s really good for
prostate, but until there’s a standard dose... some things will say between 200 and 800
and what do you say to the person? So you feel stupid because you don’t even know what
to say to them. (#1)
Pharmacists who were originally trained in a different environment, such as overseas or
in areas where herbal medicine education was emphasized and incorporated into the curriculum,
seemed more comfortable with clinical reasoning about these products. They perceived
themselves to be in a stronger position because they were confident about the knowledge, or
cultural capital, that they possessed, making them better able to make sound, evidence-based
assessments. They also seemed more likely to report due to this confidence in herbal products.
Like back home we are continually learning everything about herbs... Even in my
counselling when someone tells me they have a rash, I ask if they are taking any
medicine or non medicine ingredient because it could be because of vitamins … Let’s say
someone came me and told me I have been using this herbal drug, I will again look
through, does it cause [that reaction] or it does not, I might report it so it’s known that
this drug with this condition can cause this or that. (#8)
Pharmacists trained in hospital pharmacies were not necessarily well versed in herbal
medicines, but they were more aware of how to react to serious ADRs and understood the
importance of gathering and sharing information related to efficacy and safety of products. The
social field of a hospital pharmacy seems to differ from that of a community pharmacy.
I also work in hospital so if someone comes in with [a reaction], we have to report it…
We’re also constantly having sessions on different diseases and things like that so I don’t
95
actively seek out courses or mini-courses; it’s usually part of being in the hospital. It’s
more available; we go to talks and stuffs. If you’re in community [pharmacy practice]
then you have to seek it out. If you want to learn more, it’s not like someone’s coming to
teach you. I think people become lazy and at the end of the day, when you’ve done an 8–
10 hour shift standing all day, who wants to home and study unless you have to? So I
think people should be forced to learn about it. (#4)
A degree of uncertainty about the ADR was another common result of lack of
knowledge. Pharmacists were hesitant to report ADRs if they did not have complete information
such as results of laboratory tests (e.g., plasma concentration of suspected drug) supporting the
suspected reaction. They were also hesitant to report if they were unsure about whether the
herbal product caused the reaction, which supports other existing research as to why pharmacists
do not report. (Green, Mottram, Rowe et al., 2001)
It’s hard because we have to know the whole picture. By talking to the patient you can’t
assess [if it’s a] true adverse reaction. (#12)
In reality, a report only needs to identify a suspected product; it does not need to have a
defined causal link; however pharmacists seemed very hesitant to report reactions if they were
not quite sure they were related to the product in question. Again, pharmacists tended to defer to
physicians who would be able to get the whole picture and properly assess the patient to decide if
it is a true ADR.
It seems that the pharmacists’ perceived position within their social field, and possession
of cultural and symbolic capital – training, confidence and familiarity with herbal products and
ADR reporting – as well as exposure to an environment where training is reinforced, all
contribute to the pharmacist’s decision to report ADRs.
6.5.2 Responsibility
Pharmacists generally agreed that they had a responsibility to report ADRs, including
those associated with herbal medicines, and that it was within their scope of practice to do so:
96
I think in general it’s health care professionals’ responsibility [to educate the public about
herbs]. But I think if I found out about a[n adverse] reaction, then I think I should, it’s
my duty to report it as I think for doctors and nurses. How often does [reporting]
happen? Probably not often. (#5)
Although agreeing that ADR reporting was their responsibility, many pharmacists
admitted to not reporting. In this study we focussed on asking about herbal product related
ADRs but many participants also mentioned that they didn’t report ADRs related to either herbal
medicines or drugs.
If it’s [a] very severe [reaction] then [I tell them to] stop the medication but I don’t think
report. We don’t usually report it. I think we’re supposed to… It’s common practice
though, we don’t report. (#1)
That many pharmacists don’t report suspected ADRs supports previous findings that they
are under-reported. (Ashcroft, Morecroft, Parker, & Noyce, 2006; Herdiero, Figueiras, Polonia,
& Gestal-Otero, 2006)
Pharmacists interviewed in this study pointed out that there is a shared responsibility
between pharmacists and other health care providers to report ADRs. This overlapping
jurisdiction meant that many pharmacists tended to refer to other health care providers rather
than take on the task themselves.
Well, I know we provide [herbs], but it’s very hard to monitor it… I think there are some
other health professionals out there who are better suited, maybe, for doing that? (#9)
I think that doctors should do it, if the patient reported to them, then I just think that they
shouldn’t just take it lightly. (#7)
While pharmacists referred patients to their medical doctors, they did not perceive the
physicians to be necessarily more knowledgeable about herbs or herbal ADRs. Instead they
regarded the medical doctor as someone who was more familiar with the patient’s blood tests
and overall health and therefore better equipped to report complete information about the ADR.
The pharmacists who deferred to the physicians took a more passive stance at patient inquiry and
97
investigation. Instead they assumed a secondary role, less dominant role, within the hierarchy of
the health care system by deferring to the physician.
Sometimes it’s just like, once you send them to the doctor it’s out of sight out of mind,
you have other things to do. (#3)
Doctors in society have more power. Whatever they say, we listen to them. (#11)
In contrast, other pharmacists actively accepted the role of investigator and took it upon
themselves to seek cultural capital in the field of herbal medicines by learning about existing
products and research. They took a more involved role in assessing the patient and worked in
collaboration with physicians rather than under them.
You just try to ask if they are on any other medications to try to pinpoint any potential
interactions that are known and usually you just have to tell them, if you feel strange or
anything bad then come back and talk to us (#10)
Obviously we have a role here ... especially if it is a regular customer it is just like with
anything, we would want to follow-up on the conditions to see how things are… but then
if it is to treat something more serious as opposed to the cold then the doctor should get
involved as well. Sometimes [pharmacists] will just turn the patient away … which is
responsible too because if they can’t give them the answer then they shouldn’t really say
anything, but at the same time patients will get turned off and go to a health food store.
Hopefully pharmacies will realize that they should know something [about herbs] or be
willing to open themselves to this area. (#6)
In addition to passing the responsibility to medical doctors or other ‘more qualified’
practitioners for herbal and conventional ADRs, in the case of herbal medicines specifically,
some pharmacists would also defer responsibility for decisions about herbal products to patients.
I just tell patients I don’t know what the effect will be and I don’t know how safe they
are… I always give that disclosure. So you sort of leave it in the hands of the patient. (#5)
When viewed from the perspective of the field between pharmacist and patient, this
approach seems counterproductive. However, when seen within the context of the larger health
care system, a pharmacist who does not know about herbal medicines, expected ADRs and
research concerning herbs would conceivably disconnect from giving advice and probing about
98
ADRs because of a perceived lack of evidence. This would be considered responsible practice
within the social field of evidence-based medicine practice.
Some pharmacists specifically prompted their patients to keep them informed about
responses to herbal products. Generally these were pharmacists who actively solicited
information and took a more involved approach to their practice. These pharmacists tended to
take on the responsibility of learning at least the basics about herbal safety in order to direct
patients to the appropriate source of information. They recognized that not all other health care
providers would know enough about herbal products and assumed a role in herbal medicine
monitoring within the system as a whole, while also recognizing their own limitations. They
mentioned that they would actively follow-up with their patients after advising on an herbal
product to find out about the patient’s experience. These were often pharmacists who saw a need
to provide patients with advice and information and/or firmly believed that herbal medicines
were fundamentally no different than conventional medicines and thus an important part of
pharmacists’ practice.
The role of the pharmacist is to ensure patient care and to make sure that they are
getting… when they are getting medications that they are getting the proper medication at
the proper dose and trying to minimize any side effects that may occur and ways of
dealing with them. Medications can also include herbal products too. (#10)
These pharmacists encouraged patient-pharmacist interaction in their field of practice
which made it more likely that their patients would communicate with them about ADRs.
6.5.3 Workplace challenges
Workplace barriers to reporting ADRs included structural factors - specifically time,
complexity and type of pharmacy. Pharmacists cited a lack of time as a major obstacle to
reporting adverse events, and the task of reporting was pushed to the bottom of their priorities.
99
The type of pharmacy, chain or independent, also influenced pharmacists’ decisions about
reporting adverse reactions.
Pharmacists that did not report explained that in community pharmacies the retail setting,
or workplace structure, did not afford enough time to report ADR incidents. In the pharmacy
workplace setting, pharmacists were required to respond to customers, complete paperwork,
inventory and deal with human resource management issues, which took priority over the
performance of tasks like ADR reporting which were seen not to be of immediate importance.
People will go on about anything, that’s their way of talking or getting your attention. I’d
love to say everything is an adverse event and give it all attention but in reality it’s hard
to put into practice… I’d likely have 5 minutes or less… You’d have to be at a different
level of care than what you can get in a retail setting. You don’t really get in the chance
to get into the nitty gritty. (#2)
You know what, it’s a time thing. We’re so busy, we have so many other things you
figure it’s not a big deal or I’ll do it later and never get to it. We are bombarded from
every which way to sign a prescription to talk to someone in the aisle to check a drug
company issue, it’s tiring standing all day, you don’t get a break or lunch unless someone
is covering for you. (#11)
Complexity was also mentioned as a challenge to reporting. Many pharmacists described
ADR reporting as requiring a lot of time because it was so complex:
One thing is probably the paperwork involved and there really is just not
enough time. (#3)
I think it’s that usually you have to call this person and then this person and I just don’t
have the time to do all these things. There’s a lot of red tape and then you never see the
benefits of it so a lot of times you feel like it’s not even worth it. (#1)
Setting constraints, such as time, and the perception that the process was complex clearly
influenced pharmacists’ ability to report ADRs. The social field of the community pharmacy
setting is constrained by struggles to meet deadlines and address immediate needs of presenting
patients. Judgments are made not to report ADRs in part because the task itself does not afford
any form of capital that is worth the extra time and effort; and in part because everyday practice
100
sits within a social field between pharmacists and patients, not between pharmacists and
government. It is a responsive tendency to address the existing challenges, leaving less time and
focus on systemic knowledge that might help future patients.
Some pharmacists interviewed were generally unfamiliar with the reporting system for
herbal products.
Interviewer: Are you familiar with the adverse drug reaction reporting system?
Respondent: Not for herbals. (#1)
I think I might have reported something when I was in my internship about 8 years ago
and this is purely because we had to…and I don’t remember who I called. (#2)
When reporting adverse events, there is one form to be filled out and generally phone
calls are not used as a method of reporting to Health Canada, which demonstrates a lack of
awareness about the ADR reporting system. Lack of familiarity, however, was not the only
barrier. Even when pharmacists were aware of the reporting system for pharmaceutical
medicines, and they did not often use it to report pharmaceutical or herbal ADRs.
Pharmacists working in chain pharmacies mentioned a more constrained structural
environment, having less control over which products were stocked in the pharmacy. They also
reported having less ability to practice in they way that they want. To function in such a
restricted field changes the practice habits and decision-making for these pharmacists. In such a
situation, it serves as a constant reinforcement of workplace structures that in turn shape
pharmacists’ views of what they think their role is.
But it’s hard, you know, every company is trying to push their product and even our
company they try to push the sales on a particular product and they expect so much sales
and people ask you if it’s working then, you know, it’s hard to educate them by, you
know, by what I read. It may or may not be effective. People won’t buy it, right? We
just keep it to ourselves. (#11)
101
If pharmacists felt pressured to sell certain products then there might be the result of not
fully discussing the safety issues with patients, which could influence the likelihood of them
discovering and reporting ADRs.
Pharmacists in specialty pharmacies or independent pharmacies tended to mention a
different motivation within practice. Some tried to cater to consumer demand by learning more
about herbal products. This increased knowledge might play a role in the pharmacists’ ability to
interpret an herbal product related ADR.
For your own practice you have to read, you have to have the information. Now how
important this branch of the practice or how relevant your practice, very much depends—
it is kind of individual thing, right? If I get lots of questions about herbal products then I
think as a pharmacist and as a businessman, I have to be able to answer all these
questions. (#6)
Some pharmacists did report ADRs despite workplace pressures. They were familiar
with the reporting system and had previous experience using it.
[It] does take time, to gather all the information, and sometimes you may be the only one
doing the investigation! If you’re just by yourself [in the pharmacy], I think there’s a
certain limit of information you have… but again, I think it’s still better than nothing, if
you can report just those limited information … (#4)
Whether the pharmacists took the time to report ADRs depended at least partially on their
attitudes toward pharmacy practice and their role as a professional, that is, it depended on their
professional disposition.
6.5.4 Professional disposition
The pharmacist’s disposition was an important factor in explaining their workplace
behaviour and whether or not they reported ADRs. While self-perceived competence,
acceptance of responsibility and workplace challenges were all important aspects, the likelihood
of reporting seemed to also be related to differences in pharmacists’ professional dispositions.
All the pharmacists interviewed provided a basic level of pharmacy care to presenting patients.
102
Some pharmacists found workplace challenges to reporting ADRs insurmountable and only
addressed the immediate patient’s needs when presented with a possible ADR:
I think most of the time we just help the patient, though we don’t go one step further to
report the drug reaction. (#11)
All pharmacists made sure that the presenting patient was “safe”. This may have meant
recommending they discontinue taking the suspected product, or making suggestions for another
product to ameliorate the symptoms or replace the product with an alternative. The majority of
pharmacists however, did not provide a population or public health contribution by reporting
ADRs in order to help future patients.
Pharmacists were generally concerned about a lack of research on some herbal products
and potential interactions. They were concerned about people taking herbs if they were also
taking pharmaceutical products, because of possible interactions. But instead of ‘taking that next
step’ to contribute to overall knowledge and understanding of the risks of herbs, they did not see
the task of ADR reporting as a priority. It was considered to be lower on the priority list than
day-to-day tasks, or perhaps, the tenancy of the task was more explicitly seen as that of another
health care provider.
Those who had a strong professional disposition seemed more likely to report and less
likely to allow workplace challenges to prevent their taking that extra step. Pharmacists who saw
themselves as knowledge generators, rather than just knowledge users, were considered to have
strong professional dispositions. They made extra efforts to contribute to an overall
understanding of product safety.
I think it’s an individual choice whether as a health professional you need to also
contribute to the overall safety of medicines. (#10)
Herbal supplements are something that I don’t think will go away so it is very important
that pharmacies out there should try to get some sort of knowledge on them as there are
103
people who want to know and if they don’t get it from us they will get it from someone
else and that is where it could get a bit dicey. It all depends on how much information a
person [pharmacist] is willing to take in to give back to the customer. (#6)
You know what, I pretty much report anything just because… you know, I guess the
more information there is, then the better, and then it can sort of teased out to what’s
really important and what’s not. (#4)
This additional characteristic within their disposition, of seeing themselves as knowledge
generators, seemed to often be present in those that reported suspected ADRs. These
pharmacists were more likely to know more about herbal medicines, to learn more about safety
and made extra efforts to keep updated with regulatory processes.
6.6 Discussion
The findings from this study support previous research about under-reporting of ADRs.
(Green, Mottram, Rowe et al., 2001) Pharmacists who do not report ADRs cite structural
workplace challenges as significant barriers to reporting on both conventional and herbal
medicines. (Hazell & Shakir, 2006; Herdiero, Polonia, Gestal-Otero, & Figueiras, 2004) In
particular, a lack of time and a misconception about the complexity involved in completing the
ADR report were key obstacles to reporting in the community pharmacy setting.
At the same time, some pharmacists did report ADRs. They took it upon themselves to
accept responsibility, learn things about which they were unfamiliar and contribute to the pool of
existing knowledge. There was a continuum of pharmacists with respect to their level of
participation, or their attitude in practice. On one end there were those who performed the basic
level of care for their presenting patients and on the other, those who tried to contribute to the
larger health care system by reporting ADR information. Placement on this continuum was
dependent on the pharmacists’ professional disposition, a result of individual experiences and
personal perspective. Bourdieu contends that there is a relationship between social positions and
104
field (structure), individual dispositions (habitus) and position-taking (choices made). (Bourdieu,
1998) The decision to report ADRs seems to be largely related to the pharmacist’s placement on
a spectrum of possible professional orientations. All pharmacists acted responsibly by
addressing the presenting patients’ symptoms. They all seemed to perform a basic level of
standard care. Those whose professional disposition included a characteristic of being highly
interested in generating knowledge tended to be more up-to-date on regulatory changes. These
pharmacists were also more likely to make the extra effort to report ADRs despite workplace
challenges and overlapping jurisdictions. The pharmacists who were likely to report ADRs
seemed to want to generate knowledge, which was part of their professional disposition. They
perceived their role as one that included contributing to the overall safety of medicines. This
individual disposition, of knowledge generation seemed in part, related to social position or
social structure, and in part it appeared to be an individual characteristic.
It has been argued that perception, interpretation and understanding are formed within the
lived experience and social fabric of clinical practice and shaped by the shared cultural norms,
attitudes and beliefs into which members are socialized. (Paget, 2004) When looking at
pharmacists’ perceptions and reactions to presenting herbal product related ADRs, their thoughts
about herbal medicines, their interpretations of evidence, their understanding of the importance
(or unimportance) of prioritizing reporting all factor into their decisions of how to act. These
opinions and thoughts are shaped by their social environment during training in pharmacy
school, by the discourse of evidence based medicine, by other health care professionals, by their
patients and possibly also by their upbringing.
In addition to shared socialization, such as that during pharmacy school, our study adds
the idea that individual experiences and beliefs contribute to one’s attitude towards practice.
105
Disposition and interpretation of professional responsibility needs to be further explored. The
characteristic of a knowledge generative disposition also needs to be further explored and
explicitly defined. It seems likely that it can be, in part, developed during professional
socialization in pharmacy education and influenced by other factors still untapped. If trying to
motivate pharmacists to see themselves as knowledge generators, one must think of the
educational institution itself as a field.
A new issue highlighted by these findings is an overlap in responsibility between
pharmacists and other health care professionals. The task is within the scope of practice for
several health care providers, so although pharmacists believed that they should report (as should
doctors and nurses), they thought it was acceptable not to do it because someone else would.
This study builds on previous speculation that pharmacists consider ADR reporting as an
‘additional duty’ whereas medical doctors consider it as part of their ‘normal’ duties. (Sweis &
Wong, 2000) Pharmacists that passed on the responsibility did not see themselves as solely
responsible for the patients’ health nor did they acknowledge their contribution to the greater
health care system. The overlap in professional responsibilities influenced the choices that
pharmacists made when responding to patients and resulted in passing the responsibility for
ADR reporting to other professionals. Therefore, there is a potential for the ADR to go
unreported by anyone due to a continual passing of responsibility. According to Bourdieu
theory, this deferral to the medical professional could reflect a perceived inferior position by
these pharmacists. Further research is needed to explore this finding.
6.7 Implications
The findings presented in this paper demonstrate a necessity to educate pharmacists about
the current reporting system and what is involved in reporting. Education can change
106
misconceptions about the time and complexity involved in ADR reporting. Furthermore,
education about reporting ‘suspected’ ADRs can minimize another current barrier: the
perception that one must have all the information to report a ‘conclusive’ ADR. The finding
that pharmacists generally did not perceive themselves to be knowledgeable regarding NHPs
highlights the need for further training in this area.
The findings of this study also point towards a need to foster a strong professional
disposition within the pharmacy curriculum. Pharmacy faculties can incorporate knowledge
generation as a central role for pharmacists along with other professional values and ethics.
Other authors have found that pharmacists consider it their professional obligation to report, but
that they still do not report ADRs. (Green, Mottram, Rowe et al., 2001) Fostering a professional
disposition within the training program might enable more pharmacists to overcome the
contextual barriers to reporting.
6.8 Conclusions
The position-taking of pharmacists (whether they report ADRs) is influenced by structure
(workplace challenges) as well as habitus, or individual disposition. The idea of professional
disposition can be conceptualized as a range of personal motivations and tendencies. This study
points towards ADR reporting as possibly one outcome of having a strong professional
disposition. Further research is needed to adequately describe and characterize professional
disposition and its component elements. This study also highlights a potential neglect of tasks
that are not clearly defined exclusively in the scope of practice of pharmacists. The tasks are
passed on from pharmacists to other health professionals depending on their perceived position.
There is a need for future research examining professional disposition with respect to ADR
reporting as well as research on how professions negotiate overlapping tasks.
107
6.9 References
Alvarez-Requejo, A., Carvajal, A., Begaud, B., Moride, Y., Vega, T., & Arias, L. (1998). Under-
reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme
and sentinel system. European Journal of Clinical Pharmacology, 54(6), 483-488.
Ashcroft, D., Morecroft, C., Parker, D., & Noyce, P. (2006). Likelihood of reporting adverse
events in community pharmacy: an experimental study. Quality and Safety in Health
Care, 15, 48-52.
Barnes, J., Mills, S.Y., Abbot, N.C., Willoughby, M., & Ernst, E. (1998). Different standards for
reporting ADRs to herbal remedies and OTC medicines: face-to-face interviews with 515
users of herbal remedies. British Journal of Clinical Pharmacology, 45, 496-500.
Barnes, J. (2003). Pharmacovigilance of herbal medicines: a UK perspective. Drug Safety,
26(12), 829-851.
Bertilsson, T.M. (2004). The elementary forms of pragmatism: on different types of abduction.
European Journal of Social Theory, 7(3), 371-389.
Bourdieu, P. (1986). The forms of capital. In J.G. Richardson (Ed.), Handbook of theory and
research for the sociology of education (pp. 241-258). New York: Greenwood Press.
Bourdieu, P. (1990). In other words: Essays towards a reflexive sociology Cambridge: Polity
press
Bourdieu, P., & Wacquant, L. (1992). An invitation to reflexive sociology Chicago, IL:
University of Chicago Press
Bourdieu, P. (1993). The field of cultural production Cambridge: Polity Press
Bourdieu, P. (1998). Practical reason Cambridge: Polity press
Boyatzis, R. Transforming Qualitative Information: Thematic Analysis and Code Development
Thousand Oaks, CA: Sage; 1998.
Charrois, T., Hill, R., Vu, D., Foster, B., Boon, H., Cramer, K., & Vohra, S. (2005). Survey of
community pharmacist reporting of adverse drug reactions associated with natural health
products in CAM research in Canada: sharing successes and challenges - Abstracts from
the 2nd annual IN-CAM Symposium, November 12&13. Journal of Complementary and
Integrative Medicine, 2(1), Article 12.
Chitturi, S., & Farrell, G. (2008). Hepatotoxic slimming aids and other herbal hepatotoxins.
Journal of gastroenterology and hepatology, 23(3), 366-373.
Creswell, J. (1998). Qualitative Inquiry and Research Design: Chosing Among Five Traditions
London: Sage
Crossley, N. (2001). The phenomenological habitus and its construction. Theory and Society,
30(1), 81-120.
Denzin, N., & Lincoln, Y. (1994). Handbook of qualitative research. Thousand Oaks: Sage.
Farrell, A.M., & Staughton, R.C. (1996). Garlic burns mimicking herpes zoster [letter]. Lancet,
347(9009), 1195.
Farrell, J., Ries, N.M., & Boon, H. (2008). Pharmacists and Natural Health Products: A
systematic analysis of professional responsibilities in Canada. Pharmacy Practice, 6(1),
33-42.
Fletcher, A. (1991). Spontaneous adverse drug reaction reporting vs. event monitoring: a
comparison. J R Soc Med, 84(6), 341-344.
108
Granas, A.G., Buajordet, M., Stenberg-Nilsen, H., Harg, P., & Horn, A.M. (2007). Pharmacists'
attitudes towards the reporting of suspected adverse drug reactions in Norway.
Pharmacoepidemiology and Drug Safety, 16, 429-434.
Green, C.F., Mottram, D.R., Rowe, P.H., & Pirmohamed, M. (2001). Attitudes and knowledge of
hospital pharmacists to adverse drug reaction reporting. British Journal of Clinical
Pharmacology, 51, 81-86.
Guest, G., Bunce, A., & Johnson, L. (2006). How many interviews are enough?: An experiment
with data saturation and variability. Field Methods, 18, 59-82.
Hazell, L., & Shakir, S.A.W. (2006). Under-reporting of adverse drug reactions: A systematic
review. Drug Safety, 29(5), 385-396.
Health Canada (2002). Health Canada requests recall of certain products containing
Ephedra/ephedrine. In Health Canada (Ed.). Ottawa.
Health Canada (2007). Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Adverse Reaction Database: Health Canada.
Herdiero, M.T., Polonia, J., Gestal-Otero, J.J., & Figueiras, A. (2004). Factors that influence
spontaneous reporting of adverse drug reactions: A model centralized in the medical
professional. Journal of Evaluation in Clinical Practice, 10(4), 483-489.
Herdiero, M.T., Figueiras, A., Polonia, J., & Gestal-Otero, J. (2006). Influence of Pharmacists'
Attitudes on Adverse Drug Reaction Reporting. Drug Safety, 29(4), 331-340.
Inman, W.H. (1985). Under-reporting of adverse drug reactions. British Medical Journal,
290(6478), 1355.
Inman, W.H. (1996). Attitudes to adverse drug reaction reporting. British Journal of Clinical
Pharmacology, 41, 434-435.
Irujo, M., Beitia, G., Bes-Rastrollo, M., Figueiras, A., Hernandez-Diaz, S., & Lasheras, B.
(2007). Factors that influence under-reporting of suspected adverse drug reactions among
community pharmacists in a Spanish region. Drug Safety, 30(11), 1073-1082.
Kwan, D., Boon, H., Hirshkorn, K., Welsh, S., & Jurgens, T. (Accepted July 1 2008).
Consumers’ influence on pharmacists’ professional responsibilities with respect to
natural health products. BMC Complementary and Alternative Medicine.
Lawson, T. (1989). Abstraction, tendencies and stylised facts: a realist approach to economic
analysis. Cambridge Journal of Economics, 13, 59-78.
Lee, K.K., Chan, T.Y., Raymond, K., & Critchley, J.A. (1994). Pharmacists' attitudes toward
adverse drug reaction reporting in Hong Kong. Ann Pharmacother, 28(12), 1400-1403.
McEvoy, P., & Richards, D. (2003). Critical realism: a way forward for evaluation research in
nursing? Journal of Advanced Nursing, 43(4), 411-420.
NHPD (2003). Natural health products regulations. In N.H.P. Directorate (Ed.): Health Canada.
NHPD (2005). Baseline natural health products survey among consumers: Health Canada.
Paget, M. (2004). The unity of mistakes Philadelphia: Temple University Press
Richards, L., & Richards, T. (2002). NVivo 2.0 [Software for Qualitative Research] Melbourne:
QSR Solutions
Sweis, D., & Wong, I.C.K. (2000). Adverse drug reaction reporting according to hospital
pharmacists in Great Britain. Drug Safety, 23(2), 165-172.
Thomas, K., Nicholl, J., & Coleman, P. (2001). Use and expenditure on complementary
medicine in England: a population based survey. Complementary Therapies in Medicine,
9(1), 2-11.
109
World Health Organization (1995). Note for guidance on clinical safety data management:
definitions and standards for expidited reporting, CPMP/ICH.377/95.
110
Table 3: Pharmacist demographic information
Total participants
(n=12)
Sex
Male 3
Female 9
Years in practice
< 5 years 4
> 5 years 8
Hours worked per week at community pharmacy
Part-time (<25 hours/week) 3
Full-time (>25 hours/week) 9
Pharmacy Type
Chain pharmacy 9
Independent pharmacy 3
Training in herbal medicines or pharmacognosy
None
7
One course during pharmacy school 3
Continuing education course 1
Additional formal training 1
Self study from books, internet, journals 3
Table 4. Core questions from semi-structured interviews that pertain to risk and safety
How do you feel about the safety of herbal products?
What do you think the role of the pharmacist is with respect to herbal products?
How do you feel about giving advice on herbal products?
What information helps you make a decision about how to advise your patients?
Whose responsibility is it to report suspected adverse drug reactions associated with
herbal medicines?
Is there anything else that you would like to tell me?
111
CHAPTER 7. SUMMARY AND IMPLICATIONS
The research reported here contributes to the academic literature addressing NHP safety
monitoring in a number of ways. First, in this research, I address the ways in which consumers
responded to having had an adverse drug reaction to an NHP. Second, I assess health food store
responses to NHPs, their customers and safety concerns. Finally, I document the perspectives of
pharmacists towards NHPs and adverse drug reaction reporting. This chapter begins with a brief
summary of the results followed by a discussion of how the data from these three populations is
relevant for clinical care, policy makers and sociologists. The chapter ends with a section on
limitations of the study and the conclusions that can be drawn from the study.
7.1 Consumer Interviews
It is difficult to monitor safety issues associated with NHPs due to the over-the-counter
access of these products which means they can be selected by consumers without advice from a
health care provider. Consumers often take it upon themselves to research NHPs, or follow the
advice of friends and family, and self-prescribe NHPs. According to our research, some factors
that impact consumers’ decisions to report, or not report, possible NHP-related adverse drug
reactions (ADRs) include: individual beliefs about the severity of the illness and risk associated
with taking NHPs for their conditions, their personal value systems related to health and illness
as well as personal experiences. Our findings also demonstrate that consumers’ likelihood to
report is also related to their relationships, or perceived relationships, with health care providers.
If consumers expect that health care providers will disagree with, or disapprove of, their choices
to take NHPs, they are unlikely to discuss their suspected adverse drug reactions. The fear of
being judged was a strong theme within the consumer interviews. In general after experiencing
an ADR, consumers turned to people they believed would be accepting of their choices and
112
people whom they considered to be trustworthy sources of information. Often the consumers
interviewed for this study turned to health food store personnel rather than health care providers
of any kind.
7.2 Health food store interviews
Being in the service industry, health food store personnel were concerned with providing
reliable and satisfactory service to their customers. (Porter, 1974; Price & Arnould, 1999) This
often meant that they took time for their customers -- to listen to their concerns and to advise
them on products available in the store. These interactions enabled relationships to be built with
their customers, to the point where consumers of NHPs felt comfortable complaining to the
health food store personnel about ADRs from both NHPs and conventional medications. Where
the concerns were related to NHPs, health food store personnel took it upon themselves to accept
returns of the products as a gesture of good faith. This could be seen as respecting the wishes of
the customer and validating their complaints. In this manner, the health food store personnel
were able to maintain customer loyalty and the consumers felt that their concerns are addressed.
This service provider relationship with the customer provides an interesting opportunity for
safety monitoring. Chapter 5 explores how this relationship may be used to help collect
additional information about NHP-related ADRs. However, our data also show that some people
do report suspected NHP-related ADRs to health care providers such as pharmacists.
7.3 Pharmacist Interviews
Community pharmacist, are also in the service providing industry. Their duties as health
professionals seem, in most cases, to supersede their business motivations. However, our
findings indicate that consumers rarely report suspected ADRs to their pharmacists, thinking that
pharmacists either didn’t know enough about NHPs or that they weren’t willing to listen. Many
113
pharmacists do lack the knowledge, skills and time necessary to adequately help a patient to
investigate and report as suspect ADR associated with an NHP to Health Canada. However, our
data seems to indicate that some pharmacists with certain professional dispositions perceive
themselves as knowledge generators and are more likely to be able to help patients to report
ADRs. Our data indicate that there was a continuum of pharmacist disposition, ranging from
knowledge users (who provided a base level of care to their patients), to knowledge generators
who, in addition to base care, also contributed to overall knowledge of the profession in the area
of NHPs and ADRs by choosing to report ADRs as well as actively participate in other voluntary
professional activities.
7.4 Implications for Clinical Care
This research uncovered key clinical findings in the area of healthcare communication.
Consumers often took their health into their own hands by self-prescribing NHPs and then
dealing with the ADRs on their own primarily as a consequence of not believing there was
anyone to whom they could turn. It was apparent from the data that consumers who felt that they
weren’t being listened to with an open mind or that their concerns were not taken seriously,
rarely discussed NHP related issues with their health care providers and often turned to other
sources of information. This poor relationship with health care providers resulted in a lack of
communication about NHPs and associated ADRs.
In this way, ADR reporting by patients to health care professionals was related to their
perceived relationship. Some consumers who did have a good relationship with their health care
provider did disclose their ADR information. Those that felt they had a good relationship but did
not discuss ADR experiences cited a lack of time within the visit as the main barrier. There is an
114
opportunity to improve communication between patients and health care providers to encourage
communication and likelihood of collecting more detailed NHP related safety information.
Future research is needed in this area of patient communication related to NHP ADRs and
suspected ADRs in general. While some health care providers may not know or believe in
NHPs, their ability to discuss these issues with their patients is essential in obtaining relevant
safety information. Presently, the pharmacovigilance system assumes that pharmacists and other
health care professionals know enough about herbs and other NHPs to be able to identify and
adequately report ADRs associated with these products. This is not necessarily the case. The
voluntary nature of the reporting system also assumes that patients will seek someone out who
has the responsibility to report their ADR. Our data indicate that this is also not happening. It is
important that health care professionals actively seek out this information from their patients.
More research is also needed within the NHP industry and at the health food store level since
consumers were likely to turn to health food stores for information about NHPs and safety issues.
Health food stores are functioning as NHP pharmacies for these over-the-counter products,
which might require a change in regulation, legislation or standardization requirements for
training and reporting.
7.5 Policy Implications
This study highlights the role of a new population, health food store personnel, who
might be able to play a part in safety monitoring in a novel and unique way. This study found
that health food stores are in an important position to receive ADR information about NHPs.
Consumers trust health food store personnel and turn to them for information. Health food store
personnel also receive safety information upon filing a product return. However, health food
store personnel are not health care practitioners. Their training in NHPs varies from store to
115
store and they may not have any healthcare knowledge. (Brazier & Levine, 2002; Glisson,
Rogers, Abourashed et al., 2003; Healey, Burgess, Siebers et al., 2002) If they are being relied
upon as resources for safety monitoring and for providing information to consumers, more
research is needed about their role in NHP safety monitoring.
If health food store personnel were formally encouraged to fill a role in NHP safety
monitoring, this would raise the question of whether they have similar barriers to reporting as do
pharmacists (such as lack of time). They might also have new barriers to reporting related to
reluctance to report because of fears that products might be removed from the market and the
impact that would have on their business. In order to make the most of this unique resource,
more research is needed in the area of policy and market research to determine how health food
store personnel can contribute to current ADR monitoring systems.
Since health food stores are returning products to industry, there is also the possibility for
research in the NHP industry to see how it plays a role in safety monitoring for NHPs. NHP
regulations require industry to report ADR information to Health Canada. If they receive ADR
information via product returns, it is important to determine how this information can be
enhanced and whether industry can and will follow-up with these reports. It is also important to
evaluate strengths and limitations related to communication between health food stores, industry
and Health Canada.
7.6 Theoretical Contributions
From a theoretical perspective, this study contributes to two key areas of research. First, to
the professions literature and second to the literature on Bourdieu’s theory of practice. In his
theory on systems of professions, Abbott argues that members of professions define their
jurisdictions (the link between a profession and its work) by claiming exclusive rights over
116
particular tasks. (Abbott, 1988) The literature on professions outlines the process of task
negotiation between professions and the delineation of responsibilities based on knowledge or
skill. However, in Canada ADR reporting is a task that was not claimed by Canadian
pharmacists per se. Instead this task was conferred upon them by Health Canada. In addition,
pharmacists aren’t exclusively responsible for undertaking ADR reporting; it is a shared tenancy
between pharmacists, medical doctors, other health care professionals and now the public. It is
not an obligatory requirement in Canada (although is in some countries) (Wiholm, Moore, &
Waller, 2002), but rather a voluntary act to be performed in the interest of advancing product
knowledge and safety of health care overall. Abbott’s theory of the systems of the professions
does not adequately explore what happens to tasks like ADR reporting that are shared and were
never specifically claimed by a professional group. The ideal situation for safety monitoring
would be that all professions claim responsibility for the task and that they all contribute to ADR
reporting. However, the blurring of boundaries between task allocation results in a potential for
the task to be ignored by all professionals. ADR reporting was not perceived as a core part of
pharmacists’ jurisdiction by the participants in this study which largely explains why it is not
given priority in pharmacists’ busy work days. This lack of prioritization may be because
pharmacists feel that it belongs in another professionals’ jurisdiction, or because they do not see
its importance compared to other day-to-day demands or because they do not see it as part of the
professional role of pharmacists. It is not clear how pharmacists would react if this task was
removed from their jurisdiction and given exclusively to others such as physicians and/or health
food store personnel.
This study builds on previous speculation that pharmacists consider ADR reporting as an
‘additional duty’ whereas medical doctors consider it as part of their ‘normal’ duties. (Sweis &
117
Wong, 2000) The pharmacists in this study often did not report adverse drug reactions unless
they were in the category of knowledge generators (i.e., had strong professional disposition).
This study highlights the potential problem associated with tasks that lie within multiple
jurisdictions and suggests potentially important future research in the areas of professional task
negotiation, professional disposition, doctor-patient communication, the role of government
expectations and ADR collection mechanisms. It is important to determine how professions
negotiate tasks that belong in several jurisdictions, how these tasks are allocated and prioritized
and who finally takes responsibility for their completion.
Another theoretical contribution of this study is its application of Bourdieu’s theory of
practice to the field of pharmacy; specifically, to the concept of habitus within pharmacy.
(Bourdieu, 1977, 1990) The professional disposition of pharmacists appears to be instrumental in
guiding their actions and responses to safety concerns in the community pharmacy workplace.
The pharmacist’s perception of his or her role in practice and within the health care system is
another key aspect influencing behaviour in clinical situations. This analysis can therefore
contribute to future research in the area of pharmacy education and efforts to foster professional
disposition among pharmacy students. It is important to characterize what makes up professional
disposition, how it can be identified or fostered and how it might change within and between
professionals. Professional disposition may be a key to determining professional attitudes and
behaviours and can be further explored in pharmacy as well as in other health related disciplines.
7.7 Methodological Insights
In chapter 3, positionality was mentioned with respect to my status as not only a PhD
student in pharmaceutical sciences but also as a Naturopathic Doctor. This dichotomy of
practitioner and researcher influenced my ability to collect data by allowing me to position
118
myself to the participants in a way that made them relate to me. Traditional positivist
approaches support distance between observer and observed (de Laine, 2001), while
postmodernists assert that the participant observer’s account is necessarily a ‘joint product of the
group and the observer’. (Ashworth, 1995) I have chosen to be reflective about my position and
my experience and how it may influence me as a researcher and my own research findings.
In critical realism, positionality is taken in a spatial sense, so that for every phenomenon
under investigation, there are various (spatial) perspectives or positions from which it can be
viewed. (Bhaskar, 1975) The more perspectives from which it can be viewed, the fuller, richer
picture of the situation. By understanding my own experiences and that my knowledge is
situated, I recognize that my views are context-bound and partial. This recognition of my
positionality necessitates conscious reflexivity about my interpretations of my data and about my
interactions with my participants.
As is described in nursing literature, many of the skills considered essential to effective
clinical work are associated with interviewing skills, such as ‘careful listening, astute observation
and interpretation on several levels simultaneously’. (Borbasi, Jackson, & Wilkes, 2005; Lipson,
1989) Being an ND allowed me to feel comfortable in health food store settings and discussing
natural health products, rather than entering a field of a completely unknown culture. However,
this familiarity might have negatively influenced my ability to be objective about my participants
and their responses. When interviewing one health food store owner for example, I was
particularly troubled upon hearing the type of medical advice she was giving to her customers
despite having no training and less than a few months of experience in the field. I had to
constantly be aware of my questions to be sure that I wasn’t leading her in a particular way.
Thankfully, due to my training in interviewing skills, I was able to keep my questions open-
119
ended which allowed a wealth of data through which to interpret her responses. My
interpretation of this data in particular, differed from those of some of the other members of my
committee and we had to discuss all themes in detail. We then reached consensus on the major
themes by discussion.
In order to address the pitfalls of the insider phenomenon (Finlay, 2002), my supervisor
and I arranged a thesis advisory committee composed of individuals with differing backgrounds,
both clinically and from a research standpoint. They were able to guide me with respect to
perspectives I had overlooked. For example, their analysis of the health food store personnel
transcripts were particularly useful since I had worked at one many years ago and drew on my
experiences during my own interpretation of the data. The committee was able to offer other
views and interpretations of the data. We were able to discuss the themes and reach consensus as
a group.
Another issue with my dual perspective was that when talking to consumers, they sometimes
asked me for advice regarding their NHPs and reactions. None were urgent or severe enough
issues to warrant concern and I was able to address their questions generally or refer them to a
qualified health provider. However, if the questions had been related to their health directly, my
obligations as a practitioner would conflict with my responsibilities as a researcher. In our ethics
proposal, we clearly indicated that should the need arise for urgent care, we would assist the
participant in finding appropriate health care. When talking to consumers, I did not routinely
mention that I am trained as an ND. However, it is clearly stated on the consent form. This was
a difficult situation as I was not approaching them on a clinical level but rather as a researcher.
If they had clinical concerns, I would answer them generally at the end of the interview and then
120
offered to refer them to a practitioner who would be able to be more specific about their
particular health history and course of action.
I learned that the dual perspectives could be helpful in situating me well with people from
diverse backgrounds and opposing perspectives. However, my authority as a researcher and my
analysis could be compromised without adequate reflexivity and collaboration. In future
research, it is important to consider the practical, ethical and epistemological difficulties
surrounding the complex nature of the researcher/practitioner role.
7.8 Limitations
Limitations in this research are centered on the sample. For the retailer populations
studied (pharmacists and health food store personnel), the sample sizes were small because the
focused nature of the research question meant that theoretical saturation was reached quickly.
Efforts were made to broaden the sample size by using posters, advertisements, listservs and
internet resources. Also, efforts were made to include retailers who were part-time employees,
managers, store owners, from small independent stores, local retail chains, larger retail chains
and other diverse backgrounds. The sample size is not necessarily a significant limitation
because the sample recruited was diverse in their background, demographics and experiences,
and as such offered a wide range of opinions. Due to this diversity, it is unlikely that more
interviews would have contributed to additional themes being uncovered. (Guest, Bunce, &
Johnson, 2006) In the consumer group, after much difficulty recruiting participants, the sample
was collected via a combination of purposive sampling and the snowball technique, which may
have limited the variety of respondents. (Creswell, 1998a) The sample was composed of
primarily female participants who were highly educated, which although not representative of
the general Canadian population, is relatively similar to the demographics of NHPs users overall.
121
(Crane, 1994) Also, the range of ADRs experienced varied widely, which suggests that
additional key themes were unlikely to emerge with additional interviews. Two key groups were
missing in the samples, elderly and children. While this study focussed on the adult population,
it would be helpful to study these additional groups in order to determine if any differences exist
in their experience with ADRs.
7.9 Next Steps
The present doctoral research points to several important next steps in research. Two key
areas are highlighted below.
The first is to explore natural health product (NHP) industry relationships with
government and consumers. The 2004 NHP regulations place legal requirements on the NHP
industry that include reporting of suspected adverse reactions associated with NHPs, similar to
those currently in place for other regulated health products. If industry can be considered a
funnel through which ADR information may be channelled, this is an area of research that
warrants further exploration. (NHPD, 2003) Current research in the pharmaceutical industry
describes the delicate balance between the interests of pharmaceutical companies and regulators.
(Abraham, 1994) While this literature focuses on the pharmaceutical industry’s role, there is a
paucity of information on the NHP industry. The NHP industry is unique because their products
are already available over-the-counter and the regulations will be applied retroactively. Also,
NHPs in general have more variation and are often not patented and thus, research on the
pharmaceutical industry cannot be easily generalized to this sector. Using an institutional
sociology theoretical lens, future research could analyze NHP risk by exploring the role of
experts and expertise in regulation. (Abraham, 2004) Manufacturers and governmental decision-
makers together control the access of NHPs, thus their risk assessments can be interpreted as
122
socio-political judgments. (Abraham & Reed, 2001) The research could investigate the
relationship between public safety and the production, interpretation and communication of NHP
adverse drug reaction (ADR) assessments between industry, government and consumers. These
include current policies, standards of conduct, codes of ethics and compliance to legal
requirements. The general objectives of this research should therefore first be to determine the
key dimensions of industry influence on, and obstacles associated with industry compliance to,
the new regulations. Second, to explore industry-government relationships with respect to ADR
assessments. Third, to consider the policy implications of these relationships in the context of
evolving social dynamics. The ultimate aim of the research would be to enhance our
understanding of the role of NHP manufacturers in safety monitoring in the context of recent,
strict regulatory demands. (NHPD, 2003)
The second area of needed research stemming from this doctoral work is in the area of
professional disposition. The current doctoral work identifies a personal, individual perspective
or attitude towards practice. The tendency to report is one aspect of this larger concept of
professional disposition. Future research could explore what characteristics make up
professional disposition. This research could be conducted with pharmacists but also with
physicians and other health care professionals. It seems that there may be a range of professional
dispositions that may encompass a number of different aspects of practice. It is important to
understand how these elements come together and what influences this disposition. Is it innate,
for example, or can it be taught? Is it created as part of a socialization process during
professional education or is there something cultural about it? Perhaps it is a combination of the
above possibilities. This topic could be explored through qualitative research via participant
observation, interviews or focus groups. Participant observation is essential as professional
123
disposition doesn’t seem to be a conscious tendency and thus may not be adequately explained
through interviews alone. The characteristics, once identified, could be tested on a larger group
of practitioners through a survey to identify the range of dispositions that exist and the
constellation of elements that contribute to them.
7.10 Conclusions
This study examined the perspectives of three populations with respect to NHP ADR
reporting: consumers, health food store personnel and pharmacists. Consumers often decided to
take NHPs on their own without guidance from health care providers. If they experienced a
product-related ADR, they used their knowledge and experience to identify the product involved
and decided whether or not to discuss their experiences. Most often, consumers dealt with the
suspected ADR on their own. In some cases, usually where the reaction was more distressing or
if they perceived their experience as relevant to others, they discussed it with family or friends.
If they needed more information or advice on how to handle the ADR, they turned to trusted
resources for information. It most cases, the trusted resource was not one of their health care
providers but instead, the health food store personnel. Consumers cited poor relationships with
health care providers and the health care providers’ lack of time or interest as main reasons for
not telling them about NHP-related ADRs.
In contrast, health food store personnel were described as being attentive to consumer
needs. Although the health food store personnel in the study did not have the knowledge or skill
to identify and report ADRs to Health Canada, they did their best to address the consumers
concerns, usually by returning the product to the manufacturer for a refund. This provides a
unique but complicated opportunity to harness health food stores personnel as a way to collect
more ADR information.
124
Pharmacists, although also selling NHPs, are often not the ones that consumers turn to for
information about suspected NHP-related ADRs. Most pharmacists do not report ADRs
disclosed by patients to Health Canada, even though they acknowledge this is part of their scope
of practice. Whether a given pharmacists reports suspected ADRs appears to relate to his/her
professional disposition. Future research is needed in the area of patient communication, industry
roles, health food store regulation and professional disposition in order to improve understanding
of these facets of ADR reporting.
125
7.11 References
Abbott, A. (1988). The System of Professions. An Essay on the Division of Expert Labor
Chicago: University of Chicago Press
Abraham, J. (1994). Distributing the benefit of the doubt: Scientists, regulators and drug safety.
Science, Technology & Human Values, 19, 493.
Abraham, J., & Reed, T. (2001). Trading risk for markets: The international harmonization of
pharmaceuticals regulation. Health, Risk and Society, 3, 113-128.
Abraham, J. (2004). Scientific expertise and regulatory decision making: Standards, evidential
interpretation and social interests in the pharmaceutical sector Burlington, VT: Ashgate
Publishing
Ashworth, P. (1995). The meaning of 'participant' in participant observation. Qualitative Health
Research, 5(3), 366-387.
Bhaskar, R. (1975). A realist theory of science London: Verso
Borbasi, S., Jackson, D., & Wilkes, L. (2005). Fieldwork in nursing research: positionality,
practicalities and predicaments. Journal of Advanced Nursing, 51(5), 493-501.
Bourdieu, P. (1977). Outline of a Theory of Practice Cambridge: Cambridge University Press
Bourdieu, P. (1990). In other words: Essays towards a reflexive sociology Cambridge: Polity
press
Brazier, N., & Levine, M. (2002). An evaluation of the quality of herbal product information
provided by health food store retailers and pharmacists in a Canadian city. Can J Clin
Pharmacol, 9(2), 108-109.
Crane, F. (1994). Profiling the Health Food Store Shopper. Journal of Food Products Marketing,
2(1), 53-59.
Creswell, J. (1998). Qualitative Inquiry and Research Design: Chosing Among Five Traditions
London: Sage
de Laine, M. (2001). Fieldwork, Participation and Practice: Ethics and Dilemmas of Qualitative
Research London: Sage Publications
Finlay, L. (2002). "Outing" the researcher: the provenance, process, and practice of reflexivity.
Qualitative Health Research, 12(4), 531-545.
Glisson, J.K., Rogers, H.E., Abourashed, E.A., Ogletree, R., Hufford, C.D., & Khan, I. (2003).
Clinic at the health food store? Employee recommendations and product analysis.
Pharmacotherapy, 23(1), 64-72.
Guest, G., Bunce, A., & Johnson, L. (2006). How many interviews are enough?: An experiment
with data saturation and variability. Field Methods, 18, 59-82.
Healey, B., Burgess, C., Siebers, R., Beasley, R., Weatherall, M., & Holt, S. (2002). Do natural
health food stores require regulation? N Z Med J, 115(1161), U165.
Lipson, J. (1989). The use of self in ethnographic research. In J. Morse (Ed.), Qualitative
Nursing Research: A Contemporary Dialogue (pp. 61-75). Rockville, MD: Aspen
Publications.
NHPD (2003). Natural health products regulations. In N.H.P. Directorate (Ed.): Health Canada.
Porter, M.E. (1974). Consumer behaviour, retailer power and market performance in consumer
goods industries. The Review of Economics and Statistics, 56(4), 419-436.
Price, L.L., & Arnould, E.J. (1999). Commercial friendships: Service provider-client
relationships in context. Journal of Marketing, 63(October), 38-56.
126
Sweis, D., & Wong, I.C.K. (2000). Adverse drug reaction reporting according to hospital
pharmacists in Great Britain. Drug Safety, 23(2), 165-172.
Wiholm, B.-E., Moore, N., & Waller, P. (2002). Spontaneous Reporting Systems Outside the
US. In B.L. Strom (Ed.), Pharmacoepidemiology: John Wiley & Sons, Ltd.
127
Study Information Sheet
Project Title: Reporting of Adverse Events Associated with Herbal Products
Dear Sir or Madam:
I am writing to you requiring your assistance and participation in a research
project for my PhD thesis at the University of Toronto. I would like to invite you to
participate in my study.
What is the purpose of the study?
The purpose of this study is to explore the experiences of Canadians. This project
will describe the key factors and concerns that these groups describe with respect to
herbal products.
When and where will the study take place?
Data for the study will be collected from September to December 2007.
Who is being asked to take part and what will they do?
Consumers, like you, will be asked to participate in a short interview. During the
interview, each participant will be asked to describe his or her experiences with herbal
products, and the risks and safety of these products. The interview will last between 20
minutes and 1 hour, depending on how much information you would like to share. The
interview will be conducted at a mutually convenient time as soon as possible after
consent is given.
What are the risks and benefits of the study?
The study has minimal risk. Your participation is completely voluntary. If a
participant is uncomfortable answering a particular question, they do not have to answer.
Furthermore, participants may withdraw from the interview or study at any time.
This study will allow an understanding of reporting behaviors and barriers to the
current system to be explored. The study will contribute to research in a largely
unexplored field. The project will provide practical information about the views about
risks and safety of herbal products. These results may help the Natural Health Product
Directorate (NHPD), the division of Health Canada responsible for administering the
regulations, understand consumer needs and perspectives. Since the NHPD has shown
interest in this topic, the agency may use the data to devise additional measures designed
to specifically to educate the public or to improve herbal product regulations. A summary
of results will be distributed to participants who are interested.
Is the study confidential?
All the information collected during the research process will be kept strictly
confidential. The names of participants will not be used for any stage of the research.
An identification code will be used in place of names that will only be known to the
research team (listed below). All documentation with personal information about the
Appendix A: Study Information Sheet - Consumers
128
participant will be kept in a locked cabinet. Data from the interview that is stored on a
computer will require a password only known to the researchers. Personal information
will not be released to any one else without a court order.
Quotations from the interviews may be used in the final research report.
However, names and identifying information will not be included with these notes. The
final report may be submitted for publication in a peer-reviewed journal.
What if something new comes up during the study that affects participation in the
research?
Participants can withdraw from the study at any time, for any reason.
Will I be compensated for participating in this study?
No, you will not be compensated for participating in this study.
What are my rights as a research participant?
If you have questions about your rights as a research participant, please contact
Jill Parsons, Research Ethics Officer, Health Sciences in the Ethics Review Office,
University of Toronto, at telephone 416 946 5806 or by email: [email protected]
Your participation is important for furthering this research study. Please consider
participating. I can be contacted at the number and email address below for any
questions or concerns that you may have.
Sincerely,
Rishma Walji
PhD Candidate, Department of Pharmaceutical Sciences, University of Toronto
Tel: 416-978-6951
Other Members of the Research Team:
Dr. Heather Boon, Dr. Zubin Austin Dr. Ross Baker Dr. Joanne Barnes
Thesis Supervisor Committee Member Committee Member Committee Member
Tel: 416-946-5859
Fax: 416-978-1833
129
Study Information Sheet
Project Title: Reporting of Adverse Events Associated with Herbal Products
Dear Sir or Madam:
I am writing to you requiring your assistance and participation in a research
project for my PhD thesis at the University of Toronto. I would like to invite you to
participate in my study.
What is the purpose of the study?
The purpose of this study is to explore the experiences of Canadian pharmacists
and health food store personnel who sell herbal products. This project will describe the
key factors and concerns that these groups describe with respect to reporting side effects
associated with herbal products.
When and where will the study take place?
Data for the study will be collected from June to June 2007.
Who is being asked to take part and what will they do?
Pharmacists and health food store personnel, like you, who sell herbal products at
pharmacies and health food stores, will be asked to participate in a short interview.
During the interview, each participant will be asked to describe his or experiences with
herbal products, and the risks and safety of these products. The interview will last
between 20 minutes and 1 hour, depending on how much information you would like to
share. The interview will be conducted at a mutually convenient time as soon as possible
after consent is given.
What are the risks and benefits of the study?
The study has minimal risk. The participation of your company is completely
voluntary. If a participant is uncomfortable answering a particular question, they do not
have to answer. Furthermore, participants may withdraw from the interview or study at
any time.
This study will allow an understanding of reporting behaviors and barriers to the
current system to be explored. The study will contribute to research in a largely
unexplored field. The project will provide practical information about the views about
risks and safety of herbal products and why people chose to report or not report side
effects from herbal products. These results may help the Natural Health Product
Directorate (NHPD), the division of Health Canada responsible for administering the
regulations, understand consumer needs and perspectives. Since the NHPD has shown
interest in this topic, the agency may use the data to devise additional measures designed
to specifically to educate the public or to improve herbal product regulations.
A summary of results will be distributed to participants who are interested.
Appendix B: Study Information Letter – Retailers
130
Is the study confidential?
All the information collected during the research process will be kept strictly
confidential. The names of participants will not be used for any stage of the research.
An identification code will be used in place of names that will only be known to the
research team (listed below). All documentation with personal information about the
participant will be kept in a locked cabinet. Data from the interview that is stored on a
computer will require a password only known to the researchers. Personal information
will not be released to any one else without a court order.
Quotations from the interviews may be used in the final research report.
However, names and identifying information will not be included with these notes. The
final report may be submitted for publication in a peer-reviewed journal.
What if something new comes up during the study that affects participation in the
research?
Participants can withdraw from the study at any time, for any reason.
Will I be compensated for participating in this study?
No, you will not be compensated for participating in this study.
What are my rights as a research participant?
If you have questions about your rights as a research participant, please contact
Jill Parsons, Research Ethics Officer, Health Sciences in the Ethics Review Office,
University of Toronto, at telephone 416 946 5806 or by email: [email protected]
Your participation is important for furthering this research study. Please consider
participating. I can be contacted at the number and email address below for any
questions or concerns that you may have.
Sincerely,
Rishma Walji, B.Sc., N.D.
PhD Candidate, Department of Pharmaceutical Sciences, University of Toronto
Tel: 416-465-7779
Other Members of the Research Team:
Dr. Heather Boon, Dr. Zubin Austin Dr. Ross Baker Dr. Joanne Barnes
Thesis Supervisor Committee Member Committee Member Committee Member
Tel: 416-946-5859
Fax: 416-978-1833
131
Participant Consent Form
Reporting of Adverse Events Associated with Herbal Products.
I have read the accompanying letter of information titled Study Information Sheet.
The study has been explained to me and I agree to participate in the study described. The
researcher has addressed all my questions and concerns.
I understand that Ms Walji, a PhD student at the University of Toronto, will be
the interviewer and that this study is her thesis requirement for her degree.
I understand that any information I provide for the study is strictly confidential
and that I will only be identified by a unique code that will only be accessible to the
researcher, the research coordinator and the thesis supervisor. Quotations for the final
report will not be included if the context could lead to the identification of an individual.
All written information from this study will be stored in a locked cabinet at the
University of Toronto. Data gathered as a part of this study will be destroyed after 8
years.
I understand that complete anonymity about participating in this study cannot be
guaranteed, especially if interviews take place in a public place, where others in the
location may be aware of my participation in the study.
I understand that my participation in this study is voluntary and that I have the
right to withdraw at any time.
If you have questions about your rights as a research participant, please contact
Jill Parsons, Research Ethics Officer, Health Sciences in the Ethics Review Office,
University of Toronto, at telephone 416 946 5806 or by email: [email protected].
DATE: ____/____/____ (to be dated by participant)
day month year
SIGNATURE OF Participant: _________________________________________
PRINTED NAME OF Participant: __________________________________
DATE: ____/____/____ (to be dated by researcher)
day month year
SIGNATURE OF Researcher: _________________________________________
Rishma Walji, Researcher Heather Boon PhD, Thesis Supervisor
[email protected] [email protected]
Tel: 416-978-6951 Tel: 416-946-5859
Fax: 416-978-1833 Fax: 416-978-1833
Appendix C: Participant Consent Form - Consumers
132
Participant Consent Form
Reporting of Adverse Events Associated with Herbal Products.
I have read the accompanying letter of information titled Study Information Sheet.
The study has been explained to me and I agree to participate in the study described. The
researcher has addressed all my questions and concerns.
I understand that Rishma Walji, a PhD student at the University of Toronto, will
be the interviewer and that this study is her thesis requirement for her degree.
I understand that any information I provide for the study is strictly confidential
and that I will only be identified by a unique code that will only be accessible to the
researcher, the research coordinator and the thesis supervisor. Quotations for the final
report will not be included if the context could lead to the identification of an individual.
All written information from this study will be stored in a locked cabinet at the
University of Toronto. Data gathered as a part of this study will be destroyed after 8
years.
I understand that complete anonymity about participating in this study cannot be
guaranteed, especially if interviews take place in my pharmacy or health food store,
where others in the location may be aware of my participation in the study.
I understand that my participation in this study is voluntary and that I have the
right to withdraw at any time.
If you have questions about your rights as a research participant, please contact
Jill Parsons, Research Ethics Officer, Health Sciences in the Ethics Review Office,
University of Toronto, at telephone 416 946 5806 or by email: [email protected].
DATE: ____/____/____ (to be dated by participant)
day month year
SIGNATURE OF Participant: _________________________________________
PRINTED NAME OF Participant: __________________________________
DATE: ____/____/____ (to be dated by researcher)
day month year
SIGNATURE OF Researcher: _________________________________________
Rishma Walji, Researcher Heather Boon PhD, Thesis Supervisor
[email protected] [email protected]
Tel: 416-465-7779 Tel: 416-946-5859
Fax: 416-978-1833 Fax: 416-978-1833
Appendix D: Participant Consent Form - Retailers
133
Appendix E: Interview Guide – Consumers
Background Information for Consumer Interview to be filled out by researcher
Participant ID number:
Age:
Sex:
Health Concerns: For example:
High Blood Pressure � Heart Disease �
Diabetes � Asthma �
Other ___________________
Other Medications/
Supplements (Name):
Manufacturer: (not
needed for
conventional drug,
but for herbs)
Dose/Frequency:
Phase 2: Questions for Consumer Guided Interview
1. What prompted you to take this herbal product?
2. Where did you purchase your product?
a. Health food store? Pharmacy? Internet? Other?
3. Is this where you usually buy your herbal products? Why do you buy them from there?
4. Our research study is about side effects from herbal products, can you describe what
happened to you?
a. How soon after you took the product did it happen?
b. How severe was it?
c. Exactly what symptoms did you experience?
5. What did you do about it? Why?
a. Did you tell anyone (and why or why not)?
b. If your side effects were more mild/moderate/severe, would you have responded
differently?
6. Do you think that people should report their side effects? Why or why not?
134
a. Where would be an appropriate place to report? Medical Doctor, Pharmacist,
Naturopath, Retail store where they bought it, Manufacturer, Media, Other.
7. What kinds of side effects do you think should be reported?
8. What would prompt you to report (or not report) a side effect?
9. What do you think about the safety of herbal products in general?
a. How safe did you think the product you took was before you used it?
10. Where do you get information about herbal products? Why that source?
11. Are you familiar with the reporting system for adverse drug reactions in Canada (describe
what you have heard if anything)? What do you know about it? Have you ever used it?
What for? To send in a report? Or to look at the reports that other people have made?
12. What do you think are the major obstacles in reporting side effects from an herbal
product?
13. Are you satisfied with the current procedure of adverse event reporting system for herbal
products? Why or why not?
a. Has Health Canada and/or your health practitioner provided any information,
assistance, or feedback to you to help you become aware of side effect reporting
procedures?
b. What do you think should be done to enable reporting of side effects from herbal
products?
Added October 2007:
Would you have acted differently if the product had a label or if you knew you would get a …
(rash, diarrhea .. etc.)?
How do you feel about pharmacies and health food stores, both of which sell NHPs?
135
Appendix F: Interview Guide – Retailers
Background Information for Retailer Interview to be filled out by researcher
Participant ID number:
Position Pharmacist �
Health food store: owner � employee � manager �
Sex Male � Female �
Amount of time working in this position ______________________________________
(indicate months or years) Number of hours working per week ___________________________ (any store)
Questions for Retailer Guided Interview
1. What are the most common herbal products that you sell?
2. What do you think about the safety of these products?
3. What do you think about the safety of herbal products in general?
4. How often do people ask for your advice when taking these products?
a. What kinds of questions do they ask?
b. What kinds of risk/safety questions do they ask (if any)?
c. Can you provide some specific examples?
5. How would you describe your knowledge about herbal products?
a. How do you decide what products to recommend?
b. How do you differentiate between different brands of the same herb?
c. Where do you get your information about contra-indications or drug interactions
associated with these products?
d. What kind of training do you have about herbal medicines?
6. How often do you have consumers tell you about side effects that they have experienced?
a. Can you provide an example of when this happened?
7. What do you do about this information?
a. Do you tell the patient to stop taking the product?
b. do you report it to someone (who?)?
8. Are you familiar with the AE reporting system in Canada? (What do you know about it?)
9. What kinds of AEs would you report, if a consumer reported them to you?
a. How do you decide?
10. What do you think about the current reporting system?
136
11. What do you think are barriers to reporting?
12. Case Study: If a 56 year-old man who took an herbal weight loss product came to you and said
that they experienced (a, b, or c), how would you respond?
a. Digestive disturbances and malaise
b. A persistent skin rash on his forearms
c. Palpitations and abnormal heart rhythms, and dizziness
13. Is there anything else that you’d like to add?
Added Sept 2006:
Role of the pharmacist, role of the HFS, MD, ND, etc.
Case, if someone came in with a mild rash, then another person same rash, then another (pattern)
how would you respond?
What is the definition of an adverse event?
Where do consumers go for information?
Added Nov 2006:
EBM questions – what is research? What does it mean to be responsible?
What is the difference between a pharmacy and HFS?
Added Feb 2007:
JB: As stated during phone call: do HFS recommend herbal medicines to consumers who have
visited HFS because they have had an adverse effect to a CONVENTIONAL MEDICINE and
want to take something more natural instead – I think this is v important.
Added April 2007:
HFS perception of their role and responsibilities wrt adverse events and natural health products.
137
Appendix G: Coding Tree – Consumers
Consumer Coding Tree – Nov 21, 2007
Purchasing Decisions How they decide where to buy an NHP and why
Info Sources Where consumers get their information about NHPs
Brand/quality Any reference to preference or opinion about certain brands or
quality of one brand over another, includes media sources
Family history reference to family use of NHPs
Recommendations Any recommendations from the participant
Perceptions of
Severity How severe they thought their reaction was
Sense making Their idea about what happened and how it was related to the
product, worse before getting better
Safety of NHPs Any reference to safety of NHPs
Resolution Satisfaction with how the AE was handled
Pharmacist Any reference to perceptions of their pharmacist, includes
relationship with pharmacist
MD Any reference to perceptions of their MD, includes their
relationship the the MD
Industry Any reference to perceptions of industry, NHP manufacturing
companies, reaction of industry to report, etc
Drugs Any reference to perceptions of drugs/pharmaceutical
medications
CAM health provider Any reference to perceptions of their CAM health provider,
including ND, herbalist, etc., includes their relationship with
this provider
Adverse Event
Description Description of the AE
Action
Tx seeking another treatment
Change dose reference to changing the dose, taking less product, etc
D/c discontinuing product, dechallenging, rechallenging
Report
Trigger what made them or would make them report
To nurse helpline reported to nurse helpline
To MD reported to MD
To industry reported to industry
To friends/family told friends/family about AE
To CAM health provider reported to CAM provider
Details what they were asked to report, what info was included, how
they did it
Barriers what is or would be a barrier for reporting, lack of knowledge,
loss of access
HFS reporting to health food store
138
Appendix H: Conceptual Map – Consumers
Consumer Coding Tree
November 21, 2007
Info sources
Safety of NHPs
Industry
MD
CAM
health provider
Risk
Drugs
Pharmacist
Regulations
Perceptions Purchasing
decisions
Brand/Quality Family history
Description
Resolution
Sense making
Severity
Discontinue Other tx
Barriers
Trigger
To industry
To MD
To CAM
health provider
To Nurse
Helpline
To family
and friends
Outcome
Details
Health food store
Report Change dose
Action
Adverse Event Recommendations
Safety
139
Appendix I: Coding Tree - Retailers
CODING TREE: RETAILER PERSPECTIVES ON HERB SAFETY (June 2007)
SAFETY:
KNOWLEDGE:
Confidence – retailer’s confidence about own knowledge related to herbs and about their
knowledge, and about their ability to recommend products, etc. their own knowledge about herbs
e.g. “my issue is that I just don’t know enough about them”.
Advice Given – NOT related to safety
Recommendations – about products taken, how to take the product, which product to take for
what
Referral – to someone else more knowledgeable
Education
Pharmacist
Undergraduate – any herbal education in pharmacy school
Continuing Education – any herbal education/ training after graduation
Health Food Store – includes references to training “in store”, “classes”, past training,
self-directed learning, etc.
Research – scientific literature, evidence based, also includes other information ‘out there’ on
herbs or perceived information. References to what knowledge exists in general about herbs
Information Sources – any information sources that the retailer uses for looking up information
re: herb information, contraindication, side effects, etc.
Health care practitioner – calling a health provider for information, does not include
references to referring the patient to their doctor for safety or AE issues (see safety advice
referral doctor)
Customer feedback – any information about the herb given by another consumer e.g.
“my information is anecdotal from other patients”, “I would say that I’ve heard [from
other patients] that this product ..”
Textbooks – any reference to textbooks or journal articles used to look up information
Industry – manufacturer and chain stores e.g. “the franchise has a booklet” or “I’ll call
the company to find out answers to my questions” or “I don’t think the company could
answer my questions”
Professional Organizations – motherrisk, drug info hotline, pharmacist’s association,
drug information center
Internet – websites referred to
Media – influence of media, e.g. “a lot has to do with the way it’s marketed”
PERCEPTIONS OF:
Brand / Quality – in reference to a particular brand or quality of the product “I have problem
with quality control .. a lot of companies don’t have DIN numbers”. Includes references to
“reputable brands”.
NHP regulations – in reference to regulations for NHPs eg. “you don’t know the dose on
the label is actually in the pill, and that’s probably an issue with the ministry ..”
(brand/quality issue)
Appropriate Use – in reference to appropriate use of a herbal product, consumers using things
in a way they shouldn’t, for prevention. Depends also on getting appropriate info from
pharmacist/HFS so a knowledge section is linked below.
140
Perception of consumer – general, SE/DI, behaviour eg. “consumer usually know what they
want because they saw it on the internet or they heard from a friend”. “ I think that consumers
think ..”
Advice Asked
Frequency – how often asked advice on a product
Content – what are they asked about eg. “people ask about sleep herbs like valerian”
Perception of pharmacist – what they think, what others think of them, eg. reference to the role
pharmacists should play in herbal products eg. “I think that biomedical practitioners are narrow-
minded when they don’t take into account what patients might see as helpful”.
Also linked to merchandising
Perception of Health Food Store – what they think, what others think of them eg. in reference
to how consumers and personnel interact, their perceived knowledge
Merchandising – how to decide what to sell e.g. “we’re mandated to sell herbs” or “we
only carry brands we trust”
Perception of Medical Doctor – what they think, what others think of them
Efficacy – in reference to the efficacy of an herbal product or lack of efficacy also of herbal
meds vs conventional meds
Perceived Safety – a perception of safety of the herbal product, natural = safe, or perceived
unsafe e.g. “I don’t believe that it’s safe just because it’s natural”, or perceived unsafe.
SIDE EFFECT/ DRUG INTERACTION
Frequency – how often a side effect or drug interaction is come across
Definition – how a side effect or DI is defined by the participant, eg. reference to the time after
taking the product, the severity, the symptoms, “doesn’t agree with me” is not really an AE
Knowledge – knowledge of participant about side effects and DI
Examples – examples of side effects or drug interactions
Investigation – the process of investigating symptoms of an AE e.g. pharmacists ask about when
it occurred, what happened, etc – process they perform from their training, what are they looking
for, what conclusions it helps them come up with.
Reporting
Previous experience – has done/tried to report an AE or DI, or has never reported i.e.
what is their experience with reporting previously – includes reporting drug AE and
herbal AE
Recommendations for change – what people recommend to make the reporting system
better, eg. more education
Responsibility – whose responsibility is it to report? E.g. “I think health professionals
should be responsible for assessing health conditions and side effects”
Action
Trigger – trigger for HFS worker or pharmacist to report
Unexpected – something new that they haven’t seen
Severity – how severe the reaction is by their definition “
Patient concern – how concerned the patient is about the reaction
Pattern – if it’s a repeated pattern of events
Notoriety of product/herb – ie they have heard something about it before
Report to
MD/Health Care provider – report S/E to MD
Health Canada - file report with Health Canada
141
Manufacturer – call manufacturer
Public health – for a public health issue, eg. outbreak
Advice – related only to AE and DI
Approach – prevention, cautious, conservative e.g. “ I always tell them to
start with a low dose” or “I tell them that I don’t know much about the
product and it’s up to them”
Discontinue – stop using the product
Referral – referral to health care provider, including CAM practitioners
Recommend treatment – for side effect or reaction eg. for rash
recommend antihistamine
Recommend substitute product – in place of the product that caused the
problem
Barriers
Reporting knowledge – of reporting system, includes knowledge of or
lack of knowledge of reporting system
Complexity – to confusing
Time – takes too much time
Incidence – doesn’t happen enough, don’t see enough AEs
Patient Feedback – customers don’t tell them that there is an AE or DI
Not worth it – don’t get any acknowledgement, “what’s the point?”
Skepticism – ie the person who thought that patients were just trying to
get their money back
Lack of info - we need all the information to report it. Can’t assess if it’s
a true ADR.
Returns – return product if side effect or customer unsatisfied
Other - documentation
FREE NODES
Errors - wrong statements that are made in reference to a product or anything else during the
interview
Demographics – basic demographic info about the participant.
Role of pharmacist – any reference to the role of the pharmacist
Corporation – any reference to corporations
142
Appendix J: Conceptual Map – Retailers
Coding tree HFS and PHM – June 2007
Confidence
Recommendations
Refer
Advice Given
PHM
HFS
Education Research
Health care provider
Customer feedback
Textbooks
Industry
Prof organization
Internet
Media
Info sources
Knowledge
NHP regs
Brand/quality
Appropriate use
HFS
PHM
Consumer
Merchandising
Frequency
Content
Advice asked
MD
Efficacy
Percieved safety
Perceptions of
Frequency Example
Definition Knowledge
Investigation
Prev experience Recomend change
Responsibility
Unexpected
Severity
Pt concern
Pattern
Notoriety
Trigger
Health care provider
Health Canada
Manufacturer
Public health
Report to
Approach
Discontinue
Refer
Recomend treatment
Substitute product
Advice
Reporting knowledge
Time
Complexity
Incidence
Pt feedback
Skepticism
Lack of info
Barriers
Returns Other
Action
Reporting
Side effect/DI
SAFETY
143
Appendix K: Ethics Approval
144
145
Appendix L: Adverse Drug Reaction Reporting Form